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ABSTRACT 
 
 
Background:  Over the past 30 years, little has changed in the treatment 
modalities and prognosis of patients suffering from Glioblastoma multiforme (GBM), the 
most common and by far the most devastating adult primary malignant brain tumor.  
Conventional therapies provide only a marginal increase in survival of GBM patients, 
post-diagnosis. Therefore, more novel means of treating GBM are needed to increase 
long-term survival and quality of life for those affected.  Replication competent oncolytic 
viruses (OVs) have recently emerged as a possible option for treatment of high-grade 
gliomas. Particularly, recombinant vesicular stomatitis virus (rVSV), an enveloped, 
negative strand RNA virus, has shown promising results in preclinical studies.  Tumor 
selectivity of VSV is thought to be associated with tumor specific defects in the 
interferon (IFN) pathway.  However, largely due to insufficient attention on the role the 
immune system plays in efficacy of treatment, potential OVs have been obstructed from 
moving through the clinical trial pipeline past Phase I/II studies.  rNCP12.1 is a novel 
recombinant VSV vector possessing specific mutations in the matrix protein.  Thes 
mutations have been shown to promote viral attenuation in normal cells while 
maintaining cytotoxicity in a number of tumor cell lines.  We aim to characterize and 
further develop this novel agent for the treatment of GBM.   
 
Methods:  In order to determine differences between rNCP12.1 and wtVSV and 
to determine specificity of rNCP12.1 for tumor over normal cells, cell rounding assays, 
one-step growth curves, and cytotoxicity assays were performed in normal glial and 
tumor glial cell lines.  To understand the basis of this selectivity and whether it correlated 
with the antiviral responses of IFN, expression levels of IFN and IFN stimulated genes 
(ISGs) were quantified, production of active IFN was measured, and the ability of cells to 
inhibit viral infection in response to exogenous IFN was determined.  In vivo experiments 
were designed and carried out to test for oncolytic activity of rNCP12.1 in 
immunocompetent animal models of intracranial glioma.  A single injection of rNCP12.1 
was administered into previously implanted F98-GFP tumors.  Tumor load and 
parameters of morbidity were assessed at 15 days following tumor implantation and long 
term at the time of euthanasia.  Viral induced immune responses were assessed by the 
IFN bioassay and detection of circulating anti-VSV antibodies were achieved by Western 
blot analysis and a neutralizing antibody assay.  Experimental methods of virus 
administration for treatment of glioma were further tested including multiple injections, 
injections using different VSV serotypes, continuous infusion of virus using implantable 
osmotic pumps, and pre-infected autologous carrier cells.  These methods were designed 
to enhance anti-tumor effect by managing the negative effects of the tumor 
microenvironment and of a functional immune system on viral therapy. 
 
Results and Conclusion:  rNCP12.1 was shown to be an attenuated strain of 
VSV that has clear differences in its growth and induction of the IFN response pathway 
in normal cells.  It has a preference for growth in tumor cells as determined by viral titers, 
cell rounding, and cell viability post infection.  This preference varied based on cellular 
expression of a particular IFN phenotype.  The importance of this molecular versus 
 vi 
histological cell profile was evident even in the performance of rNCP12.1 on human 
glioma cell lines that differ in their expression of IFN.  
 
 In vivo evaluation of rNCP12.1 against a highly IFN resistant rat glioma cell line, 
F98, demonstrated its ability to decrease tumor size while eliciting a peripheral response 
to virus that protects normal tissue but also shortens its therapeutic window and the 
ability to sustain reduction of tumor over time.  Several experimental methods in delivery 
of virus proved to be beneficial, including administering an additional dose of virus using 
a different serotype to bypass antiviral neutralizing responses and by shielding virus from 
the immune system through the use of tumor carrier cells.  As an additional benefit, the 
latter was shown to have a unique pattern in eliciting tumor specific antibodies that was 
different from those increased by therapy with virus alone.  This method also increased 
recovery of virus from brain tissue even after 20 days post treatment.   
 
Our data supports the capability of rVSV vectors as treatment for GBM.  
Specifically rNCP12.1 therapy increased survival while decreasing tumor load, 
depending on method of administration.  When given alone, virus is ultimately 
immunogenic and prompts anti-viral as well as anti-tumor immune responses.  However, 
when shielded from the immune system, anti-viral responses are minimal while anti-
tumor responses are sustained.  To this end, therapy cannot be fully addressed without 
addressing the effects the immune system has on therapy and on the host.  Future studies, 
should include not only evaluation of tumor load, morbidity, and side effects of viral 
therapy but also immune responses especially those that are likely to enhance therapy 
past the acute stages of disease.   
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CHAPTER 1.    INTRODUCTION 
 
 
Glioblastoma Multiforme 
 
 
Definition and Classification  
 
Gliomas are both benign and malignant neuroepithelial tumors originating from 
the supporting glial cells of the central nervous system (CNS) [1].  The accepted standard 
for defining tumors of the CNS has been established by The World Health Organization 
(WHO) histological grading system, which subdivides tumors based on the glial cell from 
which they most likely derive including cells of astrocytic, oligodendroglial, mixed 
oligoastrocytic, or ependymal nature.  Particularly, astrocytic tumors can be classified 
into four distinct histological groups corresponding to their level of malignancy (See 
Table 1-1).  Grade I tumors such as pilocytic astrocytomas have low proliferative 
potential and are the least malignant. Grade II neoplasms are generally of low 
proliferative potential yet have a higher capacity to infiltrate surrounding normal tissue.  
For this reason, Grade II lesions often recur as high-grade tumors following initial 
treatment. Grade III and IV tumors are considered high grade, and, particularly, WHO 
grade III tumors are anaplastic lesions that are histologically malignant, displaying 
nuclear atypia and high mitotic activity. Lastly, WHO grade IV describes highly 
malignant tumors with similar histological features of grade III tumors but with enhanced 
proliferation of microvasculature and necrotic centers often surrounded by hypercellular 
areas called pseudopalisades which are thought to be cells migrating away from hypoxic 
areas of tumor [2].  Included in the Grade IV category are glioblastomas, formerly known 
as glioblastoma multiforme or GBM, the most detrimental of high-grade gliomas [3].  
 
 
 
 
 
 
Table 1-1. Histological grading of astrocytic tumors as defined by the World 
Health Organization (WHO) 
 
Histological Grade Tumor (s) 
I • Subependymal Giant Cell Astrocytoma 
• Pilocytic Astrocytoma 
II • Pilomyxoid Astrocytoma 
• Diffuse Astrocytoma 
• Pleomorphic Xanthoastrocytoma 
III • Anaplastic Astrocytoma 
IV • Glioblastoma (Glioblastoma Multiforme) 
• Giant Cell Glioblastoma 
• Gliosarcoma 
    2 
Epidemiology 
 
According to the Central Brain Tumor Registry of the United States (CBTRUS), 
there were 311,202 primary brain and CNS tumors diagnosed during 2005-2009; 201,507 
of which were malignant. Gliomas comprise 30% of all CNS tumors and 80% of all 
malignant tumors.  Of gliomas, GBM makes up over 50% and is the second most 
commonly diagnosed (16%) primary tumor second only to the nonmalignant meningioma 
(35%) (Figure 1-1).  Of CNS malignancies, GBM ranks first. Males are typically 
affected more than females at a ratio of 1.58, and whites are twice as likely to be 
diagnosed with GBM over African Americans.  The median age of diagnosis for GBM is 
64 with highest rates seen in those over the age of 75 making it a disease of advanced 
age.  As the most malignant and notorious of brain tumors, mortality is high following 
diagnosis. One-year survival is estimated at 35.7% dropping down to 5% at 5 years [4, 5].  
 
Cause(es) of glioma are largely unknown.  Because gliomas are a disease seen 
more prevalently in industrialized countries, many studies have attempted to find a 
relationship between environmental factors such as cell phone usage.  Unfortunately, 
none have been convincing other than demonstrating an increased risk with past history 
of radiotherapy to the head and/or neck.  There are known hereditary syndromes 
associated with increased risk of glioma, but these are rare. Examples of these include Li-
Fraumeni syndrome, familial adenomatous polyposis syndrome (FAPS), Lynch 
syndrome, and Neurofibromatosis (NF) 1, each of which have been associated with single 
gene mutations [6].  
 
 
Diagnosis 
 
Signs and symptoms are important in the diagnosis of CNS tumors.  Those that 
raise suspicion include constitutional symptoms such as fatigue and headache as well as 
dizziness, confusion, memory loss, and behavioral changes.  Focal neurological 
symptoms may be present and include changes in vision, speech, and motor or sensation, 
which vary based on tumor location.  Additionally, symptoms indicative of increased 
intracranial pressure from mass effect of tumor may be present and include headache 
associated with vomiting most noticeable upon awakening.  Radiological studies are 
extremely important to the diagnosis of GBM and aid in confirming tumor malignancy.  
These include computed tomography (CT) or magnetic resonance imaging (MRI), the 
latter being the study of choice as it is more sensitive to specific features of malignancy 
such as peritumoral edema and areas of abnormal intensity that correspond to foci of 
tumor cell infiltration. Often areas of central necrosis are visualized making high grade 
tumors a more likely diagnosis than low grade [7]. 
 
 
Standard Treatments for GBM  
 
Regardless of etiology, prognosis for GBM patients is grim with survival ranging 
from 3-15 months, depending on available treatment options. Negative prognostic factors  
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Figure 1-1. Distribution of primary brain tumors 
The distribution of primary brain tumors based on histology are depicted in the pie graph.  
The bar graph illustrates distribution of glial specific tumors. 
Source: Dolecek T, J. Propp, N. Stroup, and C. Kruchko (2012). CBTRUS Statistical 
Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United 
States in 2005–2009.  Neuro-oncology, 14:1-49 [4]. 
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include advanced age, infiltrative histological features, poor performance status 
(Karnofsky scale), and inability to surgically debulk tumor.  For low-grade tumors, 
prognosis is best with 5yr survival of Grade I tumors averaging 94% as tumors are 
usually cured by surgery alone.  On the other hand, surgery is often not feasible for Grade 
IV tumors due to infiltration especially into eloquent areas of the brain. Other factors 
affecting ability to operate include advanced age and comorbidities.  Regardless, the 
standard treatment for newly diagnosed GBM includes surgical resection, radiotherapy, 
and adjuvant chemotherapy.  
 
Surgical management not only provides tissue for diagnosis as well as relief from 
symptoms caused by mass effect, but the extent of resection (EOR) has been shown to 
directly influence overall survival. In a retrospective review of GBM patients who 
underwent 2 or more craniotomies for tumor resection, outcomes based on gross total 
resection (GTR) versus subtotal resection (STR) at time of diagnosis and recurrence were 
compared and a significant improvement in survival was associated with debulking of at 
least 78% of tumor mass. These numbers improved with increased percentage of 
resection [8]. Current studies are focusing on improving both surgical techniques and 
imaging strategies in order to enhance this positive effect on survival for patients who 
qualify for resection [9].  Even further, the combination of surgery and radiation was 
found to increase survival [10].  Conventional radiotherapy regimens consist of 60 Gy of 
partial-field external- beam irradiation delivered 5 days per week in fractions of 1.8 to 2.0 
Gy [7]. Since the implementation of chemotherapy as part of the standard of care, 
survival has increased from 12 to 15 months. Until 2005, there were a number of drugs 
evaluated and often experimentally used in the clinical setting as chemotherapy agents for 
GBM.  These included agents such as procarbazine, a DNA alkylating agent, and the 
nitrosourea chemotherapies such as carmustine (BCNU) or lomustine (CCNU).  In 2005 
following a groundbreaking study by the European Organisation for Research and 
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) on 
treatment of newly diagnosed GBM, another chemotherapy agent, Temozolomide (TMZ) 
became the agent of choice as this study showed an increase in survival of 3 months 
when TMZ was added to radiation versus radiation alone.  TMZ is an oral prodrug agent 
that is metabolized into its active form, which then methylates DNA at a number of sites 
causing DNA damage and subsequent cellular apoptosis. As with many chemotherapies, 
GBMs become resistant to TMZ therapy by several mechanisms that involve 
dysregulation of DNA repair systems.  Unfortunately, the ability to treat with TMZ is 
largely limited by its myelosuppressive effects [11]. 
 
Despite the most aggressive conventional therapeutic regimen, a majority of 
tumors eventually recur within 7 months [7, 12]. These tumors are typically more 
aggressive due to newly acquired genetic changes in the tumor cell population promoting 
resistance to radio- and chemotherapies [13].   
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Molecular Subtypes of Glioblastoma 
 
In accordance with the WHO system, histological characteristics are evaluated to  
classify gliomas based on glial origin and malignant potential.  This grading system often 
falls short in its ability to predict prognosis and response to treatments, as many 
histologically similar gliomas respond very different to treatment.  This may be due to 
technical error as histological grade is dependent upon interpretation by 
neuropathologists and borderline histological features often interfere with this 
interpretation [1].  On the other hand, underlying genetic profiles of histologically similar 
tumors may cause them to behave very differently in response to treatment and therefore 
affect long-term survival.  The observation that certain Grade IV gliomas have increased 
susceptibility to TMZ based on the presence or absence of mutations in a DNA repair 
enzyme promoter is an example of this genetic influence.  O6-methylguanine-DNA 
methyltransferase (MGMT) is a DNA repair enzyme that works by inhibiting cross 
linking of dsDNA which prevents the action of alkylating chemotherapeutic agents and is 
often responsible for resistance of tumors to these agents.  When methylated, the MGMT 
promoter is silenced therefore increasing the tumor’s susceptibility to TMZ. Studies have 
shown that survival with TMZ therapy is enhanced to 21.7 months versus 12 months in 
patients with unmethylated MGMT [7]. 
 
It is understood that GBMs are composed of a heterogeneic population of cells, 
and therefore several genetic subtypes are currently recognized [13]. Primary GBM 
makes up 90% of total GBMs diagnosed and arises de novo without a history of a lower 
grade precursor lesion. Primary tumors exhibit a number of frequent genetic alterations 
including EGFR amplification, homozygous deletion of the CDKN2A gene coding for 
both p16INK4a and/or p14ARF, and chromosome 10 or PTEN mutations.  In contrast, 
secondary GBMs, comprising only 10% of total GBMs, arise from a lower-grade 
precursor lesion and usually carry TP53 and IDH1 mutations in more than two thirds of 
cases. Other common genetic alterations of secondary GBMs include allelic losses on 
19q and 13q, promoter hypermethylation of the RB1 gene, and overexpression of 
PDGFR-A (reviewed in [6]). Taken together, these data clearly indicate that primary and 
secondary GBMs represent genetically different diseases yet both share similar 
histological feature [14] and while this characterization has not been shown to have an 
association with prognosis, it has been exploited in developing more targeted therapies 
[13]. 
 
This discovery of genetically associated subtypes for GBM has prompted even 
more sophisticated analyses that have uncovered more altered genes and pathways likely 
contributing to tumor behavior.  Of note is The Cancer Genome Atlas (TCGA) Research 
Network established in 2006 to generate a comprehensive database of genomic 
abnormalities in various cancers. Studies derived from information in this database, have 
exposed other associations leading to the proposal of additional genetic classes of GBM.  
One particular study revealed four well-defined genetic subtypes of GBM: Proneural, 
Neural, Classical, and Mesenchymal.  These subtypes are characterized based on the 
following genetic profiles: Classical is associated with EGFR overexpression, PTEN loss, 
and to a lesser extent chromosome 9p21 deletions targeting p16INK4a and p14ARF; 
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Mesenchymal with NF1; Proneural with PDGFRA, IDH-1, and TP53 mutations; Neural 
with the presence of neuronal markers such as NEFL, GABRA1, SYT1, and SLC12A5 
(Table 1-2).  Other defining features of these subtypes include differences in responses to 
standard therapies with the greatest response seen in Classical GBM and no benefit seen 
with Proneural subtype.  On the other hand, the classical subtype is usually associated 
with increased age, a known negative prognostic factor while Proneural tumors are 
associated with younger age [15]. 
 
This and subsequent studies prove that gene expression-based grouping of tumors 
can be a more powerful prognostic and predictive factor than histologic grade or age by 
revealing unrecognized heterogeneity of histologically similar tumors. Even newer class 
subtypes are being uncovered that not only seek to determine differences in expression of 
individual gene mutations, but also, groups of genes to identify pathways that may be 
dysregulated in a specific tumor type. One such study has shown the enrichment of gene 
subsets that merge onto targets such as NFkB1 and EGFR [16-18]. 
 
 
Importance of Chromosome 9 and IFN  
 
One pathway that has been studied for its role in tumorigenesis is the IFN 
pathway.  In the early 1990s the hunt for tumor suppressor genes increased as many 
searched to uncover genes associated with deleted chromosomal material in a number of 
tumors.  One particular deletion occurred on chromosome 9 and was found to be 
associated with multiple primary tumors and cell lines such as malignant human T cell 
lines, ALL, and melanoma [19-21]. Early on, the genetic material lost or affected was 
thought to be the interferon (IFN) gene cluster as it is located on the commonly deleted 
region of the short arm of chromosome 9, 9p21.  One of the first studies looking at the 
relationship between cancer and chromosome 9 deletions included a study by Collins et 
al 1991 that revealed deletions of 9p were found most likely in high grade tumors and 
further mapping revealed the locus to involve IFN?/? [22].  This was confirmed by 
subsequent studies that showed a prevalence of IFN gene deletions and/or sequence 
rearrangements in human glioma cell lines and high-grade primary and recurrent tumors 
[23, 24].  
 
Others proposed that the IFN gene clusters may be affected due to their proximity 
to another gene whose function could be important in tumorigenesis. After the discovery 
of p16/ink4a an inhibitor of pRb phosphorylation through negative regulation of cyclin 
D/cdk4 [25] and its location on chromosome 9 [26] the focus shifted from IFN to 
p16/ink4a as a culprit of malignancy in a number of GBM tumors [27-30].  In fact, more 
recent studies based on TCGA database confirm that the classical subtype of GBM which 
harbors mostly EGFR mutations also expresses deletions of 9p21 targeting p16/INK4a 
and p14ARF [15].  These two mutations occur simultaneously in 94% of GBMs tested. 
 
Despite p16’s correlation with chromosome 9 deletions, we still know that IFN is 
affected and that defects in the IFN pathway provide a survival advantage over normal 
cells.  Many therapies have been developed exploiting either the growth inhibitory  
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Table 1-2. Chromosomal aberrations significantly associated with molecular 
subtypes of glioblastoma multiforme 
 
Chromosomal 
Aberration* 
Gene 
Affected 
GBM Subtype 
Classical Mesenchymal Neural§ Proneural 
7p11.2 ? EGFR    ? 
7q21.2 ? CDK6    ? 
7q31.2 ? MET    ? 
7q34 ? -    ? 
7p11.2 ?? EGFR ?   ? 
4q12 ?? PDGFRA    ? 
17q11.2 ? NF1  ?   
10q23 ? PTEN    ? 
9p21.3 ? CDKN2A/ 
CDKN2B 
?    
13q14 ? RB1 ?    
9p21.3? ? CDKN2A/ 
CDKN2B?
? ? ? ?
 
*?= Low level amplification; ??= High level amplification; ? = Hemizygous deletion; 
?= Homozygous deletion 
§ Neural subtype is significantly associated with presence of neuronal markers, not 
specific chromosomal aberrations. 
Source: Verhaak, R, K. Hoadley, E. Purdom, V. Wang (2010). Integrated genomic 
analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110 [15]. 
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actions of IFN on tumor cells or the inability of tumor cells to produce protective IFN 
responses.  Heymann et al demonstrated a correlation between changes in genetic 
material and IFN bioactivity in malignant T cell lines showing that several cell lines with 
normal dosage of IFN genes had deficiencies in producing IFN or in IFN sensitivity [20]. 
 
 
Experimental Therapies for GBM  
 
Though cure is the ultimate goal, with a median survival of only 12-15 months 
post-diagnosis, therapies for GBM that are able to prolong progression free survival 
(PFS) with a high quality of life are warranted.  There are a number of studies occurring 
at various stages of the drug approval process that are aimed at doing just this (Figure    
1-2). These not only involve experimental therapies that exploit newly defined genetic 
characteristics of GBM, but they also involve the search for more efficient methods of 
administering existing chemotherapeutic agents.  Because GBM is a “local” disease in 
that there have been very few confirmed instances of extra-axial metastases, possibly due 
to short survival times post-diagnosis, improved methods of local administration are 
being developed [31-33].  Gliadel, a carmustine (BCNU)-containing implantable 
degradable polymer wafer, is FDA approved as an adjuvant treatment with surgery and 
radiation of newly diagnosed GBM as well as an adjuvant to surgery in patients with 
recurrent disease.  Its safety was proven in phase I trials and, later, phase III trials 
demonstrated an increase in survival by 8 weeks versus placebo wafers. Advantages of 
the system include the ability to bypass administering toxic levels of drug needed to cross 
the blood brain barrier when carmustine is given systemically therefore preventing side 
effects such as myelosupression.  On the other hand, wafers have been associated with 
increased intracranial pressure caused by malignant edema, seizures, and post 
implantation infections [34].  Another example of a local delivery system for GBM 
includes Convection-Enhanced [intratumoral] Delivery (CED).  This system involves 
stereotactically implanted catheters that deliver therapy by high flow infusion over a 
specified period of time.  Advantages of this system are its ability to pump drug 
uniformly through the extracellular matrix over large areas of brain. Catheters can be 
placed either within tumors or in the tumor bed after surgical resection.  Unfortunately, 
CED has been limited to small supratentorial tumors away from the sagittal sinus located 
in the midline [35]. Also, in theory, drug distribution should be uniform however 
distribution has often been found to be variable and unpredictable with CED delivery 
[36].  Nevertheless, a number of chemotherapy agents as well as targeted drugs such as 
cytotoxins have been tested using this mode of delivery [37]. 
 
Though chemotherapy is an accepted part of the therapeutic regimen for GBM, 
the agents are broadly acting and function by damaging DNA in both tumor and normal 
cells.  On the other hand, targeted therapies work by selectively killing tumor cells 
according to differences in expression of genetic pathways and markers. For example, we 
know that EGFR overexpression is found in ~50% of GBMs and the receptors are 
constitutively active in ½ of these. This path has been shown to be the major genetic 
aberration in the classical genetic subtype of GBM and is the major genetic feature of 
primary GBM tumors.  Therapies that target EGFR have been studied in several Phase  
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Figure 1-2. Description of the multi-phase drug approval process 
Source: Food and Drug Administration 
(http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm) 
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I/II trials and include the tyrosine kinase inhibitor, gefitinib, as monotherapy and as 
combination with other chemotherapeutic agents [38-40].  These drugs are considered 
antitumor therapies as they specifically inhibit the growth of tumor cells through 
inhibiting their mitogen-signaling cascade.  Unfortunately, results of clinical trials to date 
have not shown an increase in PFS or overall survival (OS) in patients treated with EGFR 
inhibitors for glioma but they have shown promising results for non-small cell lung 
cancer (NSCLC) in Phase III trials and these inhibitors are currently being marketed as 
first line of therapy in patients with specific EGFR activating mutations [41, 42].  There 
are a number of ways in which this pathway can become overactive in cancer other than 
at the receptor binding step therefore, other inhibitors directed against more downstream 
signaling factors such as PI3k/akt/mTOR have been developed and are subjects of current 
clinical trials including combination therapy with direct inhibitors of EGFR [43, 44]. 
 
Immunotherapy, another novel therapeutic strategy for treating GBM, functions 
by using the body’s immune cells and signals such as cytokines as cancer fighting agents.  
There are two types of immunotherapy, passive immunotherapy and active 
immunotherapy.  Passive immunotherapy is the application of immunological agents 
such as antibodies or cytokines that act against tumor cells without directly activating the 
immune system.  For instance monoclonal antibodies (mAb) directed against TAAs can 
be used as immunotherapy and one such agent has been FDA approved for the treatment 
of glioblastoma.  Bevacizumab is a human mAb directed against the VEGF ligand, a 
major player in the dysregulation of angiogenesis of glioblastomas.  This antibody 
sequesters VEGF and prevents binding to its receptor on the endothelium. Another 
example of passive immunity is the adoptive transfer of immune cells such as 
lymphocyte activated killer (LAK) cells or cytotoxic T lymphocytes (CTLs) that are 
activated, ex vivo, and then reintroduced to the patient either systemically, 
intratumorally, or into the tumor bed after surgical resection.  As is the case of LAKs, 
these cells undergo cytokine-dependent activation, which is usually non-specific since 
cells are never exposed directly to tumor-associated antigens (TAAs).  Alternatively, 
cells can be activated by exposure to TAAs as occurs with adoptive immunity involving 
CTLs which are then re-administered to the patient causing direct cytotoxicity upon 
contact with tumor (reviewed in [45]). 
 
Alternatively, active immunotherapy works by stimulating the immune system 
against tumor by injecting sources of TAAs such as short peptides, tumor lysates, or 
whole tumor cells, or by injecting immune cells such as dendritic cells (DCs) that have 
been coupled to and/or activated by TAAs.  In a phase I study, DCs pulsed or co-cultured 
with autologous tumor lysate were used as an adjuvant vaccine therapy in patients with 
newly diagnosed and recurrent glioblastoma after surgery and radiation but during TMZ 
treatment.  Results showed that median overall survival of vaccinated patients was 31.4 
months from time of diagnosis and three year survival rate, 47% compared to the US 
average of 14 months and 7.8%, respectively.  These results were even more pronounced 
in patients with tumors of the mesenchymal subtype, a group of tumors shown to be less 
responsive to conventional therapies [46].  An ongoing randomized, multicenter phase III 
to be completed in June of 2013 will determine whether this immunotherapy (DCVax-
Brain) is effective for newly diagnosed glioblastoma [47]. 
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Viruses have also been utilized as targeted therapies for GBM. They can work by 
introducing genes specifically in tumor cells usually by non-replicating viral vectors; 
however, more recent studies have used replicating viruses as vehicles to augment gene 
therapy.  In non-replicating vectors, genes that are crucial to viral replication are 
substituted by a therapeutic gene of interest [48].  Whether by replicating or non-
replicating vectors, possible genes that can be incorporated into the viral genome include 
suicide genes, immunomodulators, or tumor suppressors. 
 
A suicide gene is one that codes for an enzyme necessary in the metabolism of a 
non-toxic pro-drug to its active, cytotoxic form [49].  One of the most studied examples 
is the combination of the Herpes Simplex Virus (HSV) enzyme thymidine kinase (TK) 
and the pro-drug form of nucleoside analog antiviral agents such as ganciclovir (GCV) or 
valaciclovir (VCV).  These pro-drugs are phosphorylated by TK to their toxic form 
allowing them to target and kill actively proliferating cells.  An example of this 
therapeutic regimen includes the conditionally replicative adenovirus AdV-TK with the 
antiviral VCV currently undergoing phase II trials in combination with radiation for the 
treatment of resectable glioblastoma [47, 48].  Another example of a suicide gene/pro-
drug combination includes the delivery of a yeast enzyme cytosine deaminase (CD) by 
viral vector.  This enzyme converts 5-fluorocytosine (5-FC) pro-drug into its active 
metabolite, 5-fluorouracil (5-FU) [49].  A therapy using this suicide gene/prodrug 
combination is currently being studied in Phase I/II trials for recurrent glioblastoma using 
the Toca 511 retroviral replicating vector (RVV) expressing CD [48, 50]. 
 
Delivery of immune stimulatory genes has proven to be of importance 
considering the notion that the CNS is immune “privileged”. This privilege is based on 
the absence of lymph vessels and nodes within the CNS, few antigen presenting cells and 
circulating T lymphocytes, as well as presence of the blood brain barrier (BBB), the 
gatekeeper of all that moves into and out of the CNS.  Specialized immune cells however 
do exist within the CNS and include microglia that when active, serve as the brain’s 
major APC [45, 51].  Other antigen presenting cells such as dendritic cells are found 
hovering around areas associated with breaches in the BBB as in the sub-ventricular zone 
(SVZ) until they are activated. Naïve T cells are not found in the CNS [52-54] but are 
able to enter when activated peripherally.  In GBM patients, the immune system is often 
suppressed not only because of therapeutic corticosteroids that aid in minimizing the risk 
of mass-effect caused by malignancy-associated edema but also because of higher levels 
of immune suppressive cells such as regulatory T cells (T-regs), known to be involved in 
self tolerance, and higher levels of immunosuppressive cytokines such as prostaglandin 
E2 (PGE-2), TGF- ?, and IL-10 (reviewed in [55]) [56].  An example of a novel therapy 
that promotes anti-tumor responses includes the viral vector, M032, an HSV construct 
carrying the IL-12 gene.  This cytokine has been shown to trigger T-helper 1 (Th1) 
responses that aid in the recruitment of antitumor immune cells such as CTLs and NKs 
[57, 58].  Results in preclinical studies demonstrated inhibition of human xenograft brain 
tumors and treated animals experience prolonged survival, even when virus was 
administered in the hemisphere opposite the implanted tumor.  Memory of antitumor 
immunity was confirmed by the inability of re-challenge with tumor cells to establish 
tumors [58].  A phase I trial is currently underway for the treatment of patients with 
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recurrent GBM [59]. Lastly, tumor suppressors, genes that are often muted in tumor cells 
on the road to becoming malignant, can be delivered by viral vectors.  For instance, the 
tumor suppressor p53 is found to be down-regulated in over half of secondary GBMs 
[60].  This has been shown to have a negative effect on susceptibility to radiation in these 
tumors.  Ad-p53 vector is a replication-defective adenovirus vector with a deleted E1 
replication gene that is substituted by the p53 tumor suppressor gene.  This vector was 
shown to increase radiosensitivity of GBM cells in vitro [61].  In a dose-escalation, 
multicenter Phase I trial of intratumorally injected Ad-p53, functional p53 protein was 
found to be expressed in tumor tissue however transduction of tumor cells was limited, 
reaching only to within 5mm of the injection site.  This revealed an obstacle encountered 
by many of the non-replicating vectors, the issue of widespread distribution [62]. 
 
The push for more effective agents with a capacity to propagate through 
surrounding tissue turned the attention toward replication competent viruses, many of 
which have a natural affinity for replication in tumor cells. As I will discuss, these tumor 
selective viruses are broken down into two major categories, those that are naturally 
occurring and those that have been genetically engineered to grow preferentially in tumor 
cells [63]. 
 
 
Oncolytic Viruses as Novel Treatments for Cancer 
 
 
Definition and Classification 
 
Oncolytic viruses (OVs) are viruses that selectively replicate in and kill tumor 
cells.  As a result of this selectivity, normal cells are typically unharmed as infection to 
these cells should be minimal.  This selectivity is based on various characteristics of both 
tumor and virus.  Viruses, either by genetically engineered alterations or by natural 
ability, are able to exploit cellular defects that promote tumorigenesis in cancer cells.  
While these defects offer growth enhancing and survival advantages, they, inadvertently, 
weaken defense mechanisms permitting the replication and take over of viruses [64].  As 
the virus hijacks the cell’s transcriptional and translational machinery, tumor cells are left 
unable to maintain its own growth and eventually die by either apopotosis or tissue 
necrosis [65-68]. 
 
 
History 
 
The idea that viruses could be used as therapy for cancer was observed and 
documented at the turn of the 20th century when a number of patients were found to have 
spontaneously regressing tumors after experiencing acute viral infections [69].  The most 
encountered cancer displaying this phenomenon were those of blood lineage however 
cases of regression were observed in solid tumors such as cervical carcinoma as well 
[69].  Possibly the first recorded account of a case involving viral-induced tumor 
regression was discussed during an oral presentation by Dr. George Dock, a Hematology 
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professor from the University of Michigan who described a patient with acute leukemia 
that was discovered to have experienced a complete, though temporary, remission after a 
flu-like illness [70, 71]. Another popular case came from observations made by Dr. de 
Pace who presented at the International Cancer Congress in Paris in 1910 his findings 
involving a patient with cervical carcinoma who received an attenuated rabies vaccine 
after a dog bite and subsequently experienced regression of her tumor [63, 72].  Building 
on these observations, a research duo at Sloan-Kettering in New York showed the 
potential of oncolytic viruses in vivo first with animal models then in human patients 
with the first clinical trial using Egypt 101, a virus thought to be West Nile virus isolated 
from sera of infected patients.  The trial included patients with cancers ranging from 
melanoma to pancreatic adenocarcinoma and results showed that of 34 patients, 4 
displayed tumor regression and 27 demonstrated systemic infection, 14 of which viral 
replication was observed in biopsied tumor samples [73].  Keeping with the momentum 
of these findings, another trial several years later involved 30 patients with epidermoid 
cervical carcinomas who received an intratumoral injection of another potential OV, 
adenovirus (known at that time as adenoidal-pharyngeal-conjunctival virus, APC).  
Results were surprising as 65% of treated tumors had areas of necrosis, with tumor 
shedding so extensive that some patients experienced severe hemorrhage (reviewed in 
[69]) [74]. Unfortunately, these results were short lived and over half of those treated 
died from cancer within a few months of treatment [75, 76].   
 
Other studies were carried out using viruses such as mumps virus (1974) and 
hepatitis virus (1949) [77, 78].  Unfortunately, many of these studies brought negative 
attention to the field as safety concerns became paramount.  Several viruses used, like 
hepatitis B virus and West Nile virus, are extremely virulent in humans in their non-
attenuated forms.  The means by which these viruses were obtained would have been 
considered unethical under our current standards. Often, samples for therapy were 
derived from infectious body fluids or tissues from patients with active viral infections  
(reviewed in [69]).  As a result, not only was there a need for more defined standards for 
these trials but there was also a need for viral agents that were less toxic in humans.  The 
1990s brought with it a new age of discovery in molecular techniques such as 
recombinant DNA technology while interest in more novel cancer therapies in the 
research community grew.  A renewed focus developed in the field of oncolytic virology 
leading to the use of engineered viral vectors for treatment of cancer. Replication-
defective viruses, including engineered adenovirus and retrovirus vectors, were 
evaluated.  Unfortunately, these agents carried with them a number of problems including 
inadequate delivery and distribution within the tumor mass, and consequently, a lack of 
long-term efficacy.  A push for effective agents with less toxic profiles has led to studies 
using more attenuated forms of replication competent viruses, such as Herpes Simplex 
Virus (HSV), Conditionally Replicating Adenoviruses (CRAds), and paramyxoviruses 
like Newcastle Disease virus and measles viruses (reviewed in [69]) [70].  
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Examples and Mechanisms of Action  
 
Advantages of OV therapy include the ability to genetically modify or create 
“designer viruses” that have enhanced specificity for binding to and replicating in tumor 
cells.  A unique property of replicating viruses is their individual growth kinetics.  Their 
ability to replicate and produce viral progeny without re-administering additional virus is 
a kinetic advantage not possessed by conventional chemotherapy or by non-replicating 
viral vectors [70]. 
 
There are a number of viruses that have been and are currently being tested in 
both preclinical and clinical studies ranging from DNA to RNA viruses, animal to human 
viruses, and naturally occurring to genetically engineered viruses.  Each have there own 
advantages and disadvantages.  For instance, though sequelae of infection by human 
viruses such as HSV are well-recognized, the effects on therapy due to pre-existing 
immunity can potentially diminish efficacy of treatment.  On the other hand, many 
animal viruses have come to the forefront as potential therapies and while it is less likely 
that humans have come into contact with these viruses, the concern, though unlikely, of 
species adaptation causing pandemics as has been seen with swine influenza remains a 
consideration [79]. Concerning glioma, viruses from all categories are currently being 
considered as potential therapies.  As can be expected, the viruses with a longer history of 
use in cancer therapy such as HSV and AdV are further along in the clinical trial pipeline 
than others, however viruses such as VSV are beginning to emerge as plausible 
contenders.  A search on clinicaltrials.gov in January 2013 revealed at least 10 ongoing or 
completed phase I and II clinical trials of oncolytic virotherapy for GBM using a number 
of viruses from HSV to retrovirus (Table 1-3). 
 
 
Adenovirus 
 
Adenovirus (AdV) is a non-enveloped linear dsDNA virus belonging to the 
Mastadenovirus genus of the family, Adenoviridae.  AdV is commonly encountered in 
the human population especially in children under four years of age, and usually causes 
self-limited infections involving the upper respiratory tract, conjunctiva, and, less often, 
the gastrointestinal tract [80]. There are over 50 serotypes of AdV with serotype 5 being 
the most used as viral based therapies for cancer [81].  AdV is one of the more studied 
and understood oncolytic viruses and its ease of recovery and ability to alter virally coded 
proteins for tumor targeting serve as advantages of their therapeutic use [82, 83].  CRAds 
are engineered adenoviruses that harbor partial or complete deletion of viral genes 
unessential for replication in tumor cells. 
 
Onyx-15 is the first adenoviral vector in clinical trials for the treatment of glioma 
[84].  This vector lacks E1B-55kD gene, a gene thought initially to function by degrading 
cellular p53 therefore making its replication specific for transformed cells that lack p53 
activity [85].  However subsequent studies demonstrated that the most likely explanation 
for its oncolytic mechanism involves inhibition of intracellular RNA transport [86, 87]. A 
number of clinical trials for glioma have been carried out with AdVs.  Phase I studies  
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Table 1-3. Current oncolytic viral therapies in clinical trials for the treatment of GBM 
 
Virus 
(Vector) 
Characteristics Oncolytic 
Mechanism: 
Viral Factor/ 
Host Target 
Clinical 
Trials.gov 
IDa 
Delivery 
Methodb 
Phase Trial- 
Status 
Outcomesc References 
Adenovirus 
(Δ24-RGD) 
Family: 
Adenoviridae 
Structure: Non-
enveloped 
linear dsDNA 
E1A deletion/ 
pRB dys-
regulation 
Fiber knob?RGD 
motif/ CAR 
under-expression 
 
NCT-
01582516 
CED Phase I- 
recruiting 
Safety of 
intervention in 
recurrent GBM; 
PFS, OS at 6 
months 
[88-90] 
Adenovirus 
(Onyx-015) 
Family: 
Adenoviridae 
Structure: Non-
enveloped 
linear dsDNA 
E1B-55kDa 
deletion/ p53 dys-
regulation and/or 
RNA transport 
N/A i.t. Phase I- 
complete 
Intervention 
safe at MTD; 
Mild antitumor 
effect; 
4.9 mo median 
survival 
 
[84-87, 91] 
Herpes 
simplex 
virus 
(HSV1716)?
Family: 
Herpesviridae 
Structure: 
Enveloped 
linear dsDNA?
Deletion in 
ICP34.5 gene/ 
eIF2a regulated 
protein synthesis?
N/A? i.c. post-
resection?
Phase I-
complete 
Phase II- 
recruiting?
Phase I: 
Intervention 
safe at MTD; 
3 patients with 
PFS of 3 years; 
recovered virus 
from tumor 
Phase II: 
Efficacy in adult 
with recurrent 
GBM?
[92-95] 
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Table 1-3. Continued 
 
Virus 
(Vector) 
Characteristics Oncolytic 
Mechanism: 
Viral Factor/ 
Host Target 
Clinical 
Trials.gov 
IDa 
Delivery 
Methodb 
Phase Trial- 
Status 
Outcomesc References 
Herpes 
simplex 
virus 
(G207) 
Family: 
Herpesviridae 
Structure: 
enveloped 
linear dsDNA 
ICP34.5 deletion/ 
eIF2? regulated 
protein synthesis; 
UL39 replaced 
with lacZ reporter/ 
decreased neuro-
toxicity and 
increased 
sensitivity to 
antivirals  
NCT-
00028158 
NCT-
00157703 
(with 
radiation) 
 
i.t and i.c 
post-
resection 
 
Phase I/II- 
complete 
Phase I: 
Intervention 
was safe at 
MTD; modest 
increase in OS, 
PFS; virus 
recovered from 
tumor 
Phase I/II: 
Safety and 
effectiveness of 
intervention 
with radiation 
 
[96-101] 
Parvovirus 
(ParvOryx 
or H-1PV) 
?
Family: 
Parvoviridae 
Structure: non-
enveloped, 
ssDNA 
?
Naturally 
occurring/ IFN 
defects?
NCT-
01301430?
i.t + i.c. post-
resection 
versus i.v + 
i.c. post-
resection?
Phase I/IIa- 
recruiting?
Safety and 
efficacy of 
intervention in 
progressive 
primary or 
recurrent GBM; 
PFS, OS, and 
viral replication 
in tumor?
[102-107] 
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Table 1-3. Continued 
 
Virus 
(Vector) 
Characteristics Oncolytic 
Mechanism: 
Viral Factor/ 
Host Target 
Clinical 
Trials.gov 
IDa 
Delivery 
Methodb 
Phase Trial- 
Status 
Outcomesc References 
Newcastle 
disease virus 
(NDV-HUJ) 
Family: 
Paramyxo-
viridae 
Structure: 
Enveloped 
negative ssRNA 
 
Naturally 
occurring/ 
IFN defects; 
PKR and 
MxA 
deficiency 
NCT-
01174537 
i.v. Phase I/II- Not 
yet recruiting 
Phase I: 
Intervention 
was safe at 
MTD in 
recurrent 
GBM; 1 
permanent 
regression 
and 2 long 
term 
survivors 
Phase II: PFS 
in GBM 
 
[108-111] 
 
Reovirus 
(Reolysin)?
Family: 
Reoviridae 
Structure: 
Non-enveloped 
segmented 
dsRNA 
?
Naturally 
occurring/ 
overactive 
Ras pathway 
?
NCT-
00528684?
i.t.? Phase I/II- 
complete?
Phase I: 
Intervention 
was safe at 
MTD in 
refractory 
GBM; 1 long 
term survivor 
at 6 years 
Phase II: 
results 
pending?
[112-117] 
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Table 1-3. Continued 
 
Virus 
(Vector) 
Characteristics Oncolytic 
Mechanism: 
Viral Factor/ 
Host Target 
Clinical 
Trials.gov 
IDa 
Delivery 
Methodb 
Phase Trial- 
Status 
Outcomesc References 
Measles virus 
(MV-CEA) 
Family: 
Paramyxo-
viridae 
Structure: 
Enveloped 
negative ssRNA 
H protein of 
vaccine strain/ 
CD46 over-
expression 
P and V 
proteins/ 
Defective IFN 
pathway 
 
NCT-
00390299 
i.c post-
resection only 
versus i.t + i.c 
post-resection 
Phase I/II- 
complete 
Safety, PFS, 
and antiviral 
responses in 
recurrent 
glioma 
[118-123] 
Poliovirus 
(PVSRIPO)?
Family: 
Picornaviridae 
Structure: Non-
enveloped 
positive ssRNA 
?
Polio IRES? 
rhinovirus 
IRES/ 
decreased 
neuro-toxicity 
Necl-5 
(CD155) over-
expression 
NCT-
01491893?
CED? Phase I- 
recruiting?
Safety at 
MTD in 
recurrent 
GBM; PFS 
and OS?
[124-131] 
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Table 1-3. Continued 
 
Virus 
(Vector) 
Characteristics Oncolytic 
Mechanism: 
Viral Factor/ 
Host Target 
Clinical 
Trials.gov 
IDa 
Delivery 
Methodb 
Phase Trial- 
Status 
Outcomesc References 
Retrovirus 
(TOCA 511) 
Family: 
Retroviridae 
Structure: 
enveloped 
ssRNA 
Naturally 
occurring/ 
antiviral 
defects 
Cytosine 
deaminase 
insertion 
(5FC? 5FU) 
NCT-
01156584 
NCT-
01470794 
i.t. versus i.c. 
post-resection 
Phase I- 
recruiting 
Safety at 
MTD and 
efficacy in 
recurrent 
GBM; PFS at 
6 months 
[132-136] [50, 
137] 
 
 
a Keyword search on clinicaltrials.gov included glioma, glioblastoma, brain cancer, virus, oncolytic virus 
b CED, convection enhanced delivery; i.t, intratumoral; i.v, intravenous; i.c, intracranial 
cPFS, progression free survival; OS, overall survival; MTD, maximum tolerated dose 
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with Onyx-15 as adjuvant treatment for recurrent glioblastoma reported the virus to be 
well tolerated and safe at the maximum dose, however very little antitumor effect was 
observed with a median survival time of 4.9 months similar to the median survival of  
untreated patients (reviewed in [138] and [65]) [91].  There have been no additional  
clinical trials scheduled using Onyx-015 for GBM. However a modified version of the 
Onyx-015, H101, has completed Phase III trials and was approved in 2005 as an adjuvant 
therapy for the treatment of head and neck cancers in China.  H101, therefore, is the first 
oncolytic virus to be marketed for clinical use worldwide [139]. 
 
?24-RGD is another CRAd being studied as a potential therapy for GBM.  It is a 
genetically engineered vector that harbors a partial deletion of 24 base pairs in its E1A 
gene.  This deletion decreases its ability to bind to pRb so replication is permitted in cells 
with pRb defects.  Coxsackie adenovirus receptor (CAR), is a well known cellular 
receptor of many AdV serotypes and its expression has been found to be very low on 
tumor cells including glioma [140-142].  In order to bypass the need to interact with 
CAR, an alternative binding strategy used by a number of adenoviruses was inserted into 
the ?24-RGD.  The addition of the Arg-Gly-Asp (RGD) motif, known to interact with 
cellular ?v integrins, into the adenovirus fiber knob allowed this CrAd to maintain 
tropism in glioma cells in a CAR-independent fashion [88, 143].  In vivo testing of 
human glioma xenografts treated with ?24-RGD showed complete tumor regression in 9 
of 10 treated mice and increased survival in all treated mice.  These results were even 
more pronounced when viral treatment was preceded by tumor irradiation [89].  A phase 
I trial studying ?24-RGD in patients with recurrent glioma using convection enhanced 
delivery is ongoing [90].   
 
 
Herpes simplex virus 
 
HSV is an enveloped, linear dsDNA virus of the family, Herpesviridae.  Primary 
infection with HSV ranges from asymptomatic to gingivostomatitis.  It is known that 
HSV possesses a neurotropic phenotype, therefore, after initial infection, virus migrates 
through nerve endings to cranial ganglia where it remains latent.  Recurrent infections 
can manifest in a number of ways from perioral “fever” blisters, conjunctivitis, and Bell’s 
palsy, to more serious infections such as encephalitis.  HSV prevalence is high, with 
~90% of the population demonstrating seroconversion [144]. 
 
There are several advantages to using HSV as an oncolytic therapy.  It has been 
shown that HSV genes associated with neurovirulence are different from those having 
oncolytic properties which provides a means of genetic manipulation to create more 
oncolytic but less neurotropic viral vectors.  In addition, because of its sensitivity to anti-
viral drugs such as VCV and GCV, a naturally built-in safety mechanism can be used as 
precaution for uncontrolled HSV infection. Several disadvantages of HSV oncolysis 
include low production of viral progeny per cell as well as the high prevalence of 
previous infection in the adult population (reviewed in [83]). 
 
The first example of an HSV oncolytic virus is HSV1716.  It is a null mutant of  
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the gene coding for ?34.5 (ICP34.5), a virulence factor whose absence results in selective 
replication in dividing cells [92].  During viral infection, products of gene replication are 
sensed by double-stranded RNA- dependent protein kinase R (PKR) that, in turn, 
phosphorylates eIF2 into its active form, serving as an off switch of cellular protein 
synthesis.  ICP34.5 deactivates eIF2 by encouraging its dephosphorylation therefore 
allowing protein synthesis to continue. Without ICP34.5, normal cells can stop protein 
synthesis in the presence of viral infection.  Cells harboring defects in PKR or PKR 
related signals, such as the case with ras deregulated tumor cells, have unopposed protein 
synthesis in the presence of virus, allowing tumor selective replication [93, 145]. Several 
clinical trials have been carried out using HSV1716 including those looking at safety of 
intratumoral  (i.t.) injection pre-resection and intracranial injection post resection.  All 
trials demonstrated safety at the maximum dose without signs of neurotoxicity, a major 
concern with HSV related therapies.  Additionally, three patients experienced over 3 
years PFS and biological endpoints confirmed replication in tumor samples post-injection 
[94].  Phase II studies are currently being prepared in Europe using HSV1716 (Seprehvir) 
however no results have been reported to date [95]. 
 
Another HSV-based OV currently being evaluated in clinical trials is G207.  This 
virus harbors two separate genetic alterations, one being a deletion in the ICP34.5 coding 
gene, RL1.  The other alteration includes the silencing of the UL39 gene by insertion of 
LacZ.  UL39 is a gene that encodes a subunit of the viral ribonucleotide reductase (ICP6).  
Inactivation of this gene not only increases HSV susceptibility to antivirals such as GCV 
and VCV but also dampens its neurotropic phenotype, resulting in a virus unable to cause 
encephalitis.  Alterations in this gene, therefore, improve the safety profile of G207 over 
wildtype [96-98].  Previous phase I trials tested G207 by administering therapy in 2 
stages, 13% of dose was given by stereotactic injection and the remainder several days 
later at time of resection.  Results confirmed G207 to be safe with no signs of 
neurotoxicity at maximum dose.  Median time to progression was 3 months, with median 
overall survival of 23 months post-diagnosis, approximately 7 months after viral 
inoculation.  One patient experienced more than 5 years PFS, and this patient was found 
to have the highest viral load present in tumor samples collected at resection [99, 100, 
146].  Another Phase I trial was completed to determine synergistic effects of 
intratumoral G207 with either focal radiation or gamma knife surgery.  No results have 
been published to date [101]. 
 
 
Parvovirus 
 
Another DNA virus, newer in the clinical trial network for GBM, is parvovirus 
(Parvo), a small non-enveloped single-stranded DNA rodent virus surrounded by an 
icosahedral capsid. It is a member of the Parvoviridae family and represents a group of 
autologous parvoviruses that are able to replicate in and lyse tumor cells by several 
mechanisms.  First, they are able to replicate more efficiently in transformed cells as 
these cells, with their high proliferative rate, provide active factors important in DNA 
synthesis and transcriptional machinery.  These factors are crucial in the processing of 
Parvo replicative forms (RF), which are dsDNA formed during self primed DNA 
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synthesis and contain both parental and newly synthesized DNA strands [102, 147].  
Parvo is also able to inhibit IFN responses of transformed cells even after exposure to 
IFN inducers such as polyI:C by preventing the activation of specific pattern recognition 
receptors [103] .  Advantages of oncolytic parvo include its nonpathogenic phenotype in 
humans, usually only causing asymptomatic infection, unlike its relative, parvovirus B19.  
It has been shown to elicit viral replication in brain tumors following systemic 
administration, and replication is restricted to proliferating tissues.  On the other hand, 
difficulty of producing large quantities of parvovirus by co-transfection in helper-free 
virus-producing cells along with its immaturity in clinical trials threaten to limit its  
oncolytic potential (reviewed in [148]).   
 
The most studied parvovirus for treatment of glioma includes the naturally 
occurring virus, H-1PV (ParvOryx).  Preclinical studies have demonstrated its ability to 
infect glioma cells with strong cytotoxic effects [105, 149].  In vivo experiments using a 
rat glioma model, following either a single i.t. injection or multiple i.v. injections of 
ParvOryx, results showed tumor regression, a significant increase in survival, and 
evidence of viral presence in brain tumors confirming its ability to cross the BBB after 
systemic administration [106].  An ongoing Phase I/II trial of ParvOryx in patients with 
progressive primary or recurrent tumors is coming to a close and has been focused on 
determining safety and MTD in groups receiving either an initial i.t. or i.v. injection both 
followed by injection to post-resection tumor bed.  These results will be the first of any 
trial evaluating a parvovirus in patients with recurrent GBM [107]. 
 
 
Newcastle disease virus 
 
 In addition to DNA viruses, there are a number of RNA viruses that are being 
considered as treatment for GBM and are currently in varying stages of clinical trials. 
These include both naturally occurring and genetically engineered RNA viruses.  
Newcastle Disease virus (NDV) is an avian paramyxovirus of the order, 
Mononegavirales, therefore it characteristically contains a negative-sense ssRNA genome 
which codes for pleiomorphic viral particles. Though NDV is primarily a disease-causing 
agent of fowl, it has a broad host range and has been shown to infect cells of other 
species including murine and human cells [150].  Two naturally occurring, non-
engineered strains of NDV have been studied in Phase I clinical trials for glioma, NDV-
HUJ which is non-pathogenic in avian hosts (lentogenic), and the moderately pathogenic 
(mesogenic) MTH68/H strain.  Their mechanism of oncolysis has been attributed to the 
ability to exploit interferon defects in tumor cells (reviewed in [63]). Several studies have 
been geared toward improving their oncolytic activity through genetic manipulation of 
NDVs anti-IFN genes allowing for robust IFN production in normal cells leaving IFN 
defective tumor cells vulnerable to viral infection [108].   
 
Advantages of NDV oncolytic therapy include its safety profile when given 
intravenously.  Because its natural host is avian, there is no pre-established immunity to 
virus in humans.  NDV is a naturally occurring oncolytic virus and produces large 
numbers of progeny per infected cell. Disadvantages to therapy include the risk of species 
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adaptation and its high mutation rate, a characteristic of all RNA viruses [83].  Phase I 
trials have been completed using the NDV-HUJ strain in patients with recurrent GBM.  
NDV-HUJ is a gradient purified virus derived from an attenuated vaccine strain [109].  
Patients received daily i.v. injections, 5 days/week until one year of tumor progression 
was observed.  Results showed virus to be well-tolerated with no signs of toxicity other 
than transient fever associated with infection. One patient displayed complete but not 
permanent regression while this patient and 2 others experienced long term survival, 
living approximately 15 months with recurrent disease after viral treatment [109, 138].  A 
phase II trial of NDV-HUJ in recurrent glioma is ongoing and has extended the use of  
oncolytic treatment to sarcoma and neuroblastoma patients as well [111].   
 
 
Reovirus 
 
Reovirus is a non-enveloped virus with a segmented, dsRNA genome.  It is of the 
family, Reoviridae, along with its relative, rotavirus, an important enteric virus causing 
substantial disease of the gastrointestinal tract in humans.  Reovirus, on the other hand, 
causes milder GI symptoms, which usually resolve without intervention [151]. It is a 
naturally occurring oncolytic virus whose oncolytic activity stems from its ability to 
exploit cells with overactive ras or ras- signaling [112, 113]. In many cancer cells, 
upregulation of ras confers a resistance to cell death; however, this results in inhibition of 
active PKR, responsible for cellular protein shut off during viral infection [64, 112].  
Advantages of reoviral therapy include its safe profile when administered in the brain 
[114], its naturally occurring anti tumor activity through cell specific mutations to ras 
signaling, its high progeny: cell ratio, and the fact that all genes in the viral genome have 
known functions.  Disadvantages to therapy include pre-immunity in the human 
population and its high rate of mutation during replication cycles (reviewed in [83]) 
[115]). 
 
In preclinical studies, reovirus was found to inhibit growth of ipsilateral tumors in 
immunocompetent glioma rat models despite the presence of pre-existing immunity.  
Virus safety was also confirmed in non-human primates by the lack of significant toxicity 
following intracranial inoculation [114].  Reolysin, the non-attenuated Type 3 Dearing 
strain of reovirus, has been tested as an adjuvant therapy in phase I trials at doses ranging 
from 107-1010 in patients with refractory GBM.  Results showed treatment to be well 
tolerated and safe at the maximum dose delivered.  Median survival was 21 weeks with 
one patient still living at six years post treatment according to latest updates [116, 138].  
Phase II of this series has been completed using the highest dose reached from phase I 
however no results have been published to date [117]. 
 
 
Measles virus 
 
Measles virus (MV) is an enveloped, negative strand RNA virus belonging to the 
Morbillivirus genus of the family, Paramyxoviridae. It is known to be a highly infectious 
human pathogen transmitted by respiratory droplets from infected individuals.  Flu-like 
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symptoms usually occur within 10 days and progress to the characteristic maculopapular 
rash.  Small white lesions called Koplik’s spots can often be seen on the buccal mucosa 
before the development of rash [152].  With the advent of vaccination programs for 
prevention of the spread of measles, endemic transmission has been eradicated from the 
Americas since 2002 though outbreaks continue to occur worldwide [153, 154].  
 
The replication cycle of measles involves binding of viral haemagglutinin (H) 
protein to a predominantly B and T lymphocyte receptor, SLAM (signaling lymphocytic-
activation molecule) [118]. Attenuated forms of MV such as that derived from the 
Edmonston B vaccine, predominantly bind to CD46, a complement-regulatory protein 
[119] important in the protection of cells against complement-mediated lysis.  Cells 
independent of SLAM and CD46 signaling, specifically those of epithelial origin, have 
been shown to use Nectin4 for receptor activity during MV infection [155, 156].  As 
such, both CD46 and Nectin4 are often overexpressed in tumors, with CD46 shown to be 
overexpressed in glioma [157-161].  By targeting tumor specific overexpression of MV 
specific receptors, measles virus can be considered a naturally occurring oncolytic virus.  
MV-CEA is an example of an attenuated strain, which has been genetically engineered to 
express human carcinoembryonic antigen (CEA).  CEA is a tumor marker highly 
expressed in cancers ranging from colorectal to pancreatic carcinomas, however CEA 
overexpression has not been observed in gliomas.  For this reason, its presence in sera of 
patients infected with the MV-CEA construct serves as a monitor of viral gene expression 
[120].  Advantages of measles therapy include its wide host range and ability of 
attenuated virus to selectively replicate in tumor cells based on naturally acquired 
mutations in the viral attachment protein [115]. Attenuated strains are considered to have 
preferred safety profiles based on the extensive history of their use in vaccination 
programs that have improved morbidity and mortality worldwide [83].  On the other 
hand, despite altered attachment proteins, virus may still be able to bind to CD46 and 
SLAM on normal cells. This serves as a disadvantage in using measles virus as a cancer 
therapy since SLAM signaling during measles infection has been shown to facilitate 
transient immunosuppression [162].  In addition, much of the population has been 
vaccinated against the virus therefore strong immune responses directed against the H 
protein may be experienced [152].  Lastly, as with replication of most RNA viruses, 
measles has a high mutation rate due to the error-prone RNA-dependent RNA 
polymerase that could potentially alter selectivity during treatment.  
 
In vitro experiments with MV-CEA have demonstrated strong antitumor effects 
against glioma cells, which have translated into antitumor activity in subcutaneous and 
orthotopic U87 glioma animal models.  Further in vivo studies of MV-CEA in an 
orthotopic glioma model in macaque monkeys found the vector to be safe, causing no 
neurotoxicity when given intracranially [122].  An ongoing phase I trial is evaluating 
safety and MTD of MV-CEA following i.t. injection versus i.t. injection administered 
post-resection in patients with recurrent glioblastoma.  There have been no reported 
preliminary results however the study will tentatively be completed by June 2013 [123].   
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Poliovirus 
 
Another RNA virus being considered as therapy for GBM is poliovirus, a 
pathogen notorious for causing disease worldwide before the launch of a global initiative 
in the 1980’s resulted in its eradication from the Americas in 2002 [163].  Poliovirus 
(polio) is a non-enveloped +ssRNA enterovirus belonging to the family, Picornaviridae 
[164].  Polio is transmitted by fecal-oral route and usually causes asymptomatic infection 
in the majority of cases.  In instances when virus is not cleared, polio can spread through 
the blood to other sites including the CNS.  Because polio is naturally neurovirulent, 
destruction of motor neurons can cause poliomyelitis manifesting as flaccid paralysis that 
may lead to death if control of respiratory function is affected [124].  As an RNA virus, 
the replication cycle occurs exclusively in the cytoplasm of host cells.  Polio genome 
characteristically includes an important segment of RNA known as the internal ribosome 
entry site (IRES) from where one open reading frame initiates coding of a large precursor 
polypeptide that is further cleaved into the virus’s eleven proteins [115, 164]. 
 
There are several important components to polio’s oncolytic activity, the first 
involving its cellular binding receptor, CD155 (or Necl-5) [124].  Necl-5 has been shown 
to be over-expressed in a number of tumor cells including cancers of glial, breast, and 
hepatocellular origin [125, 165].  The other component of polio’s oncolytic activity 
involves the manner in which the virus is able to recruit host cell machinery for its 
benefit.  Polio uses a 5’cap independent protein translation mechanism so during its 
replication cycle, the virus must seize host cell machinery in order to form new viral 
progeny.  This is done through the actions of 2A protease (2Apro), which is able to 
cleave the scaffold (eIF4G) connecting eukaryotic mRNA 5’cap to ribosomes.  These 
cleaved scaffold fragments are then free to aid in linking the polio IRES to cellular 
ribosomes for its own translational benefit.  This takeover subsequently leads to 
inhibition of translational dependent antiviral responses and rapid cytopathic effects can 
be detected as soon as 2-3 hours post-infection [126].   
 
Many cancers with their increased need for protein synthesis in order to maintain 
their uninhibited growth have been shown to have cap-independent translation 
mechanisms [166].  Along with this independence, some tumor cells appear to have less 
control over recruitment of ribosomes to viral RNA as a number of cellular proteins 
involved in seizing viral genomes are mislocated to the nucleus and not in the cytoplasm 
where viral replication actually occurs [167].  In addition, several studies have shown that 
inhibitors of many deregulated mitogen pathways in cancers such as EGFR, which are 
known to be interconnected with eIF4G, decrease poliovirus translation and cytotoxicity 
in GBM cells [168].  This serves as another example of how deregulation of pathways 
during tumorigenesis affects susceptibility to viral infection.   
 
The construct used in preclinical and clinical studies is the PVSRIPO.  In order to 
minimize neurovirulence in normal CNS, the poliovirus IRES is exchanged for the IRES 
present in human rhinovirus type 2 (HRV2), a known pathogen of the human respiratory 
tract.  The resulting construct is a polio/rhinovirus chimera known as RIPO.  PVSRIPO 
was derived from using an attenuated Serotype 1 Sabin vaccine poliovirus instead of 
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wildtype virus [128, 169].  Advantages to poliovirus cancer therapy include its ability to 
be easily engineered especially in manipulating genes known to contribute to 
neurovirulence.  The neuro-attenuated construct, PVSRIPO, quickly kills cells with 
accelerated growth rates such as transformed cells [129].  Disadvantages include the 
extensive patient population that have already been immunized against polio however 
preclinical studies have revealed that oncolysis is not decreased by pre-existing immunity 
in animal models [124, 130].  Also, its error-prone RNA-dependent RNA polymerase has 
been shown to cause revertants implicated in poliomyelitis following vaccination.  By 
using the PVSRIPO construct with replacement of polio IRES, the known target for 
mutation in revertants, the chances of this occurring is unlikely [170].  A phase I trial is 
currently evaluating the use of PVSRIPO administered by CED in patients with recurrent 
glioma.  Outcomes to be determined include safety, maximum tolerated dose, 
progression-free survival and overall survival [131]. 
 
 
Retrovirus 
 
The last virus being considered in clinical trials for the treatment of GBM are 
retroviruses, which are enveloped ssRNA virus of the family Retroviridae.  This family 
of viruses has until recently been a less popular alternative for replicating viral therapy 
against brain tumors as it defies several important characteristics of other OVs.  First, an 
important feature of retroviruses, particularly replicating retroviral vectors (RVVs) is 
their unique replication cycle.  In order for replication of the RNA genome to occur, the 
retrovirus carries with it a reverse transcriptase that synthesizes a DNA replication 
intermediate from its RNA genome.  The intermediate is integrated into the host cell 
genome for subsequent transcription and translation using the host cell machinery.  A 
property of oncolytic viruses, as the name implies, is their ability to lyse tumor cells. 
RVVs however are non-lytic, a direct result of their need to integrate into the host 
genome (reviewed in [83]).  Integration is also known to be an important feature of 
retroviral-induced tumorigenesis. 
 
Approximately 11% of human cancers are caused by viral infections.  
Malignancies, such as lymphoma and sarcoma, have been associated specifically with 
retroviral infection [171].  Insertional mutagenesis has also proven to be an issue in 
previous gene therapy trials using replication defective retroviral vectors.  For instance, 
clinical trials for several X-linked immune diseases such as Severe Combined 
Immunodeficiency (SCID) and Wiskott-Aldrich Syndrome (WAS) resulted in 
development of acute T lymphoblastic leukemia (T-ALL) after DNA intermediates 
integrated into the host genome in close proximity to proto-oncogenes [132, 172-174].  
Therefore, the use of these viruses to treat cancer may appear to be more of a risk than a 
benefit.   
 
As we know, however, there are a number of advantages to retroviral therapy. 
First, RVV constructs, particularly those being considered for treatment of glioma, have 
two mechanisms of targeting tumor cells; they are selective for dividing cells as they do 
not contain nuclear localization signals necessary for active nuclear uptake in quiescent 
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cells [133, 175] and they selectively replicate in cells harboring defects in their antiviral 
responses.  RVVs are less immunogenic in the CNS where virus-infected cells have been 
shown to escape antiviral responses [176].  As a consequence of integration into the host 
genome, RVVs maintain a persistent infection in tumor cells, which act as a storage for 
virus that can be called upon to replicate at later times [83, 134, 175]. 
 
The most studied retrovirus for treatment of cancer is the simple 
gammaretrovirus, amphotropic murine leukemia virus (A-MLV).  Derived from this 
prototypical retrovirus is the construct Toca511, which has been genetically engineered to 
express the yeast enzyme, cytosine deaminase (CD) that converts the anticancer pro-drug 
5-fluorocytosine (5-FC) to its active form, 5-fluorouracil (5-FU).  Toca511 is the most 
used construct in preclinical and clinical trials for GBM and is a great example of an OV 
that functions by a suicide gene/pro-drug combination [56, 135].  Preclinical studies 
using an orthotopic mouse GBM xenograft model demonstrated survival of 90% of 
treated mice at ~100 days post-infection versus 40 days in controls [133].  In two 
different syngeneic immunocompetent mouse GBM models (CT26 in BALB/c mice and 
Tu-2449 in B6C3F1 mice), survival was significantly increased in BALB/c mice from 
30.5 days in controls to >90 days and from 33 days to > 180 days in B6C3F1 mice.  
Subsequent rounds of 5-FC pro-drug prolonged survival even without having to 
administer more retrovirus proving its stability after incorporation into the host genome. 
Even before the last cycle of pro-drug, tumors shrank until they were no longer detected 
microscopically [134].  Until recently, only one phase trial has been performed using a 
retrovirus for treatment of GBM.  This phase III trial, unfortunately, was unsuccessful 
most likely due to the use of a replication defective construct [136].  There are two 
ongoing phase I trials evaluating replication competent Toca 511 for the treatment of 
recurrent high-grade glioma using either intratumoral injection followed by 
administration of 5-FC [50] or post-resection injection followed by 5-FC [137].  The 
study is planned to complete in December of 2013. 
 
 
Future of Oncolytic Therapy: Challenges to Overcome 
 
As more oncolytic viruses are considered for use in cancer therapy, several 
important challenges in achieving optimal efficacy will need to be addressed as they have 
proven to be a barrier in moving therapies through the clinical trial pipeline (Figure 1-3).  
The first challenge is that of finding the most effective delivery of treatment in order to 
maintain tumor cytotoxicity.  This challenge is not necessarily unique to OV therapy, as a 
number of problems exist with the administration of chemotherapeutic agents, which 
have led to more experimental methods for administering treatment such as CED or 
polymer wafers.  One method of delivery for OV therapy includes single or multiple 
intratumoral injections.  Tissue analysis following injection often shows very little spread 
of virus within the tumor mass with most virus concentrated near the injection site [177].  
Aside from high interstitial pressure exerted by tumor mass [178], the unique tumor 
microenvironment often plays a significant role in impeding the spread of virus.  This 
microenvironment is composed not only of surrounding tumor, normal brain, and 
patrolling inflammatory cells but also players in promoting angiogenesis, growth factors,  
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Figure 1-3. Challenges of oncolytic viral therapy 
Oncolytic viruses encounter a number of obstacles in achieving therapeutic efficacy.  
These include uptake and ultimately clearance by immune mediated cells in the systemic 
circulation as well as neutralization by viral specific antibodies.  The tumor 
microenvironment can also serve as a hindrance to viral oncolysis.  For instance, 
increased pressure secondary to tumor mass and associated inflammation impede the 
intratumoral infusion of virus.  Elements of the extracellular matrix such as collagen may 
also prevent migration by sequestering virus before it reaches tumor. 
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and components of the extracellular matrix (ECM).  Collagen, a major component of the 
ECM, forms protein networks that act as physical barriers to viral penetration often 
sequestering virions before they can reach less superficial tumor cells.  Several OVs have 
been developed that express genes specific for combating this barrier such as a 
replication restricted adenovirus expressing collagen cleaving proteins, matrix 
metalloproteinases (MMPs) [179].  Co-treatment of OV with collagenase has been shown 
to be effective as well [180].   
 
Just as intravenous administration of chemotherapies result in suboptimal delivery 
due to the blood brain barrier along with drug metabolism and clearance (reviewed in  
[181]), OV therapy can be hindered also by the same factors (reviewed in [182, 183]). 
Intravenous administration exposes virus to circulating cells and factors of systemic host 
immunity that further inhibit therapy.  Though an extremely convenient method as it does 
not require an invasive procedure for administration, i.v. delivery often causes premature 
neutralization of virus even before virus is able to reach its target [184, 185].  These 
antiviral responses are also associated with morbidity in patients as seen by fever, altered 
mental status, and other signs and symptoms encountered in a number of OV trials [65, 
184, 185].  Exposure to the immune system is one of the most vexing challenges faced by 
viral therapy as it can be both a benefit and impairment to treatment.  Unfortunately, 
preclinical studies have not always been designed in a way to completely understand the 
involvement of the immune system in OV therapy.  Many preclinical studies have 
utilized immunocompromised animal models to show proof of principle of viral therapy 
in human-derived tumors [86, 186].  As we have seen, though antitumor effect is 
significant in these models, this often does not translate into tumor shrinkage in human 
trials.  Though the immune system can be suppressed in glioma patients, immunity still 
has an effect on therapeutic efficacy of virus when given intratumorally and systemically.  
In a preclinical study using an immunocompetent animal model of metastatic lung cancer 
to evaluate vesicular stomatitis virus (VSV) as cancer therapy, neutralization of i.v. 
administered virus by circulating antibodies was shown to eliminate delivery of 
unshielded “naked” virions to tumors [65, 187].  Several studies have tested a number of 
methods for circumventing the immune system.  One method uses a “cloaking device” 
which coats virus with chemical conjugates preventing binding of complement and/or 
uptake by immune cells [188].  Temporarily ablating the immune system is another 
option and several studies have looked at simultaneous administration of 
immunosuppressing agents.  Cyclophosphamide (CPA) is a multifunctional nitrogen 
mustard alkylating agent used as an anticancer drug and in the prevention of graft versus 
host disease.  Its immunosuppressive activity has been shown to be caused by the ability 
to deplete proliferating lymphocytes [189-192].  Rapamycin is another 
immunosuppressant that works by inhibiting mTORC1, a pro-tumor signaling pathway 
found to stimulate innate immune responses through type I IFN.  It has been shown in a 
number of preclinical trials to increase viral replication and positive outcomes when 
given in combination with OV therapies such as VSV, myxoma virus (Myxv), and 
vaccinia virus (JX-594) [177, 193, 194].  
 
An even more novel approach involves shielding virus from the immune system 
through the use of cellular vehicles.  Many different cell types have been used as cell 
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carriers and include T lymphocytes, mesenchymal progenitor cells, and neural stem cells 
all showing an affinity for growth within tumor or for the tumor microenvironment.  
These cells are usually infected, ex vivo, and readministered systemically for viral 
transport.  Upon infection, viruses can be transported by adhering to the surface of carrier 
cells, as has been shown with retroviral vectors.  Adherence to the surface, however, 
eliminates the ability of the cell carrier to amplify viral dose through active viral 
replication [195].  Virus can also be transported to sites of tumor by using cells 
permissive to viral replication.  This allows the cell to serve as a viral factory increasing 
the amount of virus while en route [187, 196-199].  Autologous tumor cells are currently 
being evaluated for their use as viral carriers. Host derived tumor cells, the actual targets 
of OVs, instinctively home to sites of pre-existing cancer.  They are highly permissive to 
viral replication and are able to increase original dose of virus by the time they reach the 
tumor site (Figure 1-4).  In a syngeneic model of lung cancer in immunocompetent 
animals, i.v. administration of 106 tumor cells infected with VSV at a multiplicity of 
infection (MOI) of 10 were able to amplify viral dose by a 105 at 24 hours post infection 
versus 102.5 with naked virions [187].  Though this method has sparked some controversy 
based on existing safety standards and the possibility of seeding tumor in other locations, 
preclinical results have been promising and in comparison to naked viral therapy in the 
face of pre-existing immunity, virus-carrying cells were shown to substantially improve 
survival in animals with established lung tumors, with majority of animals surviving 
>100 days post-treatment [65, 187].   
  
Another method for increasing tumor cytotoxicity includes increasing immune 
responses that are directed against tumor antigens.  Gliomas are known to be 
immunogenic as they possess a number of tumor-associated antigens (TAAs) that can 
elicit immune responses triggering the influx of various immune cells within and 
surrounding tumors.  Just as we have seen with viruses, tumors often develop ways to 
evade immune surveillance and responses either by secreting immunosuppressive 
molecules that dampen immunity (i.e. TGF? which has been found to upregulate 
regulatory T cells) [200-202], by shielding TAAs from patrolling immunity, or by the 
dysfunction in mechanisms involved in immunological activation [203].  
 
Oncolytic viruses can ignite otherwise weak antitumor immune responses.  A 
phase I trial of the HSV construct, G207, for recurrent GBM demonstrated the ability of 
this OV to increase glioma-infiltrating immunocytes (GIIs) in treated patients [99, 138].  
Viruses can also be used to modify tumor cells making them more detectable to the 
immune system.  By using autologous tumor cells as vehicles, the same method that 
provides an advantage of shielding virus from adaptive immune responses, virally-
modified tumor or viral oncolysate have been shown to also induce an immune response 
against unmodified tumor cells from which they are derived.  Several tumor models have 
tested this feature using a variety of viruses ranging from influenza, vaccinia, and NDV 
[204] for treatment of a number of cancers such as melanoma and glioma.  A phase II 
study initiated in 1975 using NDV oncolysate as a post-surgery adjuvant vaccine in 
patients with AJCC stage III melanoma has shown a >55% survival rate at 15 years from 
vaccine administration.  By analyzing the immune repertoire of surviving patients, an 
increased CD8+ T cell subset representing terminally differentiated effector cells based  
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Figure 1-4. Carrier cell strategy 
Outlined procedure involved in isolating autologous tumor cells from primary tumor 
mass and using cells as infected vehicles for the delivery of oncolytic viruses 
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on their heightened ability to produce TNF-? and IFN-?  were associated with antitumor 
effect and survival [205].  A more recent Phase I study in 2004 tested the use of irradiated 
autologous tumor cells as carriers for recombinant Newcastle disease virus (rNDV) as 
treatment for GBM.  Results showed OS of 100 weeks versus 49 weeks in controls with 
39% two year survival versus 11% in untreated.  Increased immune activity directed 
against tumor was observed in vaccinated patients by an increase in CD8+ tumor 
infiltrating lymphocytes (TIL) and memory T cell reactivity (demonstrated by IFN-? 
ELISPOT assay) [206].  As demonstrated, these key inflammatory responses are crucial 
to long-term survival and anti-tumor activity even after virus has been cleared [45]. More 
studies will be needed to further evaluate this method of delivery however preliminary 
results are promising. 
 
 
Vesicular Stomatitis Virus 
 
 
Characterization 
 
 In addition to the previously mentioned viruses that have been or are currently 
being evaluated in clinical trials for GBM, there are a number of up and coming viral 
agents that have shown promise in preclinical animal studies as well as in clinical trials 
for a number of other cancers.  One such agent is vesicular stomatitis virus (VSV).  VSV 
belongs to the order, Mononegavirales, an order of characteristically enveloped viruses 
possessing non-segmented negative sense, single stranded RNA (NNS RNA) genomes.  
Included in this order are the families Paramyxoviridae, Bornaviridae, Filoviridae, and 
Rhabdoviridae (Figure 1-5).   
 
A number of important human pathogens belong to these families and include 
respiratory syncytial virus (RSV) of the Paramyxoviridae family, Ebolavirus of the 
Filoviridae family, and Borna disease virus of the Bornaviridae family [207, 208].  VSV 
is a member of the Rhabdoviridae family, the simplest of Mononegavirales viruses.  
Much of what is known about replication and transcription of these viruses has been 
determined through studies of Rhabdoviruses particularly, VSV.  The two major genera 
of rhabdoviruses known to infect mammals are vesiculovirus, of which VSV is the 
prototype, and lyssavirus, of which rabies virus (RABV) serves as the prototype [207].  
Lyssavirus genus is made up of not only RABV but also rabies like viruses which are all 
zoonotic pathogens causing usually fatal encephalitis in animals [209].  Though RABV 
and VSV share very similar structural and genetic makeup as members of the same viral 
family, disease sequelae from their respective natural infections are very different, with 
RABV causing a slow and almost uniformly fatal and destructive disease and VSV 
causing an acute and generally mild disease with rare neurological symptoms [210].  
 
Rhabdoviruses infect a wide range of hosts from vertebrates and invertebrates to 
plants.  Aside from a few species including rabies that primarily infect vertebrates, most 
other rhabdoviruses, including VSV, are considered arboviruses, requiring transmission 
via arthropod hosts such as blackflies, sandflies, and mosquitoes.  There are several VSV  
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Figure 1-5. Select representatives of the order, Mononegavirales 
Source: Ictvonline.org- International Committee on Taxonomy for Viruses 
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serotypes found worldwide; however, two distinct serotypes are predominantly found 
within the Americas, which include New Jersey (VSV-NJ) and Indiana (VSV-IND).  The 
most prevalent serotype is VSV-NJ, accounting for ~80% of natural infections [211, 
212].  These serotypes share approximately 50% amino acid sequence homology and 
infection of one serotype does not confer protection against future infection of the other 
[207, 213]. 
 
 
Disease Manifestations and Modes of Transmission 
 
Vesicular stomatitis (VS) is the disease caused by VSV infection and presents as 
an acute, nonfatal, but debilitating disease in cattle, swine, and horses.  Signs of infection  
in animals include formation of fluid-filled vesicular lesions of the mouth, tongue, 
hooves, and teats [214], which often coalesce and rupture leaving areas of painful 
ulcerations that may cause infected animals to refuse food and water.  Eventually, 
animals experience severe weight loss with lowered milk production and productivity 
[215].  Manifestations of VS are often confused with foot and mouth disease, another 
infection of livestock caused by the picornavirus, foot and mouth virus.  This disease is 
known to be more debilitating therefore establishing the correct diagnosis is paramount as 
it can have unfavorable agricultural and economical consequences if spread of infection 
is not controlled.  Geographically, VS is more prevalent in areas surrounding the borders 
of Central and South America with outbreaks occurring seasonally, during warmer 
temperatures [212].  In the United States, outbreaks typically occur every 10 years 
however, within the last decade, they have been more consistent with bursts of infection 
observed almost annually since 2005 [216]. 
 
As noted, VSV is an arbovirus, therefore, natural infection of vertebrate hosts 
follows the bite of an infected insect.  Additional modes of transmission may occur and 
include aerosolization or contact with skin lesions of the infected.  Experimental 
inoculation of livestock can cause clinically relevant disease that is dose dependent and 
varies based on route of administration.  Viremia in experimentally inoculated livestock 
is rare but possible [217]. On the other hand, experimental inoculation of mice results in 
viremia and often death due to encephalitis depending on age of animal (adult versus 
nestling) and route of administration [212, 218-220]. 
 
VSV is not considered a major human pathogen, unlike its close relative, rabv, or 
other vesiculoviruses found worldwide such as Chandipura virus and Isfahan virus [221, 
222].  Resulting from its broad tropism, the virus can infect humans, however, infection 
is usually asymptomatic or may manifest as mild flu-like symptoms.  Seroconversion is 
rarely detected in the general population and those with positive serology usually have 
either a history of exposure to infected cattle or have handled virus in a lab setting [207]. 
 
 
    35 
VSV Structure 
 
Due to its simplicity, VSV has been the most extensively studied virus in its order 
and these studies have provided much of what is presently known about the life cycle of 
Mononegavirales as a whole.  Other attributes of VSV that deem it the prototype of 
Rhabdoviruses aside from its simple genome include its broad cell tropism and high 
yields in cell culture [207].  The VSV genome consists of 11.2 kilobases (kb), which 
serially transcribes 5 monocistronic mRNAs used to translate the 5 major viral proteins: 
the nucleoprotein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein 
(G), and the large RNA polymerase (L) (Figure 1-6). 
 
As most Rhabdoviruses, excluding some bacillus shaped plant Rhabdoviruses, 
mature VSV virions have a characteristic bullet shape measuring 180nm x 75 nm.  These 
virions acquire an envelope composed of the host cell membrane from which they bud.  
Embedded in and protruding from the envelope are G proteins arranged in trimeric 
spikes.  Surrounded by the envelope is a core ribonucleoprotein (RNP) composed of the 
NNS RNA genome encapsidated by N proteins keeping the genome compact hence 
resistant to cellular RNase.  Molecules of viral M protein are attached to the inside leaflet 
of the viral envelope between the membrane and the nucleocapsid core keeping the RNP 
in a rigid helical formation [207].  The RNA-dependent RNA polymerase (RdRp) is a 
complex formed by the P and L proteins (L-P3 complex) during transcription and L, N, 
and P (L-N-P complex) proteins during replication.  The active RdRp is also responsible 
for additional processing of transcripts which include the addition and methylation of a 
5?-cap and addition of a 3?-poly(A) tail (reviewed in [207, 223]. 
 
 
VSV Replication Cycle  
 
As with most RNA viruses, the replication cycle of VSV occurs exclusively in the 
cytoplasm.  Each VSV structural protein plays an important role in these events 
beginning with adsorption of virus at the cell membrane, followed by entry and 
uncoating, transcription, replication, assembly, and finally culminating with budding of 
infectious particles from the host cell.   
 
Specifically, binding of virions to the host cell surface occurs between viral 
glycoprotein and a universally expressed host cell receptor [207].  Phosphatidylserine 
(PS) was previously considered as the possible cellular receptor, however newer data 
challenge this proposal with one study suggesting the role of the endoplasmic reticulum 
chaperone protein gp96 as a facilitator of viral attachment with host cells [224-227].  
Following adsorption, virus is endocytosed through a clathrin-dependent receptor-
mediated pathway.  As virus is exposed to decreasing pH during endocytosis, G protein 
undergoes a conformational change resulting in fusion of the viral envelope and 
endosomal membranes.  As virus traffics through endosomal compartments, M releases 
its rigid hold on the RNP while remaining bound to the endosomal membrane allowing 
the RNP core to then be released into the cytoplasm [228].  This uncoating step leaves the 
RNP available for transcription by the pre-packaged RdRp in order for synthesis of new 
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Figure 1-6. Vesicular stomatitis virus 
Schematic of the characteristic bullet-shaped vesicular stomatitis virion, depicting the 
layout of the 11.2 kilobase negative single stranded RNA viral genome from 3’ to 5’.   
N, nucleocapsid; P, phosphoprotein; M, matrix; G, glycoprotein; L, large RNA 
polymerase 
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viral proteins needed for subsequent rounds of transcription and ultimately replication.  
Directionality of transcription of the negative sense RNA genome by the active 
polymerase occurs uninterrupted from 3’ to 5’ in the specific order of 3’(l)-N-P-M-G-L-
(t)5’ with the first event being synthesis of the 47 nucleotide RNA leader sequence, l, 
located in the 3’ untranslated region (UTR)of the genome.  This sequence is responsible 
for encouraging transcription of viral genes.  The last event involves transcription of the 
trailer sequence, t, located in the 5’ UTR.  As mentioned, each mRNA contains a 5’ cap 
and terminate with a poly(A) tail.  Transcriptional attenuation occurs with an 
approximately 20% to 30% decrease of transcript synthesis at each contiguous gene 
junction.  This results in a gradient of mRNA from the more abundant 3’ located N 
transcript to the least abundant 5’ located L transcript (reviewed in [207]. 
 
In addition to its role in transcription, RdRp is responsible for making new 
genome that can be used for amplifying transcription and for packaging into new virions.  
Therefore, a transitional product involving a positive-sense, antigenome replication 
intermediate (RI) is made by the RdRp for this purpose.  Once message is made and 
newly synthesized N and P accumulate, then genome replication can occur [207].  Next 
assembly of new virions ensues as newly synthesized genomes are encapsidated and then 
condensed into a skeleton form.  The recent 3D constructed image by cryo-electron 
microscopy of the VSV virion has revealed that assembly is initiated at the tip of the 
bullet shaped virion with M serving as a facilitator through its multiple interactions with 
neighboring M proteins, overlying plasma membrane, and the underlying RNP [229].  
The ultimate step in the life cycle is budding of newly made, mature virions preferentially 
from the basolateral surface of infected epithelial cells [230, 231].  These areas have been 
found to harbor G protein containing lipid domains [232] along with higher 
concentrations of membrane bound M protein [233] and cellular budding machinery 
[231, 234].  As these new virions are released from the cell, they attain a new envelope 
derived from the host cell membrane [207]. 
 
 
The Multifunctional Matrix Protein  
 
In order to promote quick and efficient replication, a number of viruses encode for 
proteins that have multiple functions in the viral life cycle [46, 235, 236].  One such 
example for VSV is the matrix protein (Figure 1-7).  M is comprised of only 229 amino 
acids making it the smallest of virally encoded proteins weighing in at 26kDa. Though it 
is the smallest, it is also the most abundant protein in the VS virion and participates in 
many aspects of the viral life cycle from assembly to budding [207].  In addition to the 
full-length matrix protein, M1, VSV expresses two additional shorter matrix polypeptides 
known as M2 and M3 (Figure 1-7C) [237].  These shorter proteins are synthesized from 
the same open reading frame, but from downstream AUG codons therefore exhibiting N-
terminal truncations compared to full length M1.  M2 starts with methionine at position 
33 and M3 at Methionine 51.  These proteins are incorporated into virions at very low 
levels and, as will be discussed, have been found to play a role in the virus’s 
characteristic cytopathic effects during infection [237]. 
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Figure 1-7. The matrix (M) protein 
(A) Reconstruction of cryo-EM images illustrating the four interactions of the N-terminus 
of matrix with adjacent matrix proteins and with adjacent nucleocapsid proteins.  (B) 
Crystal structure of the thermolysin cleaved globular core of the matrix protein revealing 
3 alpha helices surrounded by 7 beta sheets.  (C) Schematic of the full-length matrix 
protein depicting important functional domains including the amino acid start sites for 
matrix variants, M2 and M3.  (A) reprinted with permission from Peng G, J. Tsao, S. 
Schein, T. Green, M. Luo, and Z. Hong Zhou (2010.) CryoEM model of the bullet-
shaped vesicular stomatitis virus. Science 327 (5966): 689-93 [229] and (B) Gaudier, M., 
Y. Gaudin, and M. Knossow (2002). Crystal structure of vesicular stomatitis virus matrix 
protein. Embo J 21:2886-92 [238].  Cryo-EM, Cryo-electron microscopy; AA, amino 
acid; NCT, nucleocytoplasmic transport  
  
    39 
Matrix Structure 
 
The crystal structure of the M protein was solved in 2002 by Gaudier et al and 
was shown to be similar in structure to proteins of other NNS RNA viruses important in 
budding and viral assembly [238-241] (Figure 1-7B).  In order to achieve crystallization,  
matrix was treated with thermolysin, cleaving the protein at the N terminus and at the 
hydrophobic loop known to be involved in M polymerization. Resultant thermolysin 
cleaved M monomers (Mth) corresponded to amino acids 48-121 and 122-229 and these 
two fragments were held together by a hydrophobic, globular core [238].  A number of 
domains have been found to be responsible for the multi-functionality of matrix and a 
more recent 3D structure created from cryo-electron microscopic studies has shed more 
light on the topography of these domains and how they interact with other proteins in the 
virion.  It was shown that the N and M layers in the virion are both made up of a separate 
single helix and the N terminus of M (M-hub) has 4 contact points, important in 
maintaining the virion’s rigid bullet structure (Figure 1-7A).   Contact point 1 joins M-
hub to an N in the upper helical turn, while M-hub contact-point 2 connects M-hub to an 
N subunit in the lower helical turn, confirming previous data that the N-terminus (AA4-
21) of M is important in binding to the RNP core [242].  Contact-point 3 binds laterally to 
the C-terminus of M (MCTD) of the trailing M subunit in the same helical turn while 
contact-point 4 binds to MCTD of the M in an upper helical turn [229].  This further 
validates what is known about the protease sensitive loop of matrix[243, 244]. 
 
The functional domains of matrix have been shown to be genetically separable 
from each other with domains involved in assembly and budding being different from 
those involved in CPE [242, 245] (Figure 1-7C).  In addition, these functions are carried 
out in very different parts of the infected cell reflected by the approximately 10% of 
matrix associated with the inner leaflet of the plasma membrane, where assembly and 
budding is known to occur, with the remaining matrix located either in the cytoplasm or, 
to a lesser degree, in the host cell nucleus.  With so many roles being carried out in 
different cellular compartments by one agent, it is not surprising that separate matrix 
populations created by genetic truncations could provide the virus with several options 
for carrying out its functions simultaneously. 
 
 
Assembly and Budding 
 
During VSV assembly, as the RNP begins to form a helical structure, M subunits 
attach to the outer surface of the nucleocapsid and rigidify the forming RNP skeleton 
starting from the tip to the trunk or base of the forming bullet shaped structure.  The 
exposed surface of M not bound by neighboring M or the RNP creates an area for binding 
G trimers associated with the soon to be acquired envelope membrane [229].  The 
importance of M to assembly has been demonstrated by deletion or mutation of M 
especially seen with temperature-sensitive mutants of VSV that produce very low levels 
of spherical or pleomorphic-shaped particles at non-permissive temperatures.  
Complementation of these mutant viruses with wildtype matrix restores the classical 
bullet shape of the virions [246]. 
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The multiple interactions of M with other VSV structural proteins also help 
promote viral budding from infected host cells [229, 231]. Significance of M in budding 
was demonstrated in studies showing the transient expression of M alone causes 
evagination of host cell membrane and ultimately release of membrane-enclosed vesicles 
[247].  Point mutations in the proline rich motif, 24PPxY27, located in the N terminus of 
M (late-budding or L-domain) greatly diminishes vesicular budding and the infection 
with viruses possessing mutations in the L domain show a decrease in budding by 70% of 
wildtype infection.  This motif has been shown to facilitate budding through interactions 
with host cell E3 ubiquitin ligase, Nedd4, via its WW-domains [241, 248]. 
 
 
Cytopathic Effects 
 
In addition to its role in assembly and budding, M is responsible for the 
phenotypic cytopathic effects (CPE) observed during VSV infection.  CPE manifests as 
cell rounding, activation of apoptosis, and inhibition of host gene expression.  In baby 
hamster kidney cells (BHK), a major cell model used in studies of VSV, CPE can be 
observed as early as 1 to 2 hours post-infection at high multiplicities of infection (MOIs) 
or 4-5 hours post-infection at lower MOIs [241].  M’s importance in CPE stemmed from 
a number of studies including those using temperature sensitive mutant viruses.  For 
instance, tsO82, a mutant found to have a mutation in matrix, was non-cytopathic in 
chick embryo fibroblasts [249] and this defect correlated with an inability to shutoff host 
gene expression [245].  The fact that expression of M alone, in the absence of other viral 
proteins, is able to elicit cell rounding and apoptosis emphasizes its role in CPE [242, 
250-254]. 
 
 
Cell rounding and apoptosis 
 
Cell rounding and induction of apoptosis are well-known characteristics of VSV 
infection.  This change in cell morphology is an effect of cytoskeletal dysfunction 
specifically due to matrix interaction with tubulin as co-immunoprecipitation revealed 
interaction between the acidic C-terminus of tubulin and the basic N-terminus of M 
[251].  More recent studies, however, revealed that matrix may not associate with actin or 
tubulin for at least 1 hour post-infection [228]; however, interaction between M and 
dynamin [255] through a domain located in the N-terminus of matrix may indirectly 
affect actin components of the cytoskeletal network [256].  In support of M’s role in cell 
rounding, a temperature sensitive mutant, tsG33, known to harbor mutations in the matrix 
protein, was shown to be deficient in cell rounding in BHK-21 cells at non-permissive 
temperatures.  In this same study, M was able to cause cell rounding in the absence of 
other viral proteins and blocking M activity by microinjection of complimentary 
antisense oligonucleotides inhibited cell rounding [250]. 
 
Induction of apoptosis is also a feature of VSV-induced CPE.  Apoptosis was first 
verified by the presence of DNA laddering and nuclear fragmentation that occurred 
simultaneously with, but was not dependent on, viral replication [257, 258].  The 
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expression of M, alone, is able to elicit apoptosis and is evident by activation of caspase-
3 in HeLa and BHK cells [259].  M’s ability to activate apoptosis leads to cell rounding 
and in cells where M-induced apoptotic pathways are blocked, cell rounding is also 
inhibited [252]. 
 
 
Inhibition of host gene expression 
 
Another feature of viral-induced CPE includes the inhibition of host gene 
expression or host cell shutoff.  There are several stages of gene expression that can be 
inhibited and these not only include transcription and translation of the host genome but  
also transport of message from the nucleus into the cytoplasm as well (e.g. 
nucleocytoplasmic transport or NCT) (Figure 1-8).  As previously mentioned, leader 
RNA (l), located in the 3’ untranslated region plays a significant role in encouraging viral 
transcription [207].  Along with this role, l has been shown to be involved in inhibition of 
host cell gene expression as it migrates to the nucleus early in infection and inhibits 
initiation of RNA polymerase II and III dependent transcription [260-262].  However, l is 
not sufficient to shutoff host gene expression on its own and another viral protein was 
identified as playing a major role in this process.  That protein was found to be M [263, 
264].  Not only is matrix implicated as the viral protein involved in host shutoff, Lyles et 
al showed that its ability to do this leads to induction of apoptosis and cell rounding [253, 
254]. 
 
 
Inhibition of transcription and translation 
 
Evidence of M’s role in host shutoff include its ability to localize to the nucleus of 
infected cells [265] along with studies showing the temperature sensitive matrix mutant, 
tsO82, expresses defects in host shutoff during infection [245].  Expression of M, alone, 
inhibits not only host directed transcription but also its own transcription when expressed 
from plasmids transcribed by host RNA polymerase II, a property not possessed by other 
viral proteins [242, 254].  This inhibition was shown to be independent of promoter type 
(hIFN? cellular promoter versus SV40 viral promoter) [266].  Activity of RNA 
polyermase (RNAP) I, II, and III are effected with RNAP II being the most sensitive to 
viral inhibition [267, 268] due to inactivation of transcription factor, TFIID [269, 270].   
 
VSV host shutoff also involves inhibition during translation through alterations of 
eIF4F initiation complex [271, 272].  Inhibition at this level favors mRNAs already 
existing in host cells prior to infection while new mRNAs or mRNAs present after 
infection are not inhibited.  This along with the fact that VSV inhibits host transcription 
helps promote translation of viral mRNA as increases in viral translation occurs 
simultaneously with decreases in host mRNA translation [273]. 
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Figure 1-8. Multiple steps in the inhibition of host gene expression by VSV matrix 
protein 
There are multiple steps in the process of host gene expression that may be targeted by 
VSV in order to promote the viral life cycle.  (A) Inhibition of transcription particularly 
of genes transcribed by host RNA polymerase II (B) inhibition of NCT by binding at the 
nuclear pore complex and (C) inhibition of translation caused by viral induced alterations 
of the eIF4F. 
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Inhibition of nucleocytoplasmic transport (NCT) 
 
Lastly, inhibition of NCT is a major feature of VSV-induced CPE specifically in 
inhibition of host gene expression.  Inhibiting movement of mRNA into the cytoplasm 
would theoretically prevent expression by decreasing the availability of mRNA to the 
translation apparatus.  As stated, there is a population of matrix found in the nucleus 
unlike other viral proteins [265] and movement of M into the nucleus is supported by the 
presence of nuclear localization signals (NLS) [274].  NCT inhibition occurs when matrix  
is bound to the nuclear envelope and this activity is reversed in the presence of a mAb 
directed against M (?M) [275].  At the nuclear envelope, M specifically binds to the 
nuclear pore complex (NPC) where it alters NCT activity mediated by the nucleoporin, 
Nup98, and shuttling mRNA export factor, Rae1.  Mutant viruses unable to bind at the 
NPC are able to migrate to the nucleus but are defective in inhibition of transcription 
andNCT seen by an increase in the amount of nuclear mRNA [276-278]. 
 
More recent studies question the actual role of Matrix and Nup98/Rae1  
interactions in host cell shutoff during VSV infection.  Rae1 knockout cells were shown 
to have no effect on the accumulation of nuclear mRNA after wildtype infection however 
there was a decrease in the inhibition of host transcription.  In addition, without Rae1, M 
is unable to bind to Nup98 although M is able to bind Rae1 in the absence of Nup98.  
These data implicate the importance of Rae1 as a bridge for interaction between matrix 
and other host factors such as Nup98 and that these connections are important in CPE 
observed during VSV infection.  This also suggests a more vital role for these complexes 
in the inhibition of transcription [279]. 
 
 
Matrix domains important for CPE 
 
In addition to the aforementioned domains important to viral assembly and 
budding, genetically separable domains have also been identified as being important in 
viral induced CPE [242, 252].  These domains are summarized in Table 1-4.  PSAP 
domain located between amino acids 37-40 (37PSAP40) at the N-terminus of matrix was 
initially studied for its possible role in viral budding mechanisms.  It was believed to act 
as an L domain considering this motif is highly conserved in other vesiculoviruses [222, 
280] and has been proven to function as an L domain in a number of other viruses 
including hepatitis E virus and Ebola virus [281, 282].  In addition, another highly 
conserved region in the matrix protein much like PSAP, the 24PPxY27 motif, has been 
confirmed as an L-domain whose function is vital to VSV budding [241].  Studies 
eventually showed that this is not the case and that mutations in 37PSAP40 alone have no 
effect on budding; however, in combination with PY mutations, 37PSAP40 may help 
rescue the defective budding phenotype of PY mutants [283, 284].  Recent studies have 
implicated PSAP as being more vital to viral CPE especially as it relates to cell rounding, 
caspase activation, and ultimately, viral yield.  Substitution of 4 alanines for PSAP 
(PS>A4) resulted in a highly attenuated virus in vitro and in an in vivo mouse model.  On 
the other hand, PS>A4 resulted in the opposite phenotype in arthropod cell lines, with 
enhanced CPE seen by increased cell rounding, detachment, and activation of caspase 3  
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Table 1-4. Functional domains of VSV matrix protein 
 
Role of Matrix Amino Acid 
Domain Location 
Specific Motif References 
Dynamin Binding 1-10 NS [255] 
RNP association 1-24 NS [229] 
Budding 
1. Binds to WW 
motifs on cellular 
proteins (Nedd4) 
 
2. Binds tSG101 
 
24-27 
 
 
PPPY 
 
[229, 231, 241, 246-
248] 
 
 
37-40 
 
PSAP 
 
[282, 283] 
Mitochondrial 
targeting 
33-67 NS [285] 
CPE 
1. Cell rounding 
and apoptosis 
 
 
2. Inhibition of host 
gene expression 
 
a. 33-51 
b. 37-40 
 
a. NS 
b. PSAP 
 
a. [237, 242, 252, 
259, 265] 
b. [284, 286, 287] 
 
 
51-59 
 
 
NS 
[245, 275, 277-279, 
288] 
Assembly 123-125 LXD [231, 238, 243, 244] 
Self association 120-129 PAVLA [229, 238, 243, 244] 
 
Note: NS, not specified 
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[286, 287]. 
 
Another domain important to viral CPE was addressed in the previously 
mentioned studies using temperature sensitive mutant, tsO82 [249].  This mutant 
expresses a mutation in matrix in which a methionine at position 51 is replaced with an 
arginine (M51R).  This substitution renders it defective in host gene expression 
inhibition, and through complementation with assembly mutants, a genetic distinction 
between these functional domains was further confirmed [245].  Studies using M51R  
expressing plasmids have shown that while wildtype matrix co-localizes with 
components of the nuclear pore complex at the nuclear rim, M51R mutants do not 
suggesting NPC-matrix interactions are determined by this domain and are important for 
the inhibition of host gene expression [277, 288].  In addition, another genetically 
modified matrix mutant, M(D), which possesses alanine substitutions at positions 52-54  
show that these mutations do not inhibit the ability of matrix to migrate into the nucleus, 
however by their inability to interact with the NPC, inhibitory activity on gene expression 
is diminished [275]. 
 
Jayakar and Whitt eventually demonstrated a major influence of M51 mutations 
in the expression of the matrix protein.  Mutations introducing an alanine at this position 
in combination with the same mutation at position 33 (M33, 51A) prevented the synthesis 
of the shorter matrix protein products, M3 and M2, respectively, and resulted in synthesis 
of only the full-length matrix protein, M1.  These proteins were shown to be important in 
eliciting viral induced CPE and virions that do not express these proteins have a delay in 
cell rounding that can be recovered by co-expression of M2 and M3.  Surprisingly in 
these mutants, virus yield is not affected and inhibition of host gene expression 
determined by protein visualization of [35S] Met labeled infected cell extracts showed no 
significant differences from wild-type infection [237]. 
 
In all, viruses harboring mutations corresponding to position 51 are attenuated 
likely due to their inability to inhibit the expression of specific genes important in 
antiviral responses such as Type I interferons (IFN?/?) [266, 289-291].  It is the M51 
mutation specifically that has been the main focus of studies geared toward developing 
VSV as an oncolytic virus.  Furthermore, this mutation is thought to be responsible for 
the virus’s preferential replication in tumor cells lacking a functional IFN response 
pathway [292-294]. 
 
 
VSV as an Oncolytic Agent 
 
 
Proposed Mechanism of Oncolysis 
 
As described, the matrix protein’s role in VSV cytopathic effects are illustrated 
through its ability to prevent the expression of host genes, including those crucial to 
regulating viral infection.  Previous studies have not only demonstrated inhibition of IFN 
expression by wildtype matrix, but also that viruses expressing a host shutoff defective 
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matrix protein are actually inducers of IFN [292].  Many tumors harbor defects in the 
interferon pathway giving them a survival advantage over normal cells while leaving 
them susceptible to infection by numerous viruses including VSV.  To this end, it should 
be expected that VSV would have a growth advantage in transformed cells based on their 
inability to fight off infection.  This expectation has been proven true in a number of 
tumor cells from different origins including prostate, breast, and colon.  Furthermore, 
pretreating cells with IFN is able to protect normal cells from infection while tumor cells, 
with very little ability to respond to IFN, remain sensitive to viral infection [291]. 
 
By using matrix mutant, with the inability to shut off host gene and protein 
expression, the oncolytic potential of VSV vectors is improved.  These mutants create a 
similar environment much like the one observed with IFN pretreatment.  During 
infection, accumulating IFN forms a “cytokine cloud” around surrounding cells that 
stimulates downstream signals protecting IFN responsive cells from further infection 
while the IFN-resistant tumor cells are left vulnerable (Figure 1-9) (reviewed in [289]).  
 
 
IFN Pathway  
 
In understanding the mechanism of VSV oncolysis, it is important to have a 
general understanding of normal antiviral responses.  Innate immune responses are 
crucial in the survival of cells against VSV infection as the virus is extremely sensitive to 
the antiviral actions of the IFN pathway.  In animals with defective innate responses, such 
as IFN receptor (IFNAR)- deficient mice, VSV rapidly replicates to high levels before the 
adaptive immune response can neutralize virus [295].  Interferons (IFNs) are specific to 
vertebrates [296] and virtually all nucleated cells maintain the capacity to produce and 
respond to IFN [297]. 
 
There are two main families of IFN, designated type I (?/?) and type II (?). The 
26 genes coding for Type I IFNs are found on human chromosome 9 and include 13 
IFN? genes, 11 of which are functional, a single IFN?, and 11 IFN pseudogenes 
(reviewed in [297]).  More recently added type I IFNs include IFN ??, ??, ??, ??, and -?  
(reviewed in [298]).  Type I IFNs have multiple antiviral effects including the ability to 
activate immune effector cells such as natural killer (NK) cells, macrophages and 
dendritic cells (DCs) [296, 299].  Though IFNs are considered major players in innate 
immunity, their ability to influence DC maturation indicates a role in bridging the innate 
and adaptive immune systems.  IFNs also have antitumor effects, demonstrated by their 
connection to the tumor suppressor, p53 pathway, which is dysregulated in cancers of all 
types [300].  The IFN-I receptor, IFNAR, is found in the plasma membrane and is 
composed of two major subunits, IFNAR1 and IFNAR2.  Separately, each subunit serves 
as a docking site for intracellular signaling molecules.  Once bound to IFN, these subunits 
become a heterodimer triggering an elaborate downstream antiviral signaling cascade that 
will be discussed in more detail (Figure 1-9B).  All Type I IFNs bind to this receptor, 
however, depending on the bound IFN, distinct downstream signaling can be observed 
[301]. 
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Figure 1-9. VSV and the IFN pathway 
(A) PRRs such as RIG-I and TLRs recognize pathogens, setting off an alarm in the form 
of a downstream signaling cascade that leads to the translocation of IRF3/7 and NF?B to 
the nucleus where they initiate the expression of IFN-I genes.  (B) IFN protein is 
translated and secreted by cells into the extracellular environment where it binds to its 
receptor.  IFN works in an autocrine and paracrine fashion to increase the translocation of 
Stat 1 and 2 to the nucleus where they upregulate a host of IFN stimulated genes (ISGs). 
(C) During wtVSV infection, the matrix protein is able to block multiple stages of host 
gene expression including genes involved in creating antiviral responses.  This enables 
viral replication and subsequent infection of surrounding cells.  (D) During infection with 
VSV matrix mutants, M is unable to block host gene expression, therefore, allowing IFN 
gene expression to continue.  Tumor cells, with defects in host gene expression are 
unable to create an IFN induced antiviral state, which allows uncontrolled spread of 
virus.  (E) Cells having an intact IFN response, are able to amplify IFN signal by 
downstream ISGs, protecting other IFN responsive cells from viral infection at multiple 
stages of the viral life cycle. 
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Figure 1-9. Continued 
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Figure 1-9. Continued 
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Pattern Recognition Receptors (PRRs) 
 
There are multiple ways in which viruses elicit downstream IFN expression.  
Initial responses involve recognition of pathogen associated molecular patterns (PAMPS) 
by pattern recognition receptors (PRRs) located in various compartments of the host cell.  
Membrane associated PRRs include Toll-like receptors (TLRs) while cytosolic PRRs 
include retinoic acid–inducible gene (RIG)-I-like receptors (RLRs), and the nucleotide-  
binding domain, leucine-rich repeat–containing (NBD-LRR) proteins (NLRs) (reviewed 
in [302]).  Several PRRs are activated in response to VSV infection.  These include 
TLR3, TLR7, and RIG-I (Figure 1-9A). 
 
Upon binding of dsRNA replication intermediates, the endosome bound TLR-3  
recruits adaptor molecule TIR-domain containing adaptor inducing IFN-? (TRIF).  TRIF 
activates downstream signals by two different cascades.  The first works through 
phosphorylation of interferon regulatory factor 3 (IRF-3) and IFN regulatory factor 7 
(IRF7), which promotes formation of an IRF3/7 heterodimer that migrates to the nucleus 
where it is able to bind to IRF-binding elements in the IFN-?/? promoter. In the second 
cascade, TRIF activates Inhibitor of kappa B kinase (IKK) complex, which leads to the 
dissociation of NF-?B from its inhibitor allowing its nuclear translocation, where it binds 
to and increases expression of IFN-I genes.  Both, IRF3/7 and NF-?B are required for the 
robust transcriptional activation of type I IFN during viral infection (reviewed in [302]). 
However, it has been shown in the case of VSV, that cells with silenced TLR3 still resist 
infection proving that there must be other vital pathways involved in anti-VSV responses 
[303].  For instance, TLR-7 is another endosome associated PRR found mostly in 
dendritic cells, especially plasmacytoid DCs (pDCs).  TLR-7 predominantly binds 
ssRNA, which sparks recruitment of the adaptor protein myeloid differentiation factor 88 
(MyD88).  MyD88 activates IRF-7 downstream, which, again, forms a heterodimer with 
IRF3, promoting IFN expression in the nucleus. In comparison to TLR3, TLR7 is 
extremely important in antiviral signaling of VSV infection.  Bone marrow cells derived 
from both MyD88 and TLR7 deficient mice expressed diminished levels of IFN? in 
response to VSV infection.  This decrease in antiviral response was also observed in vivo 
as well [304]. 
 
Cytoplasmic PRRs have particular importance in eliciting IFN related antiviral 
responses as well.  These receptors, known as RLRs, work through NF-?B and IRF-3 to 
promote robust IFN-I responses.  Retinoic acid-inducible gene-I (RIG-I) and melanoma 
differentiation-associated gene-5 (Mda-5) are two recognized RLRs important in RNA 
virus signaling however RIG-I is more important to VSV infection.  RIG-I (also known 
as Ddx-58) recognizes 5’-triphosphates on viral RNAs, such as those encoded by 
negative- stranded viruses [305].  After detection, RIG-I activates the mitochondria-
bound interferon beta promoter stimulator-1 (IPS-1), which phosphorylates kinases, 
TANK-binding kinase 1 (TBK1) and IKKi that then activate IRF-3 and NF-?B, 
respectively (reviewed in [302]).  The importance of RIG-I in host responses against 
VSV has been shown through experiments in which RIG-I knockout MEFs were unable 
to upregulate IFN-? activity causing 101.5  higher viral titers than in normal cells [306]. 
Alternatively, overexpression of RIG-1 inhibits replication of VSV in L929 cells by 
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decreasing titers 102-3 versus control cells [303]. 
 
 
Interferon Stimulated Genes (ISGs) 
 
Following the initial induction of IFN-I genes, newly synthesized IFN act through 
paracrine and autocrine signaling to augment antiviral responses in a positive feedback 
loop (reviewed in [303]).  Upon binding to its receptor, IFN ignites a phosphorylation 
cascade that results in activation of tyrosine kinases, Tyk2 and Janus kinase 1 (JAK1), 
both bound to the intracellular portions of IFNAR.  Signal transducers and activators of 
transcription, known as STAT 1 and STAT2, are subsequently phosphorylated which 
promotes formation of a STAT1/2 heterodimer.  The heterodimer is transported to the 
nucleus where it binds to IRF9, forming the IFN-stimulated gene factor 3 (ISGF3) 
complex that binds to the IFN-stimulated response element (ISRE) in the promoter of a 
multitude of interferon stimulated genes (ISGs) [296].  ISGs are the major operatives of 
the IFN pathway and over 300 ISGs are known to exist though most of their functions are 
not yet understood [307, 308].  Several have well-known IFN-mediated antiviral 
activities.  These include the 2’, 5’-oligoadenylate synthetase (OAS)/RNaseL pathway.  
OAS is triggered by dsRNA to activate RNase L, which degrades both host and viral 
RNA.  Another well-known ISG is the dsRNA-activated protein kinase (PKR), which 
responds to dsRNA by phosphorylating translation initiator factor eIF-2? promoting 
cessation of protein synthesis.  Lastly, the Myxovirus resistance (Mx) proteins, which 
will be discussed in more detail, are GTPases that prevent virus infection mostly at the 
transcriptional level (reviewed in [307]).  Though important, OAS, PKR, and Mx are not 
the only ISGs involved in protection of cells against VSV.  Following IFN-I 
pretreatment, triple (OAS, PKR, Mx) knockout MEFs still mounted an antiviral response 
against VSV infection [309] confirming that other ISG effectors are obviously playing 
some role in anti-VSV responses and may include broadly acting effectors such as IRF-
1or more specific effectors such as guanylate binding proteins (GBPs). 
 
 
Interferon regulatory factor 1 
 
 Interferon regulatory factors (IRFs) are a family of transcription factors made up 
of nine members in humans and mice [310].  The first of these identified was IRF-1, 
initially shown to activate IFN-I in the absence of viral infection.  Though IFN-inducible, 
IRF-1 is constitutively active in a number of cells with levels dependent upon the cell 
cycle, which are increased during cell cycle arrest [311].  Serving as a transcription factor 
is IRF-1’s main mechanism of action and inactivating the ability to bind to DNA 
eliminates its activity [312].  IRF-1 protein is mainly located in the nucleus where it is 
known to not only increase expression of IFN but other ISGs as well including OAS, 
PKR, and GBP.  It specifically recognizes a sequence in the promoter region very similar 
to that recognized by the ISG3 complex therefore, it is thought that these two activators 
of IFN also activate a similar subset of ISGs [310].  Because IRF-1 is itself induced by 
viral infection, de novo synthesis of IRF-1 is believed to be important in eliciting IFN 
responses [313].  Though IFN-I can cause upregulation of IRF-1, its strongest inducer is 
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IFN-? therefore a number of additional stimulated genes involved in other pathways 
including apoptosis and anti-proliferation is also activated by IRF-1 [310].  
 
Aside from its role in antiviral responses, other roles of IRF-1 include antitumor 
activity [314] and modulation of the immune system, including adaptive responses 
involving sculpting the antigen specificity of CD8+ T cells [315].  Studies involving IRF-
1 knockout MEFs demonstrated IFN-I continued to be upregulated following infection 
with Newcastle disease virus though upregulation with polyI:C was impaired (reviewed 
in [310]).   
 
 
Myxovirus resistance protein 
 
Myxovirus resistance (Mx) proteins are members of the dynamin-like GTPase 
family of interferon stimulated genes [316].  There are two Mx proteins encoded by two 
separate genes in humans while there are 3 separate Mx genes in rats.  Human MxA is a 
cytoplasmic protein active against a number of RNA viruses including VSV.  Cells that 
constitutively express MxA experience a decrease in viral transcription by 50 fold [317].  
Alternatively, MxB has not been shown to have any antiviral activity [316].  In rat, Mx1 
is found in the nucleus where it inhibits nuclear replicating viruses such as influenza, 
while the cytoplasmic Mx2 is more effective against viruses that replicate in the cytosol 
such as VSV.  Mx3, like human MxB, has no known antiviral activity [318].  Mx protein 
activity is thought to attributed to the ability to sense nucleocapsid like structures and 
prevent them from participating in replication in the nucleus, in the case of Mx1, or in the 
cytoplasm, in the case of Mx2 [318]. 
 
 
Guanylate binding protein 
 
Guanylate binding proteins or GBPs are highly conserved proteins belong to the 
dynamin-like family of GTPases, like Mx proteins.  There are seven members of the 
human GBP family [319] and 11 known murine GBPs [320].  GBPs are cytoplasmic 
proteins.  Specifically, mGBP-2 has been shown to localize to intracellular vesicle-like 
structures although the importance of this localization on function has not yet been 
described [321].  GBP promoters contain several ISRE’s that are regulated by other ISGs 
such as IRF1 [322].  GBPs demonstrate antiviral activity, though weak in comparison to 
the antiviral responses of Mx proteins [322].  Particularly, HeLa cells stably transfected 
with hGBP-1 exhibited resistance to VSV-induced CPE, making less virus than control 
cells.  Cells with silenced expression of hGBP1 that were treated with IFN? produced the 
same amount of virus as cells with normal hGBP1 levels however these same cells 
pretreated with IFN-? had increased viral replication and less antiviral responses than 
parent cells.  This demonstrates that though GBP is responsive to IFN-I, upregulation is 
more important in IFN-II signaling [323].  
   
Outside of its role in antiviral responses, GBPs are implicated in having an 
antitumor effect.  Adding to the above results, the overexpression of mGBP2 enhances 
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proliferation in NIH3T3 cells similar to the effects of IFN-? while the opposite holds true 
for hGBP1 and IFN-? in HeLa cells which have anti-proliferative effects in this cell line 
[324].  Further, hGBP1 and hGBP2 were recently shown to be upregulated in EGFR 
activated cells, causing a downstream induction of matrix metalloproteinase-1 (MMP-1) 
driving invasion of GBM cells making it a novel target in treatments of GBM [325]. 
 
 
Phospholipid scramblase 1 
 
Phospholipid scramblase 1 (Plscr1) is another ISG that has been identified as a 
possible IFN-induced antiviral component in VSV infection [326].  Plscr1 is a calcium 
binding protein whose location is dependent on its state of palmitoylation.  It can either 
be found in the nucleus bound to DNA or in lipid-raft-associated plasma membrane, 
promoting calcium induced bidirectional movement of phospholipids [327].  The N 
terminal cytoplasmic domain is proline-rich and likely serves as a binding motif for other 
proteins containing SH3 and WW domains [328].  Based on location, plscr1 antiviral 
activity is believed to involve inhibition of viral adsorption and enhancement of IFN 
signaling at the plasma membrane.  Cells with decreased Plscr1 activity are insensitive to 
the antiviral effects of IFNs and are more sensitive to VSV infection, confirmed by 
elevated viral titers relative to wildtype cells.  Plscr1 is known to upregulate the 
expression of a number of other ISGs including GBPs, OAS, RNase L, and PKR [329].  
 
 
Defective IFN Responses  
 
There are a number of ways that tumor cells can bypass the anti-proliferative 
effects of IFN.  These include acquired defects in the ability to make IFN (i.e. 
chromosomal aberrations) and to respond to IFN (i.e. alterations in signaling cascade).  
As has been described, many tumors have deletions in chromosome 9 in the location of 
the IFN-I gene cluster.  Chromosome 9 aberrations are commonly encountered in GBM, 
and allow cells to escape growth arrest and induction of apoptosis [330].  The variable 
nature of IFN resistance was acknowledged in a comparison between two GBM cell 
lines, one known to have homozygous deletions in chromosome 9 and another without 
chromosomal defects [23].  Both were equally resistant to the IFN?-induced apoptosis.  
This raises the importance of non-chromosome 9 abnormalities that may lead to IFN 
resistance including dysregulation of IFN regulatory factors and other interferon 
inducible genes [331].  In an evaluation of STAT1 expression in GBM tumors, it was 
shown that tumors expressing STAT more likely expressed an inactive form located in 
the cytoplasm versus the active, nuclear form [332].  Other IFN pathway constituents that 
have been implicated in tumorigenesis include IKK complex, important in activation of 
NF-kB and the interferon regulatory factor, IRF1 [333, 334].  On a more global scale, 
downstream IFN effects on p53 signaling have been implicated in disruption of antiviral 
responses in tumor cells.  IFN can activate expression of p53 through an ISRE found in 
its promoter and as we know, p53 is a regulator of cell cycle and one of the most 
common targets of mutation in cancer [300].  
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Other Viral Antagonists of the IFN Pathway 
 
Tumor selective targeting of the IFN pathway is not unique to VSV.  In addition 
to blocking host gene expression, other viral mechanisms used to escape immune 
responses include sequestering IFN or IFN related responders and by cleaving or even 
degrading antiviral products of the IFN pathway.  There are over 170 virus-encoded IFN-
antagonists known in 93 different viruses, some highly conserved among various RNA 
families (reviewed in [335]).  An example is the conserved V proteins of the 
Paramyxoviridae family in the order Mononegavirales.  Particularly, V proteins prevent 
dimerization of the cytosolic PRR, MDA-5, and also target STAT for proteasomal 
degradation [336, 337].  The highly conserved Z proteins of New World Arenaviruses 
antagonize antiviral responses by binding to and inhibiting RIG-I activity [338].  
Comparable to VSV matrix, the non-structural NS1 proteins of influenza virus are 
multifunctional proteins with multiple mechanisms for antagonizing the IFN pathway.  
Just as matrix, NS1 can inhibit host gene expression by blocking RNA export.  NS1 can 
also bind to dsRNA which prevents activation of the OAS/RNase L pathway and inhibits 
transcription of antiviral genes by preventing dsRNA-dependent transcription factors 
from being activated [339].  Coronaviruses use its non-structural protein, Nsp1, to 
degrade cellular mRNA, a nonspecific mechanism for blocking antiviral gene expression 
[340].  Specifically, SARS coronavirus utilizes the accessory protein, ORF6 to inhibit 
transport of STAT1 to the nucleus by blocking nuclear transport protein, preventing the 
feedback loop vital for augmenting IFN responses [341].  Lastly, rabies virus, another 
member of the Rhabdoviridae family, is also able to inhibit antiviral responses during 
infection.  Unlike VSV, however, rabies uses its phosphoprotein (P) to prevent 
phosphorylation of the regulatory factor IRF-3 as well as inhibit STAT1 signaling.  
Rabies takes a targeted multistep approach to antagonizing IFN whereas VSV inhibition 
is more global [342]. 
 
 
Advantages of VSV Oncolytic Therapy 
 
As with most OVs, there are both advantages and disadvantages of using VSV as 
an oncolytic vector.  The first advantage is that VSV is a naturally tumor selective virus, 
having a replication advantage in tumor cells that harbor defects in the IFN pathway 
[294].  Even more, VSV can be easily manipulated using reverse genetic techniques to 
enhance tumor selectivity as demonstrated by the genetically engineered matrix mutants.  
Virions can also be engineered to express foreign genes, accommodating up to 4.5kb of 
foreign RNA without significantly altering replication and viral gene expression [207].  A 
more recent study reported the insertion of the hepatitis C NS protein measuring 
approximately 5.9kb without affecting replication [343].  Other examples include VSV 
vectors expressing immune enhancing molecules such as IFN? or tumor associated 
antigens that boost antitumor immunity [344, 345].  For instance, a therapeutic regimen 
using a VSV vector expressing the surrogate tumor antigen, ovalbumin, utilized a 
virolytic and immunotherapeutic approach for the treatment of ova expressing B16 
melanomas in a mouse model.  Results showed enhancement of immune activation 
against ova by increasing tumor antigen specific CD8+ T cells, which aided in  
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enhancement of viral oncolysis as well [346]. 
 
The fact that VSV is not considered a human pathogen is also a benefit of VSV 
oncolytic therapy.  Seroconversion is rarely seen in the human population so the risk of 
pre-immunity is extremely low [207].  Even in cases of pre-immunity, as has been 
observed in cattle after natural VSV infection, immunity is not durable and animals may 
be re-infected with the same VSV strain in subsequent years despite high serum 
neutralizing antibody titers [213].  Whereas DNA and lentiviral vectors run the risk of 
insertional mutagenesis due to integration into the host genome, the use of RNA viruses 
such as VSV makes insertional mutagenesis highly unlikely.  Lastly, the quick replication 
cycle makes it easier to produce large amounts of virus and its broad host range facilitates 
its therapeutic use in a multitude of tumors [291].  Viral yields in baby hamster kidney 
cells (BHK-21) are about 100,000 particles per cell, of which about 10% can be 
infectious [207].  Other cell types that have been tested include kidney, brain, and heart 
with titers equaling 107, 106, and 105 respectively [346]. 
 
 
Disadvantages of VSV Oncolytic Therapy 
 
On the other hand, there exists a number of disadvantages to VSV oncolytic 
therapy.  First, as with other RNA viruses, VSV has a high rate of mutation, with RdRp 
errors occurring every 1:10,000 nucleotides or approximately 1 mutation/virion [347].  
As a result, the risk of reversion to wildtype will continue to be a factor as VSV moves 
from bench to bedside.  Previous studies using one of the more popular VSV mutants, 
M?51, has shown that the possibility of reversion, though present is extremely rare in this 
case.  It is proposed that when using this particular IFN inducing vector, the likelihood of 
a wildtype revertant rising to dominance would be virtually impossible [289]. 
 
VSV along with several other viruses such as rabies, HSV, and measles, are 
known to be neurotoxic [348-350].  Evidence for VSV neurotoxicity stemmed from 
studies in which mice were experimentally challenged with virus given either intranasally 
or intracranially.  Understanding the neurotoxic phenotype of VSV is important 
specifically in developing VSV as an oncolytic treatment for brain tumors as protection 
of normal cells is crucial [219, 351]. 
 
One study initially aimed at determining ways of lessening neurotoxicity resulted 
in uncovering what can be considered a disadvantage, though a necessary one, of VSV 
therapy, the adaptive immune response.  As discussed, with natural infection, pre-
immunity does not protect animals, long term, against subsequent infection with the same 
serotype [213].  However, studies using experimentally infected animals revealed that 
long lasting immunity is attainable following i.v. challenge with either wtVSV or 
attenuated viruses (VSV-M51-CT9, VSV-CT1; CT mutants are defined as having 
truncated cytoplasmic domains of the VSV glycoprotein) [220].  These differences may 
be attributed to variations in routes of administration and species of infected animals, 
however adaptive immunity still serves as a hurdle to efficient delivery of viral therapy,  
therefore, understanding the natural progression of adaptive immunity is important. 
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The timeline leading to the activation of adaptive immune responses has been 
determined using a mouse model.  Within one week of infection, neutralizing 
immunoglobulin M (IgM) antibody appears first followed by appearance of neutralizing 
IgG antibodies (nAb).  Strong adaptive responses including antibody and cytotoxic T-
lymphocytes are directed against N and G proteins [352] however, nAbs are specifically 
directed towards the G protein. Further, passive immunity with ?G antibodies, but not 
antigen specific T cells, protect against systemic infection (reviewed in [207]).  The 
importance of adaptive immune effectors was revealed in studies using immunodeficient 
animals.  B-cell-deficient mice are highly sensitive to VSV and usually succumb to 
infection within 9 days.  On the other hand, T cells contribute to long-term survival as T-
cell-deficient mice succumb to neurotoxicity closer to 30 days post- infection [352].  In 
creating a safe and effective VSV therapy that can be moved from preclinical to clinical 
studies for the treatment of GBM, a balance must be met between lessening neurotoxic 
effects of viral infection and achieving optimal delivery with long lasting therapeutic 
effects.   
 
 
Examples of VSV-Derived OVs in Preclinical and Clinical Trials 
 
Several VSV-derived OVs have been well characterized with studies confirming 
increased safety and efficacy over wildtype virus [289] (reviewed in [68]) (Table 1-5).  
Vectors of interest possess mutations ranging from the phosphoprotein (VSV-rp30a) 
[353], glycoprotein (VSV?G) [354], and matrix protein (M51) (reviewed in [355]).  I 
will discuss several mutants that have been more heavily studied in preclinical and more 
recently, in clinical trials, though not for GBM. 
 
 
AV1 and AV2 
 
AV1 (attenuated virus 1) and AV2 (attenuated virus 2) are interferon-inducing 
VSV mutants originally identified by their small plaque size in non-IFN defective cells 
and large plaques in IFN defective cells [356].  These constructs are based on mutations 
found in two temperature sensitive mutants, T1026R and TP3, respectively [357].  AV1 
contains the classical M51R matrix mutation where AV2 contains two additional 
mutations V221F and S226R.  Just as previous studies have shown that, M51R mutants 
are defective specifically in their ability to inhibit NCT of IFN message, AV viral 
mutants were also found to have the same phenotype, with IFN-? mRNA found in both 
the nuclear and cytoplasmic pool of mRNAs in culture media from AV-infected cells 
[289].  A panel of tumor cells ranging from breast cancer to colon cancer were tested and 
found to be highly susceptible to infection with these attenuated viruses.  To specifically 
test attenuation in animals, AV’s were compared to wildtype virus in an 
immunocompromised PKR-/- mouse model. AV’s were tolerated up to a 107 pfu (plaque 
forming units) dose while only 10 pfu of wildtype caused death in these animals.  Several 
other studies have been carried out in tumor bearing animals, specifically using the single 
matrix mutation found in AV1.  In animals harboring lung tumors, systemic and 
intranasal administration of AVs resulted in an increase in survival relative to UV- 
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Table 1-5. VSV-derived oncolytic viruses for the treatment of GBM 
 
VSV Vector Oncolytic Mechanism 
Viral Protein/ 
Mutation(s) References 
AV1  Defects in IFN 
pathway 
Matrix/ M51R [289, 356-359] 
AV2 Defects in IFN 
pathway 
Matrix/ M51R, 
V221F, S226R 
[289, 356, 357] 
VSV-M?51 (AV3) Defects in IFN 
pathway 
Matrix/ M51 
deletion 
[187, 193, 285, 289] 
VSV-rp30a Selective adaptation 
in glioma cells 
Phosphoprotein/  
not reported 
Large 
polymerase/  
not reported 
[353, 355, 360] 
VSV-IFN? Defects in IFN 
pathway 
Insertion of IFN? [344, 361-363] 
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inactivated virus.  Tumor load was also reduced as tumors treated with UV-inactivated 
virus reached a volume of 750mm3 by 10 days post-implantation whereas AV treated 
tumors never surpassed approximately 200mm3 throughout the study [289].  Another 
study demonstrated the variability in response of tumors of the same type to VSV 
oncolysis in vivo.  Animals harboring subcutaneous prostate tumors were either treated  
intra-tumorally or systemically with wt-VSV or M51 mutant.  In one prostate tumor 
(LNCaP), both viruses caused tumor reduction however in the other prostate tumor (PC-
3), cells remained resistant and grew at the same rate as untreated tumors [358].  Lastly, 
an evaluation of M51R mutant treatment against human gliomas was carried out in a 
xenograft mouse model of subcutaneously implanted U87 tumors.  This study revealed 
that M51R mutant completely eliminated tumors within 21 days post-infection without 
viral induced morbidity whereas untreated animals reached euthanasia criteria as a result 
of tumor load by 1 week [359].  To date, no clinical studies have been carried out for 
either of these attenuated viruses. 
 
 
VSV-M?51 
 
VSV-M?51, also known as AV3 when expressing a fluorescent reporter gene, 
contains a single amino acid deletion in matrix at position 51.  Initial in vitro studies 
tested the susceptibility of primary gliomas and glioma cell lines to infection, which were 
all found to be highly susceptible to oncolysis by the mutant vector [289].  In safety and 
efficacy studies using xenograft models of U87 and U118 human malignant glioma in 
nude mice, intratumorally and intravenously administered virus markedly reduced tumors 
compared to UV inactivated treated animals.  Intravenous administration of VSV?M51 
was found to significantly prolong survival in mice with unilateral U87 tumors (median 
survival of 113 versus 46 days) and bilateral U87 tumors (73 versus 46 days).  No 
toxicity was observed in this study.  Therefore, VSV?M51given systemically was able to 
migrate to intracranial tumor and decrease tumor load while prolonging survival in this 
model [285].  
 
A subsequent study using the GFP expressing VSV?M51 construct, AV3, in an 
immunocompetent model of lung cancer sought to determine if the adaptive immune 
responses which have been shown to attenuate VSV oncolysis could be circumvented by 
using cell carriers, a novel mode of systemic administration. AV3 infected cells were able 
to shield viral antigen during transport to tumor site where they then released virus, 
infecting malignant cells and not surrounding normal tissue.  Repeat administration of 
infected cells improved therapeutic efficacy when compared to naked virion injection 
with durable viral replication observed up to 6 days post-treatment.  Two cell carriers, 
tumor derived cells and leukemic cells, were tested for their ability to migrate to tumor 
following i.v. administration. Tumor carriers were found to localize in the lungs whereas 
leukemic carriers migrated to the lungs and throughout the body [187]. 
 
Whereas most studies are based on the premise that VSV selectively targets  
tumors due to IFN defects, not all tumors fall into this category, as was described with 
VSV-resistant prostate tumors.  There are also groups of malignant gliomas that have 
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been found to have active IFN pathways resulting in less responsiveness to VSV therapy.  
Some of these tumors harbor defects in mTORC1 pathway, a pathway that signals IFN 
activation [364, 365].  A recent study tested the use mTORC1 inhibitor, rapamycin, as an 
adjuvant to VSV?M51 in vitro and in an immunocompetent intracranial rat glioma model 
to determine enhancement of antitumor effect.  By reducing IFN activity, combination 
therapy significantly increased survival while specifically targeting and reducing 
intracranial tumors [193].  As with the other AV constructs, there are no ongoing or 
previous clinical trials for VSV?M51. 
 
 
VSV-rp30a 
 
Unlike most VSV therapies, VSV-rp30a is a naturally occurring mutant derived 
through repetitive passage in glioma cells whose evolutionary pressure led to tumor 
specific mutations that enhance viral fitness in glioma cells [353].  Its increased fitness is 
attributed to two confirmed mutations, one in the P protein and the other in the L protein 
of VSV [355] however the exact mutational changes in these proteins have not been 
revealed.  In vitro studies comparing the wildtype virus to the glioma-adapted VSV-rp30a 
demonstrated a replication advantage of both viruses in human glioblastoma cell lines 
over non tumor cells marked by increased cell rounding and decreased cell viability.  As 
expected, VSV-rp30a displayed increased growth ability in tumor cells relative to 
wildtype at earlier time points.  Following IFN-? or polyI:C pre-treatment, some 
protection was observed at early time points in glioma cells with complete protection in 
normal cells.  These results corresponded to MxA expression levels following either viral 
infection or pre-treatments, with a boost in MxA observed in all normal cell types and 
varying levels in glioma cells ranging from little to no expression.  This suggests the 
variable nature of IFN defects in GBM cells which may explain differences in 
susceptibility to viral oncolysis in different tumors [353].  
 
In an immunodeficient, xenograft mouse model of human intracranial and 
metastatic glioma, VSV-rp30a was shown to not only target intracranial tumors but also 
migrated to sites of extra-cranial tumors as well.  Though longer time points were not 
included in this study in order to determine differences in survival and tumor load 
reduction, it was shown that virus effectively replicated in transplanted tumors at up to 72 
hours post-infection and that several glioma tumors possessing different genetic 
aberrations in the p53 pathway were equally susceptible [63, 360].  As of yet, no clinical 
trials are planned for VSV-rp30a. 
 
 
VSV-IFN?  (mIFN? , mouse IFN?; rIFN? , rat IFN?; hIFN? , human IFN?) 
 
Since the IFN pathway is the most accepted proposed mechanism for selective 
replication of VSV in tumor cells leading to oncolysis, a VSV construct expressing IFN? 
(VSV- IFN?) was developed.  It was originally tested for treatment of hepatocellular 
carcinoma (HCC) but has since been evaluated as treatment for multiple myeloma (MM).  
In vitro, VSV-hIFN? has been shown to have a non-lytic phenotype in normal human 
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cells while remaining oncolytic in malignant cells [344].  To verify safety in animals, 
intravenous and intranasal VSV- mIFN? was administered in immunocompetent mice 
and was shown to be significantly attenuated compared to wild-type VSV [344], however 
subsequent studies demonstrated neurotoxicity when given intravenously causing fatal 
encephalitis in inoculated animals [361].  Additional studies have evaluated VSV-
IFN? for treatment of HCC and MM.  To first determine safety and MTD, 
immunocompetent Sprague Dawley rats and rhesus macaques were administered 
intrahepatic VSV- hIFN? with no adverse events appreciated.  However, in an orthotopic 
syngeneic model of HCC in Buffalo rat, intratumoral administration caused neurotoxicity 
with VSV- hIFN? construct that lessened by using species-specific rVSV-rIFN?.  No 
results of tumor load reduction were determined in this study [361].  In studying VSV- 
hIFN? as a treatment for multiple myeloma, significantly prolonged survival and anti-
tumor activity was demonstrated in an immunocompetent mouse model of subcutaneous 
and disseminated myeloma.  Species-dependent responses were also observed in this 
study, as mIFN? construct prolonged time to progression in the mouse model over the 
use VSV-hIFN? [362].  A phase I trial at Mayo clinic testing VSV- hIFN? for treatment 
of adult primary HCC or recurrent primary liver cancer is in progress and planned to be 
complete by June 2013 [363]. 
 
As with OVs derived from different viruses, there can be differences in the 
oncolytic profile of alternate constructs derived from the same virus.  Each may possess 
their own advantages and disadvantages, therefore, an understanding of underlying tumor 
biology of the cancer type being treated is important.  Van den Pol and associates 
compared several VSV constructs in their potential as a treatment for GBM.  Of those 
tested, VSV-M51, VSV- CT9-M51 (CT9- truncation of G protein cytoplasmic tail), 
VSV-p1-GFP (insertion of GFP at the 3’ end of the genome), and VSV-p1-RFP (insertion 
of red fluorescent protein (RFP) at the 3’ end of the genome) were safest and most 
effective at destroying malignant glioma while other constructs including VSV-?G and 
VSV-rp30a were least effective [355].  These may prove to be the best vectors to 
consider for phase trials in the treatment of GBM as newer more tumor selective 
constructs become available. 
 
 
rNCP12.1 
 
rNCP12.1 (recombinant Non-CytoPathic isolate 12.1) is a novel attenuated 
replication competent VSV vector developed by Whitt and associates due to its non-
cytopathic effects in a number of cell lines [237].  It was originally isolated after 
establishment of a persistent infection in BHK-21 cells with another M mutant, M33, 
51A.  As discussed, due to the mutations at positions 33 and 51 in the matrix protein, this 
mutant is unable to express the truncated matrix products, M2 and M3.  In effect, M33, 
51A mutant is defective in cell rounding especially in BHK-21 cells while maintaining 
wildtype cytotoxicity in several other cell types, particularly HeLa and 293 cells.  No 
defects in host cell shutoff were appreciated for this mutant [237].  Because M33, 51A 
causes only ~40-50% of cells to round following infection [237], cells that remained flat 
were further cultured to maintain a persistent infection as confirmed by viral expression 
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of an inserted green fluorescent protein and from viral titers.  Resultant virus from this 
persistent infection was found to have two mutations in the matrix protein in addition to 
M33,51A.  These additional mutations are located in the C-terminus of matrix and 
correspond to T133A and S226G.  The matrix of the original non-cytopathic variant, 
NCP12, was subcloned into a wt background and this recombinant vector was designated 
rNCP12.1 [237].  
 
Whereas M33, 51A causes approximately half of BHK21 cells to round following 
infection, rNCP12.1 cell rounding is negligible in BHKs.  However, in other transformed 
cell types such as HeLa and HEK293 cells, cell rounding is present but variable [366] 
(Figure 1-10).  Therefore it was implied that the cell rounding phenotype of rNCP12.1 is 
cell type specific and may depend on the presence of some host factor.  Further 
characterization revealed that, like M33, 51A, host cell shutoff was similar to wtVSV at 
8hpi.  However, unlike wtVSV, viral gene expression was decreased especially for M and 
G proteins, which could be due to an overall increase in antiviral host response [366].  In 
keeping with other studies that support the genetic separation of domains involved in 
budding and assembly from those involved in CPE [242] rNCP12.1 budding, though 
slightly decreased from wtVSV, maintained efficiency.  Viral yields were approximately 
10 fold less than wt at 18 hours post infection (hpi).  Of the four mutations in the matrix 
of rNCP12.1, position M51 is the most important in its overall phenotype. M33A and 
T133A alone displayed CPE similar to wt whereas S226G expressed intermediate cell 
rounding but yielded virus similar to wt levels.  M51A alone made 10 fold less virus than 
wt.  More than likely, the overall phenotype of NCP12.1 is due to an additive effect of the 
combination of these mutations (Table 1-6). 
 
This phenotype has been exploited in our lab in several ways.  First, because of its 
decreased cytotoxicity in normal cells coupled with its near normal assembly and 
budding function, rNCP12.1 was used to recover a recombinant VSV vector lacking the 
M gene (?M-PLF).  Until this time, recovery of VSV vectors lacking M were impossible 
due to the inhibition of gene expression caused by expression of wt M needed for 
complementation [366].  In addition, its use has been important in developing an 
oncolytic virus for the treatment of glioblastoma.  To this end, preliminary results have 
been promising and will be described in further detail in this dissertation. 
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Figure 1-10.  Cell rounding phenotype of rNCP12 in different cell types 
rNCP12 is the parent virus of rNCP12.1.  Phase contrast micrographs, taken at 10X 
magnification, show differences of cell rounding by NCP12 and wtVSV infection in (A, 
B) BHK cells, (C, D) HeLa cells, and (E, F) HEK 293 cells at 24hpi.   
Reprinted with permission: H.R. Jayakar, VSV M protein domains involved in assembly 
and cytopathogenesis, 2001 [366]. 
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Table 1-6. Characterization of individual mutations in matrix mutants 
 
Virus Mutation Virus Yielda Cell 
Roundingb 
Host Shut Offc 
Wild-type None +++ +++ +++ 
M33A M33?A +++ +++ ND 
M51A M51?A + + ND 
M33,51A M33?A 
M51?A 
 
+++ + +++ 
T133A T133?A +++ ++++ ND 
S225G S225?G +++ ++ ND 
rNCP12.1 M33?A 
M51?A 
T133?A 
S225?G 
+ - + 
 
a +++ indicates wildtype levels of virus titers (~5x108-1x109), and + indicates atleast 10 
fold reduction in yield 
b +++ indicates >90% of cell rounding in BHK21 cells by 24hpi, and  + indicates <50% 
rounded cells; - indicates no cell rounding 
c +++ indicates >50% host cell shutoff by 8hpi; + indicates <50% host cell shutoff 
ND, not done 
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
Cells and Viruses 
 
All cells were maintained as a monolayer culture at 37ºC, 6% CO2.  All medium 
was supplemented with 100U/mL of penicillin and streptomycin (Table 2-1).  The rat 
F98 and C6 glioma and human U87 glioma cell lines were previously transduced with the 
pFB retrovirus (pFB-GFP) (Stratagene, La Jolla, CA) expressing GFP to allow 
visualization of tumor load in brain sections.  Cells stably transduced with GFP were 
sorted using flow cytometry to generate a cell population homogeneously expressing high 
levels of GFP. 
 
All recombinant VSV constructs were made in the Lab of Michael A. Whitt, PhD 
and contained genes of the Indiana serotype with the exception of the glycoprotein of the 
New Jersey serotype (GNJ) for rNCP12.1NJ-GFP (Table 2-2).   
 
 
Cell-Rounding Assay 
 
Rat glioma (C6, F98), human glioma (U87, A172, and T98G), and PRAs were 
plated in 35-mm-diameter dishes and infected with rNCP12.1-GFP (NCP12.1-dsRed in 
U87, C6, F98) at an MOI of 10 (rat glioma) and MOI of 1 (human glioma) for one hour 
at 31oC.  Inoculum was removed, and the cells were washed once with serum-free 
medium and then incubated at 37°C for varying times.  At 24hpi, medium was removed, 
and cells were washed twice with phosphate- buffered saline (PBS) and fixed with 3% 
paraformaldehyde at room temperature for 20 min, followed by two washes with PBS 
containing 20 mM glycine.  Cells were observed by bright field and fluorescence 
microscopy (Zeiss, Axiovision) to determine presence of viral and tumor cell fluorescent 
markers.   
 
 
Growth Kinetics 
 
Rat glioma cells and PRAs were seeded into 96 well plates for 24 hours then 
mock infected by incubation in serum free media or infected with either wt-VSV or 
rNCP12.1-GFP for one hour at 31oC at an MOI of 10.  Inoculum was removed and cells 
were washed with serum free (SF) DMEM three times.  Fresh D10 was added to all cell 
lines and incubated further at 37oC.  At various time points (T=6, 12, 24, 8, 72hpi; 1wpi) 
supernatant was removed and infectious virus was determined using a plaque assay on 
BHK cells. 
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Table 2-1. Cells 
 
Cell Type Obtained from Culture Medium 
BHK21 cells Lab of  Dr. Michael Whitt DMEMa + 5% FBS (D5) 
Mouse Embryonic 
Fibroblasts (MEF) 
ATCC (Manassas, VA) DMEM + 10% FBS (D10) 
L929 mouse fibroblasts Courtesy of Dr. Lawrence 
Pfeffer (Pathology, 
UTHSC) 
DMEM + 10% FBS 
Rat Fibroblasts (FR) ATCC (Manassas, VA) DMEM + 10% FBS (E10) 
Primary Rat Astrocytes 
(PRAs) 
Special Protocolb DMEM + 10% FBS 
F98 (GFP)c Rat Glioma  ATCC (Manassas, VA) DMEM + 10% FBS 
C6 (GFP) Rat Glioma ATCC (Manassas, VA) DMEM + 10% FBS 
U87 (GFP) human glioma Courtesy of the Lab of  
Neurosurgery (Christopher 
Duntsch, MD, PhD; 
UTHSC) 
EMEMd + 10% FBS 
T98G human glioma Courtesy of the Lab of  
Neurosurgery (Christopher 
Duntsch, MD, PhD; 
UTHSC) 
EMEM + 10% FBS 
A172 human glioma Courtesy of the Lab of  
Neurosurgery (Christopher 
Duntsch, MD, PhD; 
UTHSC) 
EMEM + 10% FBS 
 
aDulbecco’s Minimum Essential  Medium supplemented with 5% Fetal Bovine Serum 
b Primary rat astrocyte cultures were obtained by dissecting and removing striata from 
E17 rat embryos.  Cells were dissociated, plated, and allowed to grow to confluency for 
approximately 10 days. 
cCells were purchased and later transduced to express GFP.  Protocol described 
separately 
d Eagle’s Minimum Essential medium 
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Table 2-2. Virus constructs 
 
Virus Serotype (Strain) Constructed by 
wtVSV-GFP Indiana (N, P, M, G 
genes- San Juan; L gene- 
Mudd Summers) 
 
Michael A. Whitt, PhD 
rNCP12.1I-GFP Indiana (N, P, M, G 
genes- San Juan; L gene- 
Mudd Summers) 
 
Himangi Jayakar, PhD 
rNCP12.1NJ-GFP  New Jersey (N, P, M, G 
genes- San Juan; L gene- 
Mudd Summers, G gene- 
Ogden) 
 
Himangi Jayakar, PhD 
rNCP12.1I-dsRed Indiana (N, P, M, G 
genes- San Juan; L gene- 
Mudd Summers) 
Himangi Jayakar, PhD 
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Cytotoxicity Assay 
 
Rat glioma cells and PRAs were seeded into 96 well plates then mock infected 
with serum free media or infected with either wt-VSV or rNCP12.1 at an MOI of 10 at 
31oC for 1 hour.  Inoculum was removed and replaced with D10 and cells were incubated 
at 37oC.  At various times post infection (T=6, 12, 24, 8, 72hpi; 1wpi), supernatants were 
harvested and used to determine growth kinetics as described.  Cell viability at the same 
time points was determined using the CellTiter 96Aqueous One Solution Cell 
Proliferation Assay (Promega) according to the manufacturer’s protocol.  
 
 
IFN Protection Assay 
 
Rat glioma cells and PRAs were plated in 96 well plates and 24 well plates 
respectively.  Cells were counted after plating using a hemocytometer to confirm a 
normalized cell count.  Culture media was removed from cells and rat IFN? (rIFN?; 
provided by Dr. Lawrence Pfeffer, Department of Pathology, UTHSC) was added starting 
with 1000U (high dose experiment) and 100U (low dose experiment) of IFN at 2 fold 
serial dilutions.  Cells were incubated overnight at 37oC.  At 24 hours post-treatment, IFN 
was removed and cells were infected with wtVSV at an MOI of 3 for 1-2 hours at 31oC.  
Inoculum was then removed, fresh D5 was added, and cells were incubated at 37oC 
overnight.  At 24hpi, D5 was removed and cells were washed three times for 5 minutes 
each with 1XPBS.  Cells were then fixed with 3% paraformaldehyde for 20 minutes then 
treated with 1% TritonX-100 at room temperature for 5 minutes to permeabilize the cell 
membrane.  The cells were stained with an ?-VSV N specific monoclonal antibody 
(10G4) conjugated to Rhodamine.  Cell rounding and presence of virus was determined 
by fluorescence microscopy (Zeiss, AxioVision).  Protection was defined as the amount 
(U) of IFN at which less than 50% cells were infected. 
 
 
pI:C Induction of IFN 
 
Cells were plated in 60mm plates and cultured until 70% confluent.  Cells were 
treated for 4 hours with 25, 50, or 100?g pI:C in SF-DMEM or transfected with 0.1, 1, or 
10?g pI:C in a ratio of 1:1 with Lipofectamine 2000.  pI:C treatment mixture was 
removed, D10 was added, and cells were incubated at 37oC.  Supernatants were collected 
at 24 hours post-treatment and IFN activity was determined using the IFN bioassay 
described.  Cell lysates were harvested and stored at -20oC or used directly for qRT-PCR 
studies.  In a subsequent time course experiment, cells plated in 60mm plates were treated 
with 10?g of transfected pI:C only, and supernatants were collected at t=2.5, 4, 6, 12, 18, 
24 hours post-transfection.  Supernatants were used to determine presence of active IFN 
using the IFN bioassay and remaining cells were lysed with 1 ml Trizol reagent 
(Invitrogen), harvested, and stored at -20oC or used directly in qRT-PCR studies.   
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IFN Bioassay 
 
Supernatants from immune-stimulated cells (pI:C pretreatment or viral infection) 
were collected at various time points following treatment and applied at 2 fold serial 
dilutions on L929 mouse fibroblasts pre-plated in 96 well plates to reach 70% confluency 
at the time of the experiment.  After a 24 hour incubation, the supernatant was removed 
and L929 cells were infected with wtVSV at an MOI of 0.5 for 1 hr at 31oC.  Inoculum 
was removed, fresh media was added, and cells were incubated at 37oC.  Rat IFN? 
(rIFN?) was used as the standard for scoring of the IFN bioassay.  Units for rIFN? were 
determined with respect to the international reference standard for mouse interferon 
alpha/beta, mouse IFN-?/? (NIH) and stored in aliquots having a known titer of 
106U/mL.  At 36-48hpi, media was removed and the assay was scored as determined by 
the dilution factor at which 50% inhibition of CPE was observed [367].  This dilution was 
then compared to the known concentration at which the standard inhibited 50% CPE.  
Based on the data in Table 2-3, the highest dilution at which rIFN standard inhibited CPE 
is 1.5625U/125?L=0.0125U/?L=12.5U/mL.  From this information, we can determine 
the original amount of IFN in each sample prior to dilution (Example: CPE in sample #5 
started at 25U/125?L therefore titer of the original sample would be 200U/mL.  Sample 2 
showed no CPE therefore an additional study evaluating higher dilutions would be 
necessary.  Sample #4 showed no protection, therefore IFN titer of this sample is 
undetectable). 
 
 
Viral Infection for IFN Bioassay and ISG qRT-PCR 
 
Cells were plated in 60mm plates and grown to 80% confluency.  Cells were then 
mock-infected (SF media) or infected with either wt-VSV or rNCP12.1 at an MOI of 10, 
for 1 hour at 31oC.  Inoculum was removed and cells were washed twice with SF-
DMEM, then incubated overnight at 37oC in 2mL of D-10.  At time points, T=6, 12, 18, 
and 24hpi supernatants were harvested and centrifuged to remove cellular debris.  
Remaining cells were lysed in 1 ml Trizol reagent (Invitrogen), harvested, and stored at -
20oC or used directly in qRT-PCR studies.  In order to be used for IFN bioassays, virus 
was separated from supernatant of infected cells using Millipore Amicon Ultra-4 
centrifugal filters with Ultracel membrane of 100,000 NMWL cutoff.  Samples were 
centrifuged twice at 5000rpm for 10 minutes at 4oC, using a new filter for the second spin 
cycle.  Standardization of this IFN bioassay using virus-containing samples will be 
explained in Appendix B.  A small aliquot of ultra-filtered supernatant was used to 
ensure all virus was removed using a standard plaque assay on BHK21 cells. 
 
 
qPCR to Determine Expression of IFN?1 
 
Semi-quantitative RTPCR was carried out to detect expression of IFN?1 in virally 
treated FR and C6 rat glioma cells at 6 and 12hpi.  Infected cells were lysed in 1mL 
Trizol and total RNA was extracted.  A One step RT-PCR (Qiagen) was carried out 
according to manufacturer protocol using IFN?1 specific primers (Table 2-4).  DNA  
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Table 2-3. Scoring for IFN bioassay 
 
 
 
  
Sample 
Initial Concentration (U/125?L)?Final Concentration (U/mL)?
100?  
800 
50?  
400 
25?  
200 
12.5?  
100 
6.25?  
50 
3.125?  
25 
1.5625?  
12.5 
0.78125?  
6.25 
IFN std  - - - - - - -/+ + 
SF only + + + + + + + + 
Sample 1 - - - - -/+ + + + 
Sample 2 - - - - - - - - 
Sample 4 + + + + + + + + 
Sample 5 - - -/+ + + + + + 
Sample 6 - -/+ + + + + + + 
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Table 2-4. qRT-PCR UPL primers for interferon stimulated genes 
 
Gene Left Primer Right Primer UPL 
Probe # 
IFN?1 
(interferon beta 1 
fibroblast)  
ggtggaccctccacattg tagtcgatggagagggcagt 18 
IFN?4 
(interferon   
alpha 4) 
cagcagctcagtgacctcaa taggggaggttcttgcattc 62 
Mx1 (myxovirus/ 
influenza virus 
resistance 1) 
ccagcacctgaatgcctac tggagtactggatgatcagagg 94 
GBP1  
(guanylate 
binding  
protein 1) 
cagaaaaggaaaaggagattgaag ttctgtgtttcctccaacagc 66 
Plscr1 
(phospholipid 
scramblase 1) 
tcagattctggttcatcagcag cgtatcttccaccgcaaagt 113 
RIG-I  
(Ddx58, DEAD 
box polypeptide 
58) 
gaagattctggaccccacct tgaatgcactgcacctcatc 73 
IRF1  
(interferon 
regulatory  
factor 1)  
aagggaagttacctgaggacatc gctgaagtctccatagacagtagagag 92 
Cyclophilin B acgtggttttcggcaaagt cttggtgttctccaccttcc 97 
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fragments were separated by 2% agarose gel and visualized under UV light following 
treatment with ethidium bromide. 
 
 
Quantitative RT-PCR (qRT-PCR) to Determine Expression of IFN?1 and ISGs 
 
After Trizol extraction of total RNA, RNA concentration in each sample was 
determined by spectrophotometer at A260.  One microgram of RNA per reaction, along 
with M-MLV reverse transcriptase (Invitrogen) and random hexamers were used to 
synthesize cDNA.  Next, quantitative PCR was performed on the LightCycler 480 
(Molecular Resource Center, UTHSC) using Universal Primary Library (UPL) protocol 
for rat gene expression (Roche) (Table 2-4).  Universal probes are specific for the 
detection of the rat transcriptome and are labeled with fluorescein at the 5’ end and a dark 
quencher dye at the 3’end that allow detection by standard SYBR Green I filters.  The 
LightCycler 480 Taqman90 protocol was used which is pre-programmed to perform the 
following cycles: activation of DNA Polymerase for 5 minutes at 95 oC; amplification of 
cDNA for 40 cycles which includes 10 seconds at 95oC denature, 20 seconds at 60oC 
annealing, and 10 seconds at 72oC extension; cool down for 30 seconds at 40oC. 
 
 
Western Blot Detection of Neutralizing Antibodies 
 
To detect the presence of ?-VSV antibodies in the sera of treated animals, blood 
was collected at the time of sacrifice by transcardiac method (described below).  The 
cellular components were separated from blood by centrifugation and serum only was 
stored at -20oC until used.  104 pfu rNCP12.1 were prepared for electrophoresis in 
reducing sample buffer LSB +BME.  Proteins were separated using 9% acrylamide 10% 
SDS gel electrophoresis then transferred to polyvinylidene fluoride (PVDF) microporous 
membrane.  Membranes were blocked using 5% Non-fat dry milk/TTBS for two hours 
and viral proteins probed with rat sera from treated or control animals diluted to 1:100 or 
with positive control, R6-F, at 1:5000 (R6-F is a rabbit polyclonal antibody directed 
against detergent treated wtVSV).  Blots were incubated for two hours at room 
temperature or overnight at 4oC followed by treatment with goat ?-rat secondary 
antibody conjugated to Horse Radish Peroxidase (HRP) (Jackson ImmunoResearch 
Laboratories) at a dilution of 1:5000 for two hours at room temperature.  Signal was 
visualized using chemiluminescence (SuperSignal West Dura, Pierce) followed by 
exposure to and development of X-ray film.   
 
Neutralizing Antibody Assay 
 
In 96 well plate, BHKs were plated and cultured overnight in D5.  Serum samples 
were treated at 56oC for 35 minutes in order to neutralize any residual virus.  200 pfu of 
wtVSV were added to two fold serial dilutions (1:2 to 1:1000) of test sera.  Negative 
control included FBS only and positive control included TN-1, a polyclonal antibody 
developed in rabbit against i.v. injection of UV-inactivated intact wtVSV.  Serum or    
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TN-1 plus virus was incubated at 37oC for 35-45 minutes then added to cells overnight at 
37oC.  Neutralizing antibody titer was determined by the inverse of the dilution required 
for 50% inhibition of infection at 24 hours post-treatment (e.g. 1:1000 dilution 
corresponds with a neutralizing titer of 1000). 
 
 
Animal Studies 
 
 
Tumor Implantation 
 
All animal experiments were conducted under the guidelines of the UTHSC 
IACUC (Institutional Animal Care and Use Committee).  Both Wistar and Fischer 344 
rats were obtained from Charles River.  To establish intracranial gliomas, six week old 
250-300 gram male adult rats were anesthetized by administration of ketamine/xylazine 
i.p. at a dosage of 87mg/13 kg body weight (0.1mL/100g body weight).  Animal was 
placed in a stereotaxic frame and skin was prepped using iodine.  By sterile technique, a 
1.0 cm incision was made in the midline of the skull along the sagittal suture starting just 
behind the plane connecting the eyes.  The cranium was exposed and a Burr hole 3.0mm 
lateral to the bregma on the right of the bregmatic suture was created without 
compromising the dura.  1 x 105 rat glioma cells (C6-GFP; F98-GFP) were injected 
intracranially using a 25?L Hamilton Syringe.  Injections were given slowly over 30 
seconds at a depth of 3mm below the dura.  Following administration of cells, the needle 
was left in place for approximately 2 minutes then retracted slowly over 30 seconds.  
Following implantation, the Burr hole was sealed with bone wax and the skin incision 
was sutured using 4.0 monofilament.  Throughout the procedure, animals were kept on a 
warming blanket in order to maintain body temperature.  Post-op, animals were treated 
with oxygen to aid in recovery from anesthesia.   
 
 
Measures of Morbidity 
 
Morbidity was determined based on weight trends and the rat coma scale (RCS) 
(Table 2-5).  The RCS was developed by Christopher Duntsch, MD, PhD (UTHSC 
Department of Neurosurgery) as an adaptation of the human Glasgow coma scale (GCS), 
a widely used assessment tool for neurological function especially following traumatic 
brain injury.  Components of the RCS involve level of consciousness, motor function, 
and spontaneous eye movement.  Additional manifestations of distress are not accounted 
for in the RCS therefore we created a supplemental assessment to help determine the 
need for euthanasia which include rat-specific signs and symptoms such as chattering and 
lack of grooming (Table 2-6).  Certain signs are more severe in nature and would call for 
euthanasia when they are present as animals are less likely to recover from these. 
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Table 2-5. Rat coma scale 
 
Neurological 
Response 
Score* 
4 3 2 1 
Level of 
Consciousness 
(LOC)  
Moves 
spontaneously 
without 
stimulation 
Moves 
spontaneously 
when picked up 
for 3 seconds 
by tail and put 
back down 
 
Moves with 
pain stimulus 
Does not 
move with 
pain stimulus 
Motor N/A 
 
No motor 
deficits 
Paresis (hemi/ 
quadri/ 
forelimb/ 
hindlimb 
involvement) 
 
Plegia (hemi/ 
quadri/ 
forelimb/ 
hindlimb 
involvement) 
Eyes Opens 
spontaneously 
Opens with 
stimulation 
Open to pain 
stimulus 
Does not open 
 
 
*Highest total score, 11 (4+3+4); Lowest total score, 3 (1+1+1) 
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Table 2-6. Additional signs of distress 
 
Sign Severity Predicted Outcome 
Sneezing/ coughing Low Usually recover 
Bowel changes (usually 
diarrhea) 
Low 
Porphyrin stain around 
eyes 
Low 
Ruffled hair Medium Monitor weight and RCS 
every day versus every 3 
days 
Huddles in corner Medium 
Hunched Medium 
Chattering/ vocalizing Medium 
Urine stained coat High Pending death 
Late seizure activity High 
Increased work of 
breathing 
High 
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Cerebrospinal Fluid (CSF) Collection 
 
The procedure for CSF collection was adapted from the protocol described in 
Sharma et al, 2010 [368] and performed as a terminal procedure.  Immediately following 
induction of deep anesthesia, animal was placed in position on the CSF collection 
apparatus provided by the UTHSC Department of Comparative Medicine, Laboratory 
Animal Care Unit, in order to maintain proper head positioning and easier identification 
of access to the cisterna magna, located between the occipital protuberance and the 
posterior tubercle of the atlas. Once secured, hair covering the occipital region was 
shaved.  A winged 25 gauge x 3/4 inch needle (BD Vacutainer Safe Lok) with infusion 
tubing was connected to a 1cc syringe.  The needle was slowly inserted into the site of the 
cisterna magna directly below the occipital protuberance at an angle as close to parallel as 
possible to the position of the spine.  Once dura mater was penetrated as detected by a 
subtle decrease in resistance, gentle negative pressure was applied by slow suction using 
the 1cc syringe.  Approximately 50 -70?L of CSF can be obtained by this method. 
 
 
Transcardiac Blood Collection 
 
Collection of blood by transcardiac method was performed as a terminal 
procedure following induction of deep anesthesia.  A 1-2cm incision was made on the 
skin of the abdomen and widened with scissors to make a skin flap for access to the intra-
abdominal cavity.  After entering the abdomen, the xiphoid process was elevated and the 
diaphragm was appreciated.  The diaphragm was pierced with the scissors and the 
incision was widened in order to enter the thoracic cavity inferiorly.  Once inside the 
thoracic cavity, the left ventricle of the heart was identified and 0.2 cc heparin was 
injected to prevent coagulation during blood collection.  After ~30-60 seconds, a 27 
gauge x ½ needle attached to a 3cc syringe was inserted into the left ventricle and blood 
was collected and stored immediately on dry ice to be used for subsequent studies.   
 
 
Preparation of Concentrated Virus for Intracranial Injections 
 
Forty 150mm plates of BHKs were grown to 80-90% confluency.  Cells were 
infected at an MOI of 3 in 10mL of SF-DME (no penicillin or streptomycin, -P/S) for 1 
hour at 31oC.  After one hour, 10mL additional SF-DME -P/S was added to cells and 
cells were incubated at 37oC overnight.  Supernatants from infected cells were harvested 
and cellular debris was removed by centrifugation (2550rpm for 10 minutes at 4oC using 
JS 4.2 rotor).  A small aliquot of supernatant was collected and stored at -20oC for later 
titering.  Next supernatant was passed over a 20% sucrose cushion (TN pH 7.2) and virus  
was pelleted at 28,000 rpm for 60 minutes at 4oC.  Viral pellet was resuspended in 100?L 
sterile TN pH 7.2 + 10% sucrose.  A small aliquot of pelleted virus was tittered using a 
standard plaque assay on BHKs and viral yield was compared to titers of pre-pellet 
aliquot to determine efficiency of recovery.   
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rNCP12.1 Single Injection 
 
Three to five days post-tumor implantation, rats were divided randomly into 
groups and viral injection was administered using the same injection procedure as 
performed for tumor implantation.  Through the pre-existing Burr hole, a single dose of 
rNCP12.1-GFP at either 105, 106, 107, or 108 pfu/ 25?L Tris-Saline + 10% sucrose (TN-
10) buffer was administered by Hamilton syringe. Vehicle only (TN-10) was given to 
control animals.  Animals were monitored daily for changes in weight and for signs of 
illness or treatment-related neurological deficits.  On day 15 post-tumor implantation, 
animals were sacrificed and the brains were harvested for further tissue processing.  A 
second group of treated and control animals were followed until RCS score, weights, 
and/or other clinical signs called for euthanasia. 
 
 
Alzet Pump 
 
On day five post- tumor implantation, ALZET pumps were prepared and filled 
with viral agent or viral vehicle in a sterile field according to manufacturer’s instructions.  
Pumps were placed in 0.9% sterile saline and incubated for 4-6 hours at 37oC as priming 
for the delivery of agent at the time of implantation.  Animals were anesthetized and 
placed onto the stereotaxic frame.  The previous incision site created during tumor 
implantation was opened and slightly widened to allow enough space for the pump 
implant.  Injection of rNCP12.1-GFP was administered as described.  Following 
injection, pre-filled ALZET pumps were implanted taking care to not damage the catheter 
and needle.  The needle was inserted directly into the pre-made Burr hole.  Once in place, 
the overlying skin was sutured with the pump in order to secure it into place.  The 
incision site was again sutured with 4.0 monofilament.  Animals were followed until RCS 
score, weights, and/or other clinical signs called for euthanasia. 
 
 
Serotype Switch 
 
On day 5, post-tumor implantation, rats were divided randomly into groups and 
viral injection was administered as described.  A single dose of rNCP12.1-GFP, Indiana 
serotype was administered at a dose of 109 pfu/ 10?L TN buffer by Hamilton syringe.  
Control animals received TN buffer vehicle only.  On day 10, post-tumor implantation, a 
second dose of 109 pfu/ 10?L rNCP12.1-GFP was administered.  Half of treated animals 
received Indiana serotype as the second injection and the other half received New Jersey 
serotype.  On day15 post-tumor implantation, animals were sacrificed and the brains were 
harvested for further tissue processing.  A second group of treated and control animals 
were followed until RCS score, weights, and/or other clinical signs called for euthanasia.   
    78 
Test for Tumorigenicity of Pre-Infected Tumor Cells 
 
Three 10cm dishes of F98-GFP cells were plated and grown overnight.  Cells 
were infected at an MOI of 0.1 or 10 with rNCP12.1-GFP for one hour at 31oC.  Cells 
were washed three times with SF-DME, trypsinized, centrifuged and resuspended in 5mL 
of PBS.  Uninfected cells were also trypsinized, centrifuged and resuspended in 5mL of 
PBS.  Cells were counted and aliquots of infected (MOI of 0.1 and 10) to uninfected cells 
at a ratio of 1:10 or 1:1 were made based on cell counts using a hemocytometer.  A total 
of 100,000 cells/10?l were prepared and implanted by the standard protocol. 
 
 
Pre-Infected Tumor Cell Carriers in Tumor Bearing Rats 
 
F98-GFP glioma cells were plated in 10cm dishes and grown overnight.  Cells 
were infected at MOI of 3 for one hour at 31oC.  Cells were washed three times with SF-
DME, trypsinized, centrifuged, and resuspended in 5mL PBS.  Cells were diluted to 1000 
cells/ 10?L and implanted per usual protocol.  
 
 
Recovery of Virus from PC-Treated Animals 
 
Sera, CSF, and non-fixed brain tissue from several animals was harvested.  A 
0.5cm3 area starting at the needle track continuing rostrally was excised from brain tissue 
and placed in 2mL PBS in a 15mL conical centrifuge tube.  Tissue was homogenized for 
2-3 minutes and cellular debris was removed by centrifugation.  One hundred microliters 
of each sample was added to cultured BHK cells for 1 hour at 31oC.  Samples were 
removed, warm agar containing D5 was applied, and cells were incubated at 37oC.  At 
24-36 hpi, agar was removed and cells were fixed and stained to detect VSV 
nucleocapsid using an ?VSV-N mAb (10G4) conjugated to Rhodamine.  Fluorescence 
images were captured and processed using Zeiss Axiovision.  
 
 
Tissue Processing 
 
Brains were harvested at the time of sacrifice following vascular perfusion and 
fixation.  For all experiments, perfusion included a vascular flush of 200mL 0.9% NaCl 
followed by fixation with 200mL 4% paraformaldehyde.  For brain tissue harvested from 
animals treated with rNCP12.1-GFP pre-infected tumor cells, only a vascular flush of 
400mL 0.9% saline was done without fixative as tissue was needed for qRT-PCR 
analysis.  Following fixation, brains were soaked in 4% paraformaldehyde (except for 
brain tissue harvested for qRT-PCR) for 24 hours and then 20% sucrose for 2 days.  
Cryosectioning of brain tissue was done starting at the site of injection (needle track) in 
10 ?m thick sections for samples used for Hematoxylin (Gill’s) and Eosin Y (Fisher 
Scientific, Suwanee, GA) (H&E) staining and at 14?m thick sections for 
immunohistochemistry (IHC).  The site of sectioning at and adjacent to the needle track 
was chosen as we assume this is the most likely site for tumor implantation although 
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variations do occur.  For IHC staining of tissue, sections were treated with 2% NFDM 
(nonfat dry milk) in 0.2M PBS/0.3% triton X-100 to block nonspecific staining.  Tissue 
was washed three times for 15 minutes each in PBS at room temperature.  The primary 
antibodies, rabbit -?GFAP at 1:80 and mouse-?VSV N protein (10G4) at 1:3, were used 
to probe for the astrocytic marker, GFAP, and VSV Nucleocapsid (N) protein, 
respectively.  Signal was amplified using the secondary antibodies, goat-?rabbit 
conjugated to Cy5 (blue) and goat -?mouse conjugated to Cy3 (red) (Jackson 
ImmunoResearch Laboratories) both at a concentration of 1:100 for 1-2 hours at room 
temperature.  All antibodies were diluted in 0.1% Triton-X /PBS containing the serum of 
the species from which antibody was derived.  Lastly, slides were washed and 
coverslipped.  Fluorescent markers were visualized using laser scanning confocal 
microscopy (Zeiss LSM 510 AIM version 3.2 software).  Slices were captured at 
magnifications of 0.4X, 10X, 20X, and 40X. 
 
 
Tumor Measurement 
 
Tumor surface area was determined based on images collected from fluorescence 
microscopy (Leica).  Using NIH Image J software, an outline of GFP- expressing tumors 
was traced and surface area was determined using a pre-set calibrated scale in millimeters 
(Set Scale command).  For rNCP12.1 pre-infected tumor cell experiment only, 
ImageScope (Aperio ePathology Solutions) software was used to measure and calculate 
tumor load. 
 
 
Statistical Analysis 
 
All data were analyzed using Prism Graphpad 6.0 software and expressed as mean ± 
standard deviation.  A One-Way ANOVA with multiple comparisons to an untreated 
control group was done for experiments having 3 or more groups while a two tailed t-test 
was used for comparison of the means for experiments having no more than two groups.  
For the evaluation of rNCP12.1-GFP pre-infected cells, multiple t-tests were done 
comparing treated versus untreated groups at each time point.  The Kaplan-Meier 
analysis of survival for animal experiments was done using a log-rank (Mantel-Cox) test.  
P values of <0.05 were considered to be statistically significant. 
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CHAPTER 3.    RESULTS 
 
 
In Vitro Characterization of rNCP12.1 
 
 
rNCP12.1 Retains Its Non-Cytopathic Phenotype in Normal Brain Cells While 
Remaining Cytopathic in Most Tumor Cell Lines 
 
As discussed, rNCP12.1 is a recombinant VSV vector harboring mutations that 
prevent its ability to form the truncated forms of the matrix protein.  This promotes its 
non-cytopathic phenotype in a number of cell lines including BHK21 cells.  In evaluating 
rNCP12.1 as a potential oncolytic virus for the treatment of malignant brain tumors, we 
wanted to first establish the cell rounding phenotype in cells of glial origin as this is 
associated with viral-induced cytopathic effects.  In order to do so, a cell rounding assay 
was performed in primary rat astrocytes (PRAs) and in two rat glioma cell lines, F98-
GFP and C6-GFP. Cells were infected with both wtVSV and rNCP12.1 at an MOI of 10 
and cell rounding was observed at 24hpi.  rNC12.1- infectedPRAs demonstrated minimal 
cell rounding at 24hpi in comparison to those infected with wtVSV.  This was similar to 
cell rounding previously seen in BHK-21 cells.  On the other hand, rNCP12.1 infection in 
F98 cells caused rounding and cells became detached from the culture plate by 24hpi 
comparable to wtVSV infection.  C6 glioma cells demonstrated a cell rounding variant in 
which the majority of cells were rounded but not detached from the plate (data not 
shown).  The cell rounding phenotype of rNCP12.1 infection was also determined using 
an MOI of 1 versus 10 in three human glioma cell lines, U87-GFP, A172, and T98G 
(Figure 3-1).  As with rat glioma cells, there was variation in cell rounding.  T98G 
glioma cells were least sensitive to rNCP12.1 infection with very few rounded cells. 
Though cells were not rounded, they did display a decrease in confluency at 24hpi in 
comparison to uninfected cells (Figure 3-1E and F).  Both U87-GFP (Figure 3-1A  
and B) and A172 (Figure 3-1C and D) human glioma cells were highly sensitive to 
rNCP12.1 infection and demonstrated wildtype like cell rounding. 
 
We next sought to determine if the observed cell rounding phenotypes with 
rNCP12.1 infection corresponded to differences in cell viability.  An MTS cytotoxicity 
assay was used in order to measure viability following infection at an MOI of 10 over a 
time range of 6 hours to 1week (168 hours) (Figure 3-2A).  In F98-GFP glioma cells, 
rNCP12.1 maintained close to wildtype cytotoxicity.  Viability decreased at a similar rate 
to wildtype infection, dropping to 32% within 48hpi.  C6-GFP glioma cells were ~90% 
viable relative to uninfected cells following infection with both viruses during the first 
day of infection, eventually dropping to approximately 40% by 48 hours.  As expected, 
cytotoxicity in PRAs showed the greatest attenuation during rNCP12.1 infection, with 
cells maintaining 65-70% viability at one week post-infection.  In contrast, wt-VSV 
infection in PRAs displayed a similar cytotoxic profile to that observed in F98 glioma 
with viability dropping to nearly 30% by 48hpi.  
 
In addition to the lack of cell rounding, cell specific differences in viral yield were  
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Figure 3-1. Cell rounding phenotype of rNCP12.1 in human glioma cells 
Human glioma cell lines, (A, B) U87-GFP (C, D) A172 (E, F) T98G were infected with 
either (B) rNCP12.1-dsRed or (D,F) rNCP12.1-GFP at an MOI of 10 for 1 hour at 31oC.  
At 24hpi, culture medium was removed and cells were fixed with 3% paraformaldehyde.  
Images were obtained by bright field and fluorescence microscopy at 10X magnification 
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Figure 3-2. Characterization of rNCP12.1 in glioma cells 
(A) MTS cell viability assay measuring cytotoxicity of F98-GFP glioma and primary rat 
astrocytes (PRAs) following infection with either wtVSV or rNCP12.1 at an MOI of 10. 
At t= 6, 12, 24, 48, 72hpi, and 1wkpi, culture medium was removed and MTS reagents 
using Cell Titer Assay (Promega) were added to cells for 4 hours at 37oC. Cell viability 
was calculated based on changes in absorbance at 490nm, (A490).  Values are reported as 
percent (%) absorbance relative to uninfected cells at the same time point.  (B) Growth 
Curve for rNCP12.1 versus wtVSV in PRAs and glioma cells.  Astrocytes or glioma cells 
(F98-GFP, C6-GFP) were infected with either wtVSV or rNCP12.1-GFP at an MOI of 
10.  At t=12, 24, 48, 72hpi and 1wpi, supernatants were harvested and used to determine 
viral titer by standard plaque assay in BHK cells.  [pfu, plaque forming units; hpi, hours 
post infection; wpi, week post infection] 
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observed.  To determine viral yield in glial cells, one step growth curves were obtained 
over the course of 1 week following infection in rat non-tumor and tumor glial cells  
(Figure 3-2B).  Supernatants from cells infected at an MOI of 10 were collected at 
various time-points and titers were obtained using a standard plaque assay in BHK cells.  
 
Previous studies have shown that rNCP12.1 viral yield in BHK cells is 10 fold 
lower than that of wtVSV [237].  Similar to these results, rNCP12.1 yields were 10-100 
fold lower than wtVSV at several time points during infection in both tumor and non-
tumor cell lines.  However, in glioma cells, rNCP12.1 titers eventually reached wtVSV 
titers by 72hpi whereas rNCP12.1 was consistently 10 fold lower throughout all time 
points in primary astrocytes.  We also observed that wtVSV growth in primary astrocytes 
was attenuated with yields 101-104 fold lower than titers obtained from wtVSV infection 
in tumor cell lines throughout the time course.  Mutations in rNCP12.1 had the most 
effect on viral yield in primary astrocytes with titers also ranging between 101-104 fold 
lower than rNCP12.1 titers in glioma cells.  There were also cell specific differences in 
the rate of viral production.  Though viral yields were different between wtVSV and 
rNCP12.1 in PRAs, the rate of infectious particles produced over time were congruent.  
Rates of viral yield in F98 cells were similar with exception of an earlier drop in yield 
during rNCP12.1 infection at 48hpi compared to a drop at 72hpi with wtVSV infection.  
On the other hand, consistent with results from the cell viability assay, C6 glioma cells 
lagged behind in viral yield during the first 48 hours of infection in comparison to F98.  
Whereas wtVSV slowly increased over 48 hours to yields similar in F98, rNCP12.1 titers 
remained stagnant at approximately 2x106 pfu/mL during this same time period, 
eventually increasing to wtVSV titers by 72hpi.   
 
These results confirm those of previous studies showing variations in VSV-
induced CPE and growth based on cell type [237, 358, 366, 369].  In the glial cells tested, 
there was a correlation between cell rounding and cell viability, which paralleled viral 
growth kinetics.  Growth and cytotoxicity of rNPC12.1 in PRAs were better controlled 
throughout infection whereas C6s revealed early but non-sustainable control that 
ultimately ended in cell death.  F98s, however, were less effective at controlling infection 
and therefore were more sensitive to the cytopathic effects of rNCP12.1. 
 
 
rNCP12.1 Upregulates IFN?  Expression and Increases Production of Active IFN 
over wtVSV in a Cell Specific Manner  
 
It has been shown that VSV-induced cell rounding and apoptosis are genetically 
linked with inhibition of host cell gene expression during infection [245, 250-254, 275].  
This inhibition is attributed to inhibition by the matrix protein at various stages of gene 
expression including transcription, nucleocytoplasmic transport, and protein translation.  
The expression of IFN and IFN stimulated genes are known to be greatly affected by M 
protein and VS virions harboring specific mutations in matrix have defects in the 
inhibition of IFN related antiviral responses [266, 289-291].  To determine if the matrix 
mutant, rNCP12.1, possessed the same inability to inhibit these responses following 
infection in both normal and tumor brain cells, we compared levels of IFN? expression 
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following infection with wtVSV and rNCP12.1 in the C6 glioma cell line compared to a 
rat fibroblast cell line (FR).  Using semi-quantitative reverse transcriptase-polymerase 
chain reaction (RT-PCR), we first tested for presence of IFN? message following 
infection with either wtVSV or rNCP12.1 at an MOI of 10 at 6 and 12hpi (Figure 3-3A).  
We saw that wtVSV induced very low levels of IFN? expression at both time points in 
FR cells while almost negligible amounts were expressed in C6 cells.  rNCP12.1, on the 
other hand, induced a robust expression of IFN? which was present at both time points in 
FR cells.  IFN? levels were also induced in C6 cells comparable to levels in FR cells at 
6hpi however this signal decreased tremendously by 12hpi.  Expression levels were 
normalized to the housekeeping gene, ?-actin, however expression levels of ?-actin were 
affected by infection in C6 glioma cells.  As a result, all subsequent RT-PCR experiments 
used Cyclophilin B as the housekeeping gene as its expression levels were not affected by 
infection with wtVSV or rNCP12.1 (discussed in Appendix A).  We next used 
quantitative RT-PCR (qRT-PCR) to obtain more precise expression levels of IFN? in FR 
cells, primary astrocytes, and both glioma cell lines at 24hpi (Figure 3-3B).  We found 
that both wtVSV and rNCP12.1 upregulated transcription of IFN? however, rNCP12.1 
increased message 3x103 fold greater than wildtype in primary astrocytes.  rNCP12.1 also 
upregulated IFN? in glioma cells ~102 fold over wildtype though these levels were 
exponentially lower than levels observed in primary astrocytes. 
 
We next determined if upregulation of message following infection corresponded 
with an increase in production of active IFN through the use of an IFN bioassay.  In this 
assay, L929 murine cells are exposed to harvested supernatant of immuno-stimulated 
cells and evaluated for inhibition of viral-induced CPE.  We first tested the ability of our 
bioassay to detect IFN produced by the glial cells in response to polyinosinic: 
polycytidylic acid (pI:C), a synthetic dsRNA molecule used to elicit antiviral responses 
predominantly through the TLR3 pathway.  Cells were either treated for 6 hours with 
pI:C containing media or by transfection of pI:C at increasing concentrations.  After 6 
hours, fresh media was added and samples were harvested at 24 hours following pI:C 
treatment.  Mouse embryonic fibroblasts (MEF) were used as a positive control (Figure 
3-3C).  Cells exposed to pI:C containing media were unable to produce detectable IFN 
regardless of cell type at any concentration of pI:C.  In line with what is known about 
pI:C induced antiviral responses, transfection of pI:C was superior in inducing an 
interferon response in all cell types tested, with the highest dose of 10?g eliciting the 
most robust production of IFN.  PRAs produced the greatest amount of active IFN 
(5.3x103 U/mL), similar to control cells, while F98 levels were less than 102 U/mL.  We 
then followed the induction of IFN using this predetermined dose of transfected pI:C over 
a 24 hour time period in glioma cells.  FR cells were used as the positive control for this 
study (Figure 3-3D).  Starting at 4 hours, a gradual production of biologically active IFN 
in FR cells was observed with amounts greater than104 U/mL being produced by 24 
hours after treatment.  F98 glioma cells again produced the least amount of IFN 
throughout the study with levels less than 102 U/mL throughout the time course.  C6 
glioma cells produced comparable amounts of active IFN to F98 glioma at earlier 
timepoints with an increase in production, exceeding 102 U/mL by 24 hours. 
 
Once the ability to produce active IFN detectable by our IFN bioassay was  
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Figure 3-3. Cell and viral specific comparisons of IFN responses 
(A) Semi-quantitative RT-PCR and (B) qRTPCR verifying specificity of primers in FR 
and C6 cells.  Cells were infected with either rNCP12.1 or wtVSV at an MOI of 10 for 1h 
at 31oC.  At 6 and 12hpi, cells were harvested, RNA was extracted using trizol reagent, 
and extracted RNA was amplified.  rNCP12.1 infection resulted in increased IFN signal 
at both time points similarly in FR cells while signal increased in C6 cells at 6h with 
dissipation of signal by 12hpi.  Results were normalized to the housekeeping gene, ?-
actin.  Of note, changes in basal levels of ? -actin were observed following viral infection 
C6 glioma cells, therefore expression levels of IFN ?1 were unable to be normalized in 
this cell line.  (B) For qRT-PCR, expression levels were normalized to Cyclophilin B 
gene.  Values are presented as means of duplicates with standard errors.  (C) IFN activity 
following treatment with (C, D) pI:C or (E) virus.  (C) Cells were either treated with 
various amounts (?g) of pI:C in culture media or with transfected pI:C using 
lipofectamine 2000 (Invitrogen).  At 24h after treatment, supernatant was collected and 
used for detection of IFN activity using an IFN bioassay in L929 murine cells.  Values 
obtained are based on comparisons to antiviral activity of the rat IFN (rIFN) standard for 
each bioassay.  IFN activity is expressed in units (U)/mL.  (D) Detection of IFN activity 
following treatment of 10?g transfected pI:C at t =2.5, 4, 6, 12, 18, 24 hours post 
transfection.  There is a gradual increase in IFN activity starting at 4 hours post-
treatment, extending to 24 hours.  (E) Detection of IFN activity following viral infection.  
Cell lines were infected with wtVSV or rNCP12.1-GFP at an MOI of 10 for 1h at 31oC.  
At several time points following infection (t= 6, 12, 18, 24hpi), supernatants were 
collected and residual virus was removed by ultrafiltration using Amicon filters 
(Millipore).  Virus free supernatant was then used to detect IFN activity.  (F) Ratio of 
IFN gene expression: IFN activity.  Using data obtained from qRT-PCR and IFN 
bioassay described above, a combined graph was constructed revealing cellular and viral 
differences in the translation of IFN message into biologically active IFN.  
pI:C= polyinosinic:polycytidylic acid; Level of significance denoted by “*” to “****” 
from low to very high significance, respectively. 
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confirmed, we tested the supernatant from virally infected glial cells for presence of 
active IFN to determine if upregulation of IFN? message corresponded with IFN activity. 
 
Supernatant of virally stimulated cells was harvested from 6-24hpi and residual 
virus was separated by ultra-filtration so that IFN activity could be determined more 
accurately using the IFN bioassay (Figure 3-3E).  We found that wtVSV infection did 
not result in detectable levels of IFN in the FR control cell line or in any glioma cell line, 
however a low amount of 6.25U/mL IFN was detected at 24hpi in the primary astrocytes.  
Therefore, though wtVSV induced the synthesis of IFN? message, this did not 
significantly translate into active protein in the glial cell lines. This observation is 
consistent with results from a number of studies that suggest matrix protein inhibits IFN 
responses at multiple levels of gene expression including nucleocytoplasmic transport of 
mRNA and protein translation.  On the other hand, the rNCP12.1 matrix mutant 
stimulated the production of biologically active IFN in control cells, primary astrocytes, 
and glioma cell lines.  FR cells produced copious amounts of IFN with levels totaling 
2.56x104U/mL at 24hpi, comparable to induction of IFN gene expression in these cells.  
In comparison, though rNCP12.1-induced expression of IFN?  was 10 fold higher in 
primary astrocytes than FR cells, they produced a maximum of 1.6x103 U/mL of IFN at 
24hpi, 16 fold less than FR cells.  Not surprisingly, glioma cells produced active IFN 
during rNCP12.1 infection.  F98-GFP produced the least active IFN at 24hpi (1.3x102 
U/mL) while C6s produced approximately 8 fold more IFN than F98 at the same time 
point despite its lower induction of IFN? transcription.  In addition, IFN levels in C6s 
remained steady, maintaining 800U/mL of IFN over all time points.  This steady state of 
IFN produced by C6 cells corresponds to the stagnant viral yield and delayed viral-
induced cytotoxicity by rNCP12.1 infection over the same time period.  In comparison to 
primary astrocytes, this amount was approximately 16 fold higher at the earliest time 
point tested (6hpi) however IFN production in PRAs, eventually increased to surpass C6 
levels by 18hpi.  These results suggest that not only is the quantity of active IFN 
produced important in eliciting a protective antiviral state in infected cells during viral 
replication but the ability to amplify IFN signaling is important as well. 
 
 
IFN?  Gene Expression Does Not Correlate with Production of Active IFN in 
Primary Rat Astrocytes 
 
Based on a recent review by Vogel and Marcotte, 40% of the variability in protein 
synthesis can be attributed to the abundance of mRNA.  The other 60% is due to post-
transcriptional events such as protein stability or regulatory mechanisms of translation 
[370].  Generally, message in mammalian cells is less stable and is produced at a much 
lower rate than proteins.  The average rate of synthesis of transcripts has been shown to 
be approximately two mRNA per hour compared to dozens of protein 
molecules/mRNA/h [370].  This rate tends to vary based on cell type, protein of interest 
(metabolic proteins versus proteins involved in transcriptional regulation), and cellular 
conditions.  Nevertheless, most studies use mRNA abundance as a means of predicting 
the likelihood of detecting its coded protein.  In our studies, all three parameters appear to 
play a role in the correlation between mRNA abundance and protein activity.  It must be 
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noted, however, that these studies do not aim to correlate mRNA message with the total 
amount of protein produced but rather to the amount of active protein produced under 
variable conditions.  A comparison of IFN gene expression to production of active IFN 
following mutant and wildtype infection revealed notable cell and viral specific 
differences in the ability to elicit the IFN mediated antiviral pathway.  In each cell type, 
though wtVSV induced gene expression of IFN? over non-infected cells, this did not 
correlate with production of active IFN.  rNCP12.1 however induced expression of IFN? 
which translated to active IFN, though still not according to the expected rate of 
synthesis.  Interestingly, this deviation was more pronounced in primary astrocytes.  
Whereas the ratio of active IFN to message corresponded to approximately 1:10 in the 
control cell line and in both glioma cell lines, values were more disproportionate in 
primary astrocytes with a ratio closer to 1:103 at 24hpi (Figure 3-3F). 
 
In evaluating the IFN response from this perspective, these results not only 
reinforce the influence of the matrix protein in the antiviral response pathway but they 
also confirm that a number of variables effect adherence to the rate of production of 
mRNA to protein.  We specifically see the effects of cell type as primary astrocytes 
produced much lower amounts of active IFN relative to its level of induction of gene 
expression following rNCP12.1 infection.  Despite this disparity, PRAs demonstrated a 
greater response to the active IFN produced which was evident not only in cell viability 
but in the production of infectious virus over time.  On the other hand, though C6 glioma 
cells produced detectable amounts of active IFN following rNCP12.1 infection that 
correlated more with the induction of IFN? gene expression, these cells responded less to 
IFN which was also evident in cell viability, cell rounding, and viral growth kinetics.   
 
 
Primary Astrocytes Are Highly Sensitive to the Anti-Viral Effects of IFN While 
Glioma Cells Are Not 
 
In order to determine if differences in the ability to produce IFN correlated with 
IFN sensitivity in glial cell lines, we performed a protection assay in which cells were 
pretreated with escalating doses of rat IFN? (r IFN?) (0-1000 units) for 24 hours then 
infected with wtVSV at an MOI of 3.  At 24hpi, cells were stained by 
immunofluorescence to detect VSV nucleocapsid (N).  Response to interferon was graded 
by the gross detection of staining in IFN treated versus untreated cells.  Protection was 
defined as samples with less than 50% VSV-N positive cells (Table 3-1).   
 
Primary astrocytes were protected starting at 3.125 U of IFN.  C6s were also 
protected from viral infection but at higher doses of IFN, starting close to 100U.  F98s, 
however, were not protected from viral infection even at the highest dose of 1000 units 
(Table 3-1 and Figure 3-4).  These results suggest the glioma cell lines are less sensitive 
to the antiviral effects of IFN and confirm the results of previous studies that the level of 
IFN sensitivity can vary among tumor cell types even when derived from the same 
histological cell of origin [358, 371].  
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Table 3-1. Sensitivity to antiviral effects of IFN 
 
Cell 
Type 
IFN (U) 
High Dose  Low Dose 
1000 250 125 62.5  100 50 25 12.5 6.25 3.125 2.562 1.562 
PRA + + + +  + + + + + + + - 
C6 + + + -  + - - - - - - - 
F98 - - - -  - - - - - - - - 
 
Note: +, protection (<50% cells positive for N protein staining);  -, no protection (>50% 
cells positive for N protein staining). 
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Figure 3-4. Representative fluorescence micrographs showing infection of cells 
with wtVSV following IFN pre-treatment 
(A) C6-GFP, (B) F98-GFP, and (C) Primary rat astrocytes were pre-treated with various 
doses of IFN then infected with wtVSV at an MOI of 3. Cells were then labeled with 
anti-VSV N antibody conjugated to Rhodamine at 24hpi and visualized by fluorescence 
microscopy at 10X magnification. 
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As the above experiments have demonstrated, matrix mutations in rNCP12.1 alter 
its ability to cause cell rounding and apoptosis in normal cells, which appears to be 
correlated with its ability to promote IFN? gene expression and, ultimately, IFN 
production.  On the other hand, these defects reveal a spectrum of phenotypes in tumor 
cells of glial origin with F98 displaying a high IFN resistance, high CPE phenotype and 
C6 glioma cells displaying a more intermediate IFN resistance with an intermediate CPE 
phenotype. 
 
 
IFN Activity Following rNCP12.1 Infection Is Associated with Induction of ISGs in 
Primary Astrocytes While Glioma Cells Vary in Their Ability to Elicit Downstream 
IFN Responses 
 
In order to evaluate involvement of specific elements of the IFN pathway and 
how they correlate with cytopathic effects and IFN production in tumor cells, we 
surveyed the expression of interferon stimulated genes by qRT-PCR at 24 hours 
following viral infection using the cell fraction collected from the previous IFN bioassay 
studies.  Key ISGs that have been shown to be elevated following exposure to IFN and/or 
viral infection were considered [289, 333, 371, 372].  According to data obtained by 
Stojdl et al [289], expression of ISGs are time specific following VSV infection and this 
expression may vary depending on alterations in the matrix protein.  For instance, 
primary transcriptional responders appear during early infection (3-6hpi).  These include 
ISG15 and IFN? and are dependent on factors that bind interferon stimulated response 
elements (ISRE) in the IFN? promoter region such as IRF3 and NF?B.  IRF-1 and RIG-I 
have been shown in separate studies to be upregulated early in infection and may 
therefore be considered primary transcriptional responders.  In addition, these two ISGs 
have been shown to be constitutively active in a number of cell lines including astrocytes 
[310, 372] and are directly upregulated by viral infection even in the absence of 
interferon [310, 373].  Mx-1/2, GBP-1, and Plscr-1 are considered secondary 
transcription responders, appearing 6-12 hpi.  These responders are dependent on the 
activity of ISGF3, a heterotrimer formed by IRF9, Stat 1, and Stat2 as has been 
described.  Lastly, responders such as IFN?4 appear latest in infection, usually after 12 
hours. These genes are known as tertiary transcription responders and are dependent on 
IRF7 for their activation [289].  Other studies, however, consider IFN?4 an immediate 
early response gene, showing upregulation as early as 4hpi even in the absence of active 
protein synthesis [374].  Nevertheless, expression of secondary responders is inhibited by 
wtVSV infection whereas mutants defective in inhibition of host gene expression 
promote expression of these responders.  By blocking this step, wtVSV consequently 
inhibits the transcription of tertiary responders as well. 
 
As expected, rNCP12.1 induced the expression of all ISGs over wildtype in 
primary astrocytes, similar to induction in FR cells (Figure 3-5A-F).  Of the ISGs tested, 
only plscr1 was not significantly induced by infection and no significant differences in 
expression levels were observed between wtVSV and rNCP12.1 (Figure 3-5F).  Glioma 
cell lines were more variable in their ISG expression.  F98 glioma cells are both resistant 
to IFN and unable to produce amounts of active IFN that would be protective against  
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Figure 3-5. Differences in interferon stimulated genes (ISGs) following viral 
infection with wtVSV or rNCP12.1-GFP   
(A) IFN?4, (B) Ddx-58 (RIG-I), (C) IRF-1, (D) Mx1/Mx2, (E) GBP-1, (F) Plscr-1.  Cells 
were infected at an MOI of 10 for 1 hour at 31oC.  Cells were then harvested, RNA was 
extracted, amplified, and quantified using qRTPCR at 24 hours of infection. Expression 
levels are normalized to the cellular Cyclophilin B gene and are presented as means of 
duplicates ± SD.  Expression levels vary based on gene tested (see y axis for different 
scales) 
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viral infection.  In parallel,the induction of most ISGs tested was lowest in F98s 
following infection compared to other cell types.  rNCP12.1 upregulated all secondary 
ISG responders significantly over wtVSV (Figure 3-5D-F).  Interestingly, plscr1, a 
secondary responder that was not induced in the other cell lines, was expressed 
approximately 10 fold higher after rNCP12.1 infection relative to wtVSV in F98 and to 
expression in the other cell lines (Figure 3-5F).  In addition, expression of the primary 
responder, IRF1, and tertiary responder, IFN?4, were induced by both viruses at similar 
levels in the glioma cell lines.  C6 glioma cells, having a more intermediate resistance to 
IFN, also varied in ISG expression. Both GBP1 and Mx1/2, secondary ISGs, were 
induced by rNCP12.1 infection similar to induction in PRAs although the induction of 
GBP1 was not significant.   Like PRAs, these cells were low in their induction of plscr1 
with both wtVSV and rNCP12.1 (Figure 3-5D-F).  Unexpectedly, IRF1 induction did not 
follow the pattern of higher induction with rNCP12.1 infection. Rather, wtVSV induced 
IRF-1 expression 2.5 fold higher than rNCP12.1 (Figure 3-5C).  Another primary 
responder, Ddx58, had a greater induction in C6s after rNCP12.1 infection with 
expression approximately 2.5 fold higher than rNCP12.1 infection in primary astrocytes 
(Figure 3-5B).  These data are represented by a heat map depicted in Figure 3-6. 
 
 
rNCP12.1 Alters the Temporal Expression of Ddx-58 (RIG-I) in Glial Cells 
 
Ddx58 or RIG-I is important in the detection of viral RNA and therefore in 
eliciting IFN mediated antiviral responses during infection.  In addition, it is a known 
ISG that is upregulated early during infection.  Ddx-58 is also a known activator of NF?B 
[372] that has been implicated as a determinant in resistance to the apoptotic effects of 
IFN.  Like IRF-1, Ddx-58 was found to be constitutively expressed in primary human 
astrocytes with increased levels following wtVSV infection reaching optimal expression 
by 4hpi then falling back to baseline by 8hpi [372].  Our results demonstrate that Ddx-58 
expression is low but slightly elevated at 24 hours following wtVSV infection in both rat 
fibroblasts and primary rat astrocytes (Figure 3-5B).  Both glioma cells showed higher 
expression following wtVSV infection with C6 expression 50 fold higher than uninfected 
cells.  There was an even greater rise in expression in both glioma and normal cells 
following rNCP12.1 infection with levels more than 100 fold higher in all cell types over 
uninfected cells.  As with wtVSV infection, rNCP12.1 induced expression of Ddx58 in 
C6 glioma that was double the levels of induction in other cell types.  In comparison to 
results by Furr et al [372], our results showed that Ddx58 expression was still elevated 
however at low levels even at 24hpi and this expression was greatly enhanced by the 
matrix mutations found in rNCP12.1.  We also see that in C6 glioma, which 
demonstrated stagnant viral yield, fixed cell viability, and unwavering levels of active 
IFN during the first 24-48 hours of rNCP12.1 infection, Ddx58 levels are highly elevated 
even more so than normal cells.  It could be that the upregulation of Ddx58 in these cells 
is involved in delaying apoptosis during the first 2 days of infection via downstream Ddx-
58 stimulated effectors. 
 
Though there are obvious host specific differences in IFN responses following 
rNCP12.1 infection, the overall inability of glioma cells to produce a sustainable antiviral  
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Heatmap Key 
Figure 3-6. Heat map representation of IFN stimulated gene (ISG) expression in 
normal and tumor glial cells following viral infection 
N/A= not available for comparison
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IFN response in comparison to the protective antiviral responses elicited in normal cells 
contributes to the oncolytic capacity of this vector.  Based on these differences, we next 
evaluated the oncolytic activity of rNCP12.1 in an in vivo model of intracranial glioma. 
 
 
Efficacy of rNCP12.1 in an Immunocompetent Intracranial Model of Glioma 
 
 
Intracranial Administration of rNCP12.1 Is Safe Relative to wtVSV in Non-Tumor 
Bearing Animals 
 
The mortality and morbidity caused by VSV infection varies based on immune 
status of host as well as mode of administration.  This has been studied using 
experimental murine models in which intranasal administration of VSV leads to a less 
fatal encephalitic disease whereas intracranial administration of virus usually results in a 
fatal disease marked by severe neurological symptoms within 2 weeks post-infection 
[219, 351, 375].  Younger animals are more susceptible to viral neurotoxicity; however, 
attenuated strains of VSV demonstrate mild disease regardless of age.  Hence, we wanted 
to first determine mortality and morbidity in animals receiving rNCP12.1 intracranially 
relative to wildtype.  This was carried out in an immunocompetent non-tumor bearing 
model.  On day zero, six week old Wistar rats weighing ~250-350 grams were given an 
intracranial injection of 109 pfu rNCP12.1-GFP or wtVSV-GFP.  Along with survival, 
weight trends were followed throughout the study.  Animals were sacrificed at day 15 
post-infection or when criteria for euthanasia were met.  As expected, we found that wt-
VSV caused severe neurotoxicity with all animals succumbing to infection by 8 days 
post-infection.  On the other hand, neurotoxicity of rNCP12.1 was attenuated with 
animals surviving to the end of the study.  In addition, average weight of rNCP12.1-
infected animals progressed at a comparable rate to animals receiving only viral vehicle 
(Tris-Saline + 10% sucrose, TN sucrose) (data not shown). Based on these studies we 
concluded that rNCP12.1 could safely be administered intracranially for the treatment of 
glioma in this rat model. 
 
 
rNCP12.1 Decreases Tumor Load in a Dose Dependent Manner Without Causing 
Morbidity in an Intracranial Model of C6-GFP Glioma 
 
Our initial evaluation of the oncolytic activity of rNCP12.1 against intracranially 
implanted glioma was first executed in a rat model using C6-GFP glioma cells in the 
immunocompetent Wistar rat.  This model was chosen as previous studies by our lab 
demonstrated in vitro proof-of-principle of the oncolytic activity of a replication 
restricted rVSV vector in a co-culture of C6 glioma with normal CNS cells from various 
brain structures [354].  On day zero, cells were implanted intracranially as described and 
allowed to grow for three days.  At three days post tumor implantation, animals were 
given varying doses of intratumorally injected virus.  Animals were then euthanized at 15 
days post infection in order to assess differences in tumor size based on fluorescence 
from GFP expressing tumor compared to animals treated with viral vehicle (TN-sucrose).  
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Tumor sizes were measured from cryo-sections by circumscribing the tumor area defined 
by GFP fluorescence using NIH ImageJ software as described in Chapter 2.  
Measurements based on fluorescence were compared to those obtained by H&E staining 
of tissue and found to be indistinguishable (data not shown).   
 
We found that tumor size inversely correlated with dose of VSV.  The highest 
dose tested of 108 pfu demonstrated the greatest decrease in tumor load of 82% relative to 
vehicle treated tumors while the lowest dose of 105 pfu resulted in 15% tumor load 
reduction (Figure 3-7A). Surprisingly, three of five animals treated with 108 pfu had 
nearly undetectable tumors.  In addition, weight trends were followed in animals 
receiving the highest dose of rNCP12.1 (107 and 108 pfu).  Weights decreased 
accordingly in all groups following tumor implantation but gradually increased over the 
next few days before virus administration.  On the day following treatment, all animals 
decreased in weight with animals receiving a higher dose of virus decreasing the most 
over the first 24 hours of infection (5.2g versus 1.2g in vehicle only).  The animals in this 
treatment group also experienced an extended duration of weight decline seen on day 5, 
whereas, an increase in weight was observed in the other two groups at this time point.  
However, by day six, average weights of all groups rose at similar rates though animals 
receiving the highest dose of virus had an overall lower average weight at each time 
point.  Despite this, no group experienced more than a 5% decrease in weight during the 
study and by day 15, all animals had gained at least 50 grams over their pre-tumor 
implantation weight (Figure 3-7B).  Together, these results suggest that one dose of 
rNCP12.1 does not cause significant morbidity or mortality as all animals survived to the 
end of the study with an overall increase in weight over time.  Therefore this oncolytic 
virus appeared to be safe for administration in the brains of tumor bearing animals. In 
addition, we concluded a single dose of rNCP12.1 was effective at reducing tumor 
growth in a dose-dependent manner when given intracranially in the C6 glioma bearing 
Wistar rat model. 
 
 
Comparison of the F98 Glioma/ Fischer Rat Model 
 
Because C6 gliomas are derived from outbred Wistar rat, they have been shown to 
be immunogenic in inbred rats causing tumors to often regress spontaneously by 4 weeks 
post-implantation.  As a result, this model, though appropriate for short term studies, is 
not appropriate for studies in which long term survival would be determined [376, 377]. 
Therefore, the syngeneic F98 glioma/ Fischer rat model was used for the remainder of 
our studies.  The F98 glioma cell line was chemically induced by giving the mutagenic 
alkylating agent, ethylnitrosourea (ENU), to pregnant Fischer rats resulting in offspring 
harboring spontaneous brain tumors [378, 379].  F98 tumors are refractory to most 
therapies and demonstrate an invasive pattern of growth.  As few as 10-100 tumor cells 
are capable of developing into an aggressive tumor and, with an engraftment rate of 
>90% following intracranial administration, this model is considered a reliable 
experimental model capable of mimicking human disease [376, 380].  Further, time of 
progression from implantation to adverse neurological changes caused by tumor mass 
effect is short, occurring in about 2 weeks post-implantation.  Therefore this model is  
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Figure 3-7. Dose-dependent reduction of C6 tumors after rNCP12.1 treatment  
C6-GFP glioma bearing adult Wistar rats were inoculated with a single dose of 
intratumoral (i.t.) virus on day 3 post tumor implantation (pti).  Four treatment groups 
included a single injection of rNCP12.1-GFP at 105, 106, 107, or 108 pfu (n=5). Animals 
were euthanized at day 15 pti and tumor load was determined based on tumor 
measurements from fluorescence images using NIH ImageJ software. (A) Tumor size is 
represented by percent (%) reduction compared to control tumors.  (B) Weight trends of 
animals treated in higher dose (107 and 108 pfu) of rNCP12.1 compared to animals in 
control (vehicle) group.  Weights at each time point are an average of those obtained for 
each treatment group.  Unpublished data from Himangi Jayakar and Qihong Zhou, 2005. 
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effective at allowing us to study survival as well as the possible immunological responses  
elicited against virus and/or against tumor as a result of viral treatment. 
 
We carried out a comparative study of tumor anatomy and histology between the 
C6-Wistar rat model and F98-Fischer rat model.  F98 glioma cell line was previously 
transduced with the pFB retrovirus expressing GFP (pFB-GFP) to allow visualization of 
tumor.  As described, either 105 C6 glioma cells or F98 glioma cells were implanted 
intracranially in Wister or Fischer rat, respectively.  On day 15, post-tumor implantation, 
animals were euthanized and brains were harvested for analysis of tumor load following 
H&E staining and fluorescence microscopy for visualization of GFP expressing tumors. 
Representative images in Figure 3-8 demonstrate the gross and microscopic features of 
these tumors.  While C6 gliomas are less aggressive and more immunogenic, forming a 
well-demarcated tumor mass at 15 days following implantation (Figure 3-8A-C), F98 
gliomas are more infiltrative and tend to invade surrounding normal tissue much like 
high-grade human gliomas (Figure 3-8D-F). 
 
We next sought to determine the growth kinetics of implanted F98 tumors to 
gauge changes in tumor size over several time points and the reproducibility of 
establishing tumors following implantation (Figure 3-9A).  105 cells were implanted 
intracranially as decribed and animals were euthanized at 3, 6, 9, and 15 days post tumor 
implantation.  Brains were harvested and assessed for tumor load based on GFP 
expression of F98 glioma cells.  We found that establishment of tumors were 
reproducible at each time point and that tumor size gradually increased as expected over 
time.  Measure of morbidity was determined not only by weight trends throughout the 
study but also by changes in neurological function as assessed by the rat coma scale 
(described in Chapter 2).  In this study, average weight of animals never dropped below 
10% of starting weight (Figure 3-9B) and neuroscores ranged between 9.5-11 with the 
lowest scores occurring at day 12 (Figure 3-9C).  This range of neuroscores is expected 
as tumor load usually begins to cause neurological dysfunction within 2 weeks of 
implantation.  As experienced in this study, there are often additional neurological signs 
and symptoms not measurable with the rat coma scale that may occur.  These additional 
neurological signs, when observed, range from changes in grooming to staggering during 
ambulation (ataxia).  Based on symptomology, animals may require euthanasia even 
when neuroscores and weights are within normal limits.  An explanation of these 
additional symptoms that are considered in criteria for euthanasia can be found in 
Chapter 2. 
 
 
Intracranial Administration of rNCP12.1 Is Safe but Results in a Non-Durable 
Reduction of Tumor Load in the F98 Glioma Model 
 
With reproducibility of tumor implantation and growth established, we next tested 
the oncolytic activity of rNCP12.1 against F98 glioma in vivo in order to determine if the 
antitumor activity we observed in our in vitro studies translated into the intracranial 
animal model.  Because the highest dose tested in C6-Wistar model of 108 pfu was well 
tolerated and most effective, we decided to increase the dose to 109 pfu for subsequent  
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Figure 3-8. Comparison of the C6 and F98 rat intracranial glioma models  
Coronal sections of brain tissue harboring  (A-C) C6 and (D-F) F98 intracranial gliomas 
in Wistar and Fischer rats, respectively.  (A, D) H&E stained sections taken at 1.25X 
magnification.  Brain tissue in the right hemisphere reveals increased cellular infiltration 
and a tumor mass that is causing compression of the ventricles and a midline shift toward 
the contralateral side of the brain.  (B&E) Fluorescence microscopy illuminating the GFP 
(green) expressing tumor.  (C, F) Fluorescence confocal microscopy at 60X 
magnification of both C6 (C) and F98 (F) gliomas within brain tissue. 
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Figure 3-9. Tumor progression of F98-GFP glioma in Fischer rat over time 
(A) Fischer rat were implanted with 100,000 cells resuspended in 20?L of PBS on day 
zero.  Animals were sacrificed every three days for 15 days in order to determine tumor 
load by GFP expressing tumor cells (See inset fluorescence micrographs).  (B) Weight 
trends and (C) Neuroscores measured every three days before euthanasia (n=3). 
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studies.  As described in Chapter 2, F98-GFP gliomas were implanted in six week old 
male Fischer rat and allowed to grow for three days at which point one intratumoral 
injection of 109 pfu rNCP12.1-GFP was administered (Figure 3-10).   
At 15 days following tumor implantation, the first group of rNCP12.1 treated 
animals (n=9) was sacrificed and brains were harvested and assessed for tumor size.  We 
found that at 15 days post infection, tumor size was 66% smaller (p< 0.0013) than 
vehicle-treated controls (Figure 3-11A).  Representative fluorescence micrographs are 
seen in Figure 3-11Bi, iii).  Morbidity at time of sacrifice was minimal as determined by 
weight trends (Figure 3-12A) and neuroscore (Figure 3-12C).  Weight trends following 
tumor implantation and up to one day post-treatment were as expected based on similar 
findings observed during the previous dose escalation study in Wistar rats.  By 48 hours 
post-infection, weight trends in vehicle treated animals continued to increase and on 
average animals weighed approximately 20g more than starting weights (day 0).  On the 
other hand, virally treated animals continued to decline in weight up to 4 days post-
infection at which point weights plateaued and slightly increased at several time points 
until the end of the study.  At the most, weight of virally treated animals decreased 15.5% 
(day 11) of starting weight but never exceeded a 20% decline.  Neuroscores for both 
vehicle only and rNCP12.1 treated animals ranged between 10 and 11 with the most 
common decrease in score attributed to changes in spontaneous movement.   
Another group of treated animals (n=9) were used to determine survival.  These 
animals were allowed to live until criteria for euthanasia were met based on effects of 
viral treatment, weight trends, and/or tumor load.  Based on log rank analysis of the 
Kaplan-Meier survival curve comparing vehicle treated to rNCP12.1 treated animals, 
there was a small yet significant difference in survival in animals receiving virus 
(p=0.0063) (Figure 3-12E).  Median survival of virus-treated animals was 29 days 
compared to 23 days in those treated with vehicle.  Despite the remarkable decrease in 
tumor size due to rNCP12.1 treatment observed at 15 days post tumor implantation, at the 
time of sacrifice, tumors were not significantly different than vehicle-treated animals, 
displaying only an 11% decrease in tumor load (Figure 3-11A and Bii, iv).  
Immunohistochemical analysis of cryosections from an animal in the acute group 
was performed.  H&E stain shows areas of hypercellularity marked by necrotic tissue 
with infiltrating blood cells possibly marking areas where tumor became hemorrhagic  
Figure 3-10. Timeline for the single rNCP12.1- GFP injection study in Fischer rat 
Day 0 3 
Tumor 
Virus 
injection 
Survival 
15 
Sacrifice 
(Acute) 
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Figure 3-11. Comparisons of tumor properties in animals treated with a single i.t 
injection of rNCP12.1-GFP 
Comparison of tumor load as a percentage of tumor load in uninfected animals in animals 
from the (A) acute arm of study sacrificed at 15 days following tumor implantation; 
(p=0.0013) and survival arm, sacrificed when criteria for euthanasia were met (p=0.2829, 
ns). (B) Representative fluorescence micrographs demonstrating tumor size in (i) acute 
control animals (ii) acute virus-treated animals (iii) survival control animals (iv) survival 
virus-treated animals.  (C) Micrographs of brain tissue from a treated animal in the acute 
arm, demonstrating patterns of inflammation and of viral infection relative to tumor.  (i) 
H&E stain (ii) Fluorescence; F98-GFP tumor cells (green); Virus (Red).  (D) Additional 
labeled tissue samples from the same animal illustrating tumor (green), virus (red), and 
GFAP astrocytic marker (Blue) (i) left (untreated) hemisphere (ii) 10X magnification of 
right (treated) hemisphere, (iii) 20X magnification (iv) 40X magnification. 
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Figure 3-12.  Measures of morbidity of animals treated with a single i.t. injection of 
rNCP12.1-GFP 
Weight trends of animals in the (A) acute and (B) survival arms.  Neuroscores of animals 
in (C) acute and (D) survival arms.  (E) Kaplan-Meier survival analysis demonstrating a 
significant difference in survival between virus-treated animals and controls.  Statistical 
data performed using Log-rank (Mantel-Cox) test; P= 0.0063.  
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due to leaky tumor associated blood vessels (Figure 3-11Ci).  In correlation, staining of 
virus for VSV-N using a rhodamine-conjugated antibody demonstrated areas of increased 
GFP expression near the surface of the brain with positive rhodamine (red) labeling 
intraparenchymally (Figure 3-11Cii).  Additional tissue was double labeled for detection 
of the astrocytic marker, GFAP (glial fibrillary acidic protein) (blue) and virus (red).  The 
uninfected hemisphere is shown for comparison and demonstrates the normal presence of 
GFAP astrocytic marker in the area of the subventricular zone (Figure 3-11Di).  Staining 
of tissue in the right hemisphere reveals GFP expressing tumor with GFAP present within 
the tumor as well as surrounding normal tissue.  Additionally, we see virus present 
specifically within the tumor mass (Figure 3-11Dii, iv) with some evidence of viral 
presence in the immediate surrounding normal tissue (Figure 3-11Div). 
 
Morbidity based on weight trends (Figure 3-12B) and neuroscores (Figure         
3-12D) were also followed in the survival arm.  Weights in the survival study were 
followed for all animals throughout the study but only weights up to medium survival for 
both groups were plotted.  Trends following tumor implantation and up to one day, post 
treatment, were consistent with the previously described studies.  Unlike in the acute 
study, weights in survival study animals began increasing by day 2 post-treatment and at 
day 16, weights of virally treated animals had surpassed those of control animals.  They 
continued to increase for several more days while weights of control animals decreased 
until animals were sacrificed.  Though delayed, weight trends of virally treated animals 
eventually decreased by day 19 and continued declining until animals were euthanized.   
Although weights never declined >20% of starting weight in either group, the decreasing 
trend correlated with progression to death in each group.  Neuroscores remained between 
10-11 for all animals in both groups up to day 15.  Scores were not recorded following 
this time point. 
 
 
One Intracranial Dose of rNCP12.1 Induces Both Innate and Adaptive Immune 
Responses in F98 Glioma Bearing Rats by 15 Days Post-Infection 
 
As discussed, immune responses play a very important role in the success of viral 
therapies.  A balance between protecting the host from adverse viral effects and allowing 
optimal viral replication in order to kill tumor and elicit long term anti-tumor responses 
must exist.  To this end, the immune system is often referred to as a double-edged sword 
in that oncolytic potential is maximized by both inhibition and promotion of various 
features of immunity.  For example, previous studies showed that promoting IFN 
responses aids in protection of normal cells [289, 344], yet blocking IFN responses 
through the use of IFN pathway inhibitors such as rapamycin, can prolong viral activity 
allowing a longer therapeutic window [193].  The same is said for adaptive immune 
responses, particularly neutralizing antibodies that help clear virus for protection of the 
infected host while limiting the duration of antitumor activity.  
 
In the present studies, we evaluated serum collected by transcardiac method from 
animals treated with 1x109pfu rNCP12.1 in the acute study at the time of sacrifice.  These 
results were also compared to sera from F98 tumor bearing animals of a subsequent study 
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in which a single intracranial injection of a slightly higher dose (2x109pfu) of rNCP12.1 
was administered.  Innate (IFN; Figure 3-13A) activity was determined using the 
described IFN bioassay.  An adaptive (anti-rNCP12.1 antibodies; Figure 3-13B and C) 
response was determined by the presence of circulating antibodies using Western blot 
analysis and a neutralizing antibody assay.  Antibodies were detected in the sera and were 
mostly directed against VSV glyocoprotein (G) as well as matrix (M), which are the two 
major antigens that give antibody responses during VSV infection.  The anti-G response 
produces neutralizing antibody and is protective against infection in animals.  Some anti-
N antibodies were observed but with a lower signal than those directed against the other 
viral antigens.  Anti-rNCP12.1 neutralizing antibodies (nAbs) were detected using a 
neutralizing assay in which sera of infected animals was treated at 56oC for 35 minutes in 
order to inactivate any residual virus [344].  Serial dilutions (1:2 to 1:1000) of heat-
inactivated sera was combined with 200 pfu of wtVSV inoculum and incubated together 
for 45 minutes at 37oC to allow potential binding of antibody and viral antigen.  
Serum/inoculum mix was then applied to BHK cells to determine the dilution at which 
50% inhibition of CPE was observed relative to fetal bovine serum/inoculum (negative 
control).  Neutralization is plotted as the inverse of the dilution required for 50% 
inhibition of infection at 24 hours post-treatment.  The positive control is a polyclonal 
antibody developed in rabbits following immunization with intact UV- inactivated virus 
(TN-1).  It is the antibody used by our lab for neutralization experiments and in the 
detection of VSV proteins for other molecular techniques. The dilution of TN-1 needed 
for 50% inhibition was 1:800 therefore the titer plotted in the neutralization assay is 800.  
 
Similar to in vitro studies, rNCP12.1 induces systemic production of detectable 
IFN in vivo.  Regardless of dose, IFN activity ranged from 2-4x102 U/mL.  One of the 4 
animals in the lower dose group displayed ~10 fold lower IFN activity than other 
animals.  When compared to the nAb detection assay, nAb against rNCP12.1 were 
consistently present in almost all treated animals with titers ranging between 600-1000, 
with some animals having even greater neutralizing activity than the positive control.  
Not surprisingly, the one animal with the least detected IFN activity also expressed the 
lowest titer of anti-rNCP12.1 nAb signifying a possible error in delivery of initial dose of 
virus.  All sera was evaluated for presence of virus using our standard plaque assay in 
BHKs and no infectious virus was detected in any samples (data not shown). 
 
From these results, we conclude that in the first 2 weeks of treatment, an obvious 
decrease in tumor load is experienced in animals receiving one intratumoral dose of 109 
pfu rNCP12.1.  These results were accompanied by low morbidity as seen by weight 
trends and neurological scoring as well as induction of both peripheral innate (IFN) and 
adaptive (nAb) immune responses.  Nonetheless, reduction in tumor load was not 
sustainable though it did result in a significant yet minor prolongation in survival of 
treated animals.  Gliomas eventually recurred at an accelerated rate with tumors of virus-
treated animals being comparable in size to those treated with vehicle only.  
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Figure 3-13. Detection of immune responses at day 15 in animals treated with a 
single injection of rNCP12.1 
(A) IFN activity as measured by the IFN bioassay (units (U)/ mL).  Detection of anti-
VSV antibodies in sera of treated animals by (B) Western Blot analysis confirming 
presence of circulating antibodies directed against VSV antigens.  Serum was diluted to 
1:100 for each tested sample.  R6F, diluted at 1:5000, was used as the positive control.  It 
is a polyclonal antibody developed in rabbits immunized with detergent disrupted 
wtVSV.  Negative (untreated) control was serum from tumor-bearing animals not treated 
with virus.  (C) Detection of anti-VSV neutralizing antibodies (nAb) in sera of treated 
animals using a neutralizing assay.  Neutralizing titer was determined as the dilution of 
sample needed for 50% inhibition of wtVSV.  TN-1, a polyclonal antibody developed in 
rabbits immunized with intact UV inactivated virus, served as the positive control.  TN-1 
requires at least a dilution of 1:800 for 50% inhibition of wtVSV induced CPE therefore 
the nAb titer is 800 
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Evaluation of Various Methods of Viral Administration on Safety and Efficacy of 
rNCP12.1 as an Oncolytic Treatment for Intracranial Glioma 
 
As demonstrated, components of both innate and adaptive immunity are elicited 
in response to rNCP12.1 infection in vivo.  Due to this phenomenon, a number of delivery 
methods have been proposed as potential ways of enhancing effectiveness of viral 
therapy.  These methods are based on their ability to either shield virus from the immune 
system or modulate the immune system by suppressing certain aspects of immunity long 
enough to achieve optimal oncolysis.  Other methods consider the role of the tumor 
microenvironment in hindering spread of virus.  This includes, but is not limited to, 
increases in pressure caused by the tumor mass and associated inflammation that can 
prevent infusion of virus within the tumor as well as sequestration of virus by 
components of the extracellular matrix [178-181].  In the following studies, we have 
tested a number of delivery methods and their effects on efficacy of treatment and safety 
as seen through weight trends, neuroscore, and overall survival, taking into account the 
role of both tumor microenvironment as well as components of the immune system. 
 
 
Constant Infusion of rNCP12.1 over Time by Infusion Pumps Is Not a More 
Effective Method of Viral Delivery 
 
Taking into account the effects of the microenvironment on the oncolytic efficacy 
of viral therapy, we tested the use of subcutaneously implanted micro-osmotic pumps 
(Alzet Model 1003D) in their ability to reduce tumor by infusing a small yet constant 
dose of virus over time.  These implantable pumps are loaded with a pre-determined 
concentrated volume of therapy and implanted subcutaneously where they deliver a 
continuous flow (1?L/hour) of therapeutic agent over a limited time frame (three days).  
Considering our therapeutic agent of choice is a virus with a potency that is sensitive to 
temperature and time, we first performed a stability study in which we tested changes in 
initial titers of virus over 3 days at 37oC.  Alzet pumps containing 5x1010 pfu/mL 
rNCP12.1 were incubated at 37oC for three days.  Viral titers were tested at t=0, 4, 8, and 
24 hours then every 24 hours for the next 2 days using our standard plaque assay in BHK 
cells.  We found that viral activity decreased approximately 10 fold every 24 hours for 
the first two days eventually dropping to no infectious virus by three days under the 
specified conditions (Figure 3-14).  Though this temperature is an estimate of body 
temperature in the animal model and is likely lower given the superficial implantation 
site of the pumps, these results provided an idea of changes in virus concentration that 
should be expected during the study. We therefore assume that our delivered virus by the 
end of the first day of infusion would be approximately10 fold lower than the loading 
dose with day two titers being 100 fold lower.  In addition, it is likely that no infectious 
virus would be infused by the end of day three.  
 
Next, we evaluated this delivery system using our oncolytic virus in an 
immunocompetent F98 glioma model.  Fischer rats were implanted with F98 glioma cells 
on day zero as described.  At five days post-implantation, animals were given a single 
dose of rNCP12.1 by intratumoral injection.  On the same day as injection, Alzet pumps 
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Figure 3-14. Stability of rNCP12.1 during the use of Alzet infusion pumps 
A starting titer of 5x1010pfu of rNCP12.1 was added to Alzet pumps then incubated for 
three days at 37oC.  Titers were performed at t=0, 4, 8, 24, 48, 72 hours in order to 
determine viral stability over time.  Titers decreased 10 fold every day for two days with 
no infectious virus detected at the end of the study 
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containing varying doses of rNCP12.1 were secured subcutaneously and allowed to 
infuse virus at a rate of 1?L/hour (24?L/day) from days 5-8 (Table 3-2; Figure 3-15A).  
Animals were followed carefully with weights and neuroscore checked every three days 
until criteria for euthanasia were met. 
 
We observed a non-significant (p= 0.5932) 27% decrease in tumor size of animals 
receiving the medium dose of virus versus 18% decrease in low dose and 4% decrease in 
high dose treated animals as compared to control animals (no vehicle).  Interestingly, 
animals receiving vehicle only displayed the highest decrease in tumor load with tumors 
reduced by 34% by the end of the study (Figure 3-16A).  Representative micrographs of 
tumors are shown in Figure 3-16B.  Weight trends (Figure 3-16C) and neuroscores 
(Figure 3-16D) were measured every three days with more frequent checks if additional 
signs of distress were observed.   
 
Specifically, weight trends compared to the previous study were much more 
affected.  Control animals not receiving any vehicle demonstrated expected trends in 
weight with a slight fall after tumor implantation followed by a rise and then subsequent 
fall as animals started to experience effects of tumor burden.  Animals receiving vehicle 
only displayed similar trends in weight as control animals, though at an approximately 15 
grams lower weight at each time point.  Virus treated animals all displayed a continuous 
decline in weight following therapy until time of sacrifice.  Animals receiving low dose 
lost less weight than animals in the other two groups with weight at time of sacrifice 
approximately 27% lower than starting weight.  Neuroscores using the RCS on average 
were lower compared to scores of animals that received only one intratumoral injection 
of rNCP12.1.  Animals in the high dose group surprisingly maintained a neuroscore 
between 10-11 whereas scores averaged approximately 9-10 by the end of the study for 
all groups including control animals.  Low and medium dosed animals experienced the 
most neurological decline with neuroscores ranging from 9.0 to 9.5 during the last few 
days of life.  As we saw with a single injection, tumors were not significantly different 
between treated and untreated animals however unlike animals that received one injection 
of virus, survival was not significantly different between the treated groups nor were they 
significantly different from control (Figure 3-16E).  The only significant difference in 
survival was observed by comparing survival of control animals that received vehicle and 
animals receiving the lowest dose of rNCP12.1 (Figure 3-16F).  Median survival was 21 
days and 27 days, respectively.  Though animals receiving vehicle only had the smallest 
tumors on average, they also had the lowest overall survival (Table 3-3). 
 
In summary, continuous infusion after initial injection of rNCP12.1 did not 
enhance anti-tumor activity or survival.  There was no significant difference in tumor size 
based on dosing of initial injection or infusion.  Survival was not enhanced compared to 
control animals.  However it appears that animals receiving vehicle had an overall lower 
survival that was significantly different from animals treated with low dose virus.  The 
infusion method appeared to have a negative effect on morbidity and animals in the study 
had an overall lower average weight and neuroscore than observed in previous studies not 
using this method.  In conclusion, this method of delivery was not effective at enhancing 
tumor reduction and in improving morbidity in treated animals. 
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Table 3-2. Description of treatment groups in Alzet pump study 
 
Treatment Group? Injection Dose? Overall Pump Infusion 
Dose?
Low? 4x10
8
 pfu? 1.6x10
7
 pfu?
Medium? 1x10
9
 pfu? 4x10
7
 pfu?
High? 2.5x10
9
 pfu? 1x10
8
 pfu?
 
 
 
 
 
 
 
Figure 3-15. Timeline for Alzet pump delivery study 
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Figure 3-16. Comparison of tumor load in animals treated with varying doses of 
rNCP12.1 delivered by Alzet pump infusion 
At day five, post-tumor implantation, animals were given one i.t. injection of rNCP12.1 
at varying doses per group.  On the same day, Alzet pumps were implanted and infusion 
of virus occurred over three days.  Animals were sacrificed when criteria for euthanasia 
were met.  (A) There was no significant difference in size of tumors between treated and 
untreated (p = 0.5932).  Level of significance determined by One Way ANOVA using 
mean values of exact tumor size (mm2).  (B) Representative fluorescence micrographs of 
each group demonstrating GFP expressing tumor.  Morbidity of animals as determined by 
(C) Weight trends and (D) Neuroscore.  (E) Kaplan-Meier survival analysis 
demonstrating a significant difference in survival.  Statistical data performed using Log-
rank (Mantel-Cox) test; P= 0.0140.  (F) Kaplan-Meier survival analysis demonstrating a 
significant difference in survival between Control (vehicle) animals and Low Dose 
animals; P= 0.0073.  Statistical data performed using Log-rank (Mantel-Cox) test  
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Table 3-3. Summary of survival for animals treated in Alzet pump study relative 
to vehicle control 
 
Treatment Group*? Median Survival (Days)? Significant 
Survival  
(vs Control-Vehicle)?
Control? 23.5? No?
Control (Vehicle)? 21? -?
Low? 27? Yes?
Medium? 23.5? No?
High? 25? No?
 
*Control-tumors implanted on day 0 with no further surgeries; Vehicle Control- 
implanted tumors on day 0 with injection of viral vehicle only (TN-sucrose) on day 5 
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Switching Serotype Enhances Survival and Prolongs Tumor Reduction in F98 
Glioma Bearing Animals 
 
In an effort to overcome the effects of the adaptive immune system, specifically 
of neutralizing antibodies, on viral therapy, we performed a study in which we 
administered two separate doses of rNCP12.1, intratumorally.  As previously discussed, 
VSV has two major serotypes, New Jersey and Indiana.  The glycoprotein of these 
serotypes possess only 50% amino acid sequence homology therefore infection of one 
serotype should not protect against subsequent infection with the other serotype.  For the 
initial dose, all treated animals received rNCP12.1, Indiana serotype G protein (GI).  For 
the second dose, animals received either the same rNCP12.1 (GI) or rNCP12.1 having a 
G protein from the New Jersey serotype (GNJ).  Hence, group Ind/Ind received two 
injections of the same serotype and Group Ind/NJ received the New Jersey serotype for 
the second injection. The timeline of the study is depicted in Figure 3-17 with a 
description of dosing in Table 3-4.  There were two separate groups based on time of 
sacrifice, an acute study to determine tumor load at 15 days post-tumor implantation and 
a second group sacrificed when euthanasia criteria were met.  At 15 days post-tumor 
implantation, tumors from animals in both treated groups were found to be 63-65% 
smaller than tumors from animals receiving vehicle only (p=0.0149) (Figure 3-18A).  
Representative tumor images are shown in Figure 3-18B-G.  Morbidity as determined by 
weight trends (Figure 3-19A) and neuroscores (Figure 3-19B) were assessed throughout 
the 15 days.  Animals receiving treatment regardless of serotype experienced near 
identical weight trends with the largest decrease in weight of approximately 30% 
experienced at 12 days post-tumor implantation followed by a 25% increase in weight by 
day 15.  Control animals displayed a gradual decline with weights at sacrifice 
approximately 15% lower than starting weight.   All animals maintained a neuroscore of 
11 in the first 15 days (data not shown).  Past 15 days post-implantation, tumors were 
reduced in size though non-significantly (Figure 3-18A).  Of note, animals in the Ind/NJ 
treatment arm had 54% smaller tumors than control animals whereas, tumors in the 
Ind/Ind treatment arm were 19% reduced.  Weights were more varied later in the study 
with Ind/Ind animals weighing ~15-25 grams more than animals in the Ind/NJ group 
(Figure 3-19B).  The largest decrease in weight of 22% of the starting weight in the 
Ind/NJ group was observed at day 15, post-tumor implantation, and the largest decrease 
of 13.4% in the Ind/Ind group observed at day 12.  Neuroscores were again maintained at 
11 during the first 15 days with scores dropping as low as 7 and 8 by the time of sacrifice 
in Ind/Ind treated animals and Ind/NJ treated animals respectively (Figure 3-19C).  For 
both treatment groups, there was an identical and significant increase in survival with 
median survival of 24 days compared to median survival of 20 days in control animals 
(Figure  3-19D).   
 
From these studies we conclude that double injections of rNCP12.1 administered 
at a 5 day interval significantly decreased tumor load with minimal morbidity by 15 days 
some morbidity demonstrated by neurological deficits toward the very end of the study. 
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Figure 3-17. Time line of Indiana/New Jersey double injection study 
 
 
 
 
Table 3-4. Description of treatment groups in Indiana/New Jersey double 
injection study 
 
Treatment Group Serotype Dose 
Ind/Ind 1. Indiana ?? Indiana? 109 pfu for ALL injections 
Ind/NJ 1. Indiana ?? New Jersey?
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Figure 3-18. Evaluation of animals treated with Indiana/Indiana versus 
Indiana/New Jersey double injection 
On day five, post-tumor implantation, animals were given one i.t. injection of 109 pfu of 
rNCP12.1I-GFP.  On day 10 post-tumor implantation, animals were given a second 
injection of a 109 pfu dose of either rNCP12.1I-GFP or rNCP12.1NJ-GFP.  Animals were 
either sacrificed at day 15 post-tumor implantation (acute arm) or when euthanasia 
criteria were met (survival arm).  (A) Comparison of tumor load demonstrated 
significantly smaller tumors in both treated groups (p=0.0149) for animals sacrificed at 
day 15.  However, there was no significant difference in the size of tumors in treated 
animals of the survival arm relative to control (p= 0.1329), though tumors of animals 
receiving a serotype switch for the second injection did have 54% smaller tumors.  
Representative fluorescence micrographs of animals in acute arm receiving (B) no 
treatment, (C) two doses of Indiana serotype, or (D) one dose of Indiana serotype and one 
dose of New Jersey serotype and animals in the survival arm receiving (E) no treatment, 
(F) two doses of Indiana serotype, or (G) one dose of Indiana serotype and one dose of 
New Jersey.  Levels of significance were determined by One Way ANOVA using mean 
values of exact tumor size (mm2). 
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Figure 3-19. Morbidity of animals treated in the Indiana/Indiana versus 
Indiana/New Jersey double injection study 
Morbidity of animals in acute arm as determined by (A) Weight trends.  Morbidity of 
animals in survival arm as determined by (B) Weight trends and (C) Neuroscore 
(D) Kaplan-Meier analysis of survival demonstrating a significant difference in both 
treated groups relative to control (vehicle); P < 0.0001.  Statistical data performed using 
Log-rank (Mantel-Cox) test. 
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Administration of rNCP12.1 by Tumor “Carrier Cells” as a Potential Method of 
Delivering Virus for the Treatment of Intracranial Glioma  
 
 
Infected tumor carrier cells are unable to form intracranial glioma 
 
In order to determine if infected tumor cells maintained the ability to form tumors 
intracranially, we infected F98 glioma cells in vitro at an MOI of 0.1 or 10.  At one hour 
post-infection, cells were harvested and combined with uninfected cells at a ratio of 1:1 
or 1:10 (infected: uninfected).  Accordingly, 4 different treatment arms (Group 1-4) were 
prepared and tested (1. MOI of 1 at 1:1 infected: uninfected cells; 2. MOI of 1 at 1:10 
infected: uninfected cells; 3. MOI of 10 at 1:1 infected: uninfected cells; 4. MOI of 10 at 
1:10 infected: uninfected cells) (Table 3-5).  On day zero, 105 cells prepared for each 
treatment group were intracranially implanted in Fischer rats.  Weight trends and 
neuroscores were assessed daily for morbidity, and at 15 days after implanting cells, 
animals were sacrificed and brains were harvested and processed for further analyses of 
tumor load and presence of virus (Figure 3-20).   
 
We found that only implanted cells that were never infected in vitro (control) 
developed into visible tumors while all animals receiving pre-infected cells (PC) did not 
have visible tumors based on detection of GFP expressing cells (Figure 3-21A).  All 
animals experienced a similar drop in weight, one day post tumor implantation of ~10% 
which gradually increased in all groups except control animals and animals of the Group 
1 treatment arm.  Control animals continued to decline in weight until day 7 post 
implantation at which point weights increased until the end of the study.  Group 1 
animals maintained a steady weight following their initial drop on day one post-
implantation (Figure 3-21B).  Neuroscores were stable with an RCS of 11 throughout the 
study for all groups except animals in treatment Group 1 with scores averaging between 
9.5-10 during the second half of the study (Figure 3-21C).   
 
From these results, we concluded that implantation of pre-infected tumor cells lost 
tumorigenicity as a result of viral infection.  Furthermore, following exposure to infected 
tumor cells, non-infected cells became infected also losing their ability to form tumors.  
Animals tolerated this treatment well without significant morbidity.  This pilot study 
provided the information needed to next evaluate infected tumor cells as vehicles for 
oncolytic rNCP12.1 viral treatment. 
 
 
Pre-infected tumor cell carriers cause tumor load reduction with moderate 
morbidity at early time points with later time points inconclusive 
 
To test the efficacy and safety of using pre-infected tumor cells as carriers for 
virus in our glioma model, we first established F98-GFP gliomas in 6 week old male 
Fischer rats as described.  On day four post-implantation, F98-GFP cells were infected in 
vitro at an MOI of 3.  At 1 hour post-infection, 103 cells were harvested and re-suspended 
in 10mL PBS vehicle.  These cells were injected into the previous injection site used for 
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Table 3-5. Description of treatment groups in evaluation of pre-infected tumor 
cell implantation study 
 
Treatment Group MOI Ratio Infected: Uninfected # of Cells Implanted 
1 0.1 1:1 
105 cells/10?L 
vehicle (PBS) 
2 1:10 
3 10 1:1 
4 1:10 
 
 
 
 
 
 
 
Figure 3-20. Timeline for evaluation of pre-infected tumor cell implantation study 
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Figure 3-21. Evaluation of tumor implantation by rNCP12.1-GFP pre-infected F98 
glioma 
At day zero, F98 glioma cells were infected in vitro at an MOI of 0.1 or 10 and cells were 
harvested and combined with uninfected cells at a ratio of 1:1 or 1:10, infected: 
uninfected.  105 cells were prepared for each treatment group and intracranially implanted 
and on day 15, animals were sacrificed.  (A) Comparison of tumor load.  Only animals 
receiving vehicle only treated glioma cells (control) formed detectable tumors.  Morbidity 
of animals as determined by (B) weight trends and (C) neuroscore. 
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tumor implantation (Figure 3-22).  For comparison, several animals received 
intratumoral injections of rNCP12.1 virus only (free virus, FV) similar to previous studies 
(Table 3-6).  Control animals received 10?L PBS vehicle only.  Tumor sizes were 
calculated using ImageScope (Aperio ePathology Solutions) and were based on 
measurements obtained from H&E stained tissue as well as fluorescence from GFP 
expressing tumors (Figure 3-23B-O).  Up to 15 days post-treatment, PC treated tumor 
growth significantly lagged behind that of control with tumor growth reduced by as much 
as 69% during the first 10 days after treatment (p=0.013) (Figure 3-23A).  By day 15, PC 
treated tumors were identical in size to control tumors while FV-treated tumors were 
reduced in size by 29%.  On day 20, all tumors had decreased in size including control 
tumors however in comparison to control, PC-treated tumors were 63% smaller than 
controls and the FV-treated tumor was 68% smaller, though not significantly.  
Interestingly, one animal that received pre-infected cells had no evidence of residual 
tumor at this time point (Figure 3-23L).  Unfortunately, after day 20, tumors were unable 
to be analyzed as a consequence of tissue processing for this study.  Whereas animals in 
all previous studies underwent perfusion with 4% paraformaldehyde, animals in this 
study were perfused with normal saline in order to preserve tissue for qRT-PCR studies 
therefore brain samples were extremely fragile during cutting of tissue.  Weight trends 
were also assessed and found to be similar to previous studies in the first week post-
tumor implantation (Figure 3-23P).  Control animals maintained the greatest average 
weights with weights increasing until the end of the study whereas FV treated animals 
also experienced a gradual increase in weight though at a slower rate than in controls.  On 
the other hand, weight trends in PC-treated animals gradually decreased until the end of 
study with average weights dropping approximately 30% from starting weights.  
Neuroscores were stable early in the study with most animals maintaining a score of 11 
for both control and treatment groups (Figure 3-23F).  Neuroscores later in the study 
were lower for control and PC-treated animals, decreasing to 9 by day 25 post-treatment. 
 
 
Infectious virus can be recovered from brain tissue of PC-treated animals 
 
One advantage of using carrier cells includes the ability to not only shield virus 
from the immune system, but carrier cells also serve as in vivo “factories” of virus, 
amplifying treatment even after initial dose is given.  To determine the presence of 
replicating virus in the CNS and in the periphery during treatment, several samples were 
collected at various time-points before euthanasia.  Samples included sera, cerebrospinal 
fluid (CSF), and brain tissue.  Brain tissue was homogenized in PBS and all samples were 
then centrifuged to remove cellular debris.  Only cell-free supernatants were used in the 
detection of virus.  One hundred microliters of each sample was added to cultured BHK 
cells for 1 hour at 31oC.  Samples were then removed and warm agar containing D5 was 
applied.  At 24-36hpi, agar was removed and cells were fixed and stained to detect VSV 
nucleocapsid using a Rhodamine conjugated anti-VSV N monoclonal antibody.  At three 
days post-treatment, infectious virus was recovered from homogenized brain tissue of PC 
treated animals (Figure 3-24A).  Surprisingly, no virus was recovered after day three, 
however on day 24 and 25, infectious virus was again recovered from homogenized brain 
tissue (Figure 3-24B and C).  Virus was not recovered from sera or CSF of PC-treated 
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Figure 3-22. Timeline of rNCP12.1-GFP pre-infected cell study 
 
 
 
 
Table 3-6. Description of treatment groups in rNCP12.1-GFP pre-infected cell 
study 
 
Treatment Group? Dose of rNCP12.1-GFP?
Pre-infected cells (PC)? 1000 cells infected at MOI of 3?
Free virus (FV)? 10
9
pfu free virus?
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Figure 3-23. Evaluation of rNCP12.1-GFP pre-infected F98 cells as treatment in 
rat intracranial model of glioma 
On day four post-tumor implantation, F98 cells were infected with rNCP12.1-GFP in 
vitro at an MOI of 3 and 1000 infected cells were injected intratumorally.  Animals were 
euthanized at t=3, 6, 10, 15, 20, 25 days post-treatment.  (A) Comparison of tumor load 
demonstrated smaller tumors in PC-treated animals reaching significant levels at day 10 
(p=0.01326).  By day 15, PC-treated tumors reached the size of control tumors.  FV-
treated tumor was 29% smaller than controls, though not significantly.  On day 20, PC-
treated tumors regressed in size with tumors 63% smaller than controls while the FV-
treated tumor was 68% smaller but not significantly.  Representative H&E and 
fluorescence micrographs of (B, D, F,  H, K, M) control versus (C, E, G, I, L, N) PC-
treated and (J, O) FV treated animals on (B,C) day 3, (D,E) day 6, (F,G) day 10, (H,I,J) 
day 15, (K-O) day 20.  Images were taken at 0.4X magnification using ImageScope 
(Aperio ePathology Solutions).  Morbidity of animals was determined by (P) Weight 
trends and (Q) Neuroscore. 
§, average tumor size of animals sacrificed at day 18 and day 20 post-treatment 
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Figure 3-23. Continued 
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Figure 3-23. Continued 
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Figure 3-24. Detection of virus in PC- and FV- treated animals  
Brain tissue and sera of treated animals were collected and used to recover infectious 
virus particles.  Supernatant from homogenized brain tissue of animals treated with pre-
infected cells contained infectious virus particles at (A) day 3, (B) day 24, (C) day 25.  
Virus was recovered from serum of the FV-treated animal at (D) day 15.  Images on the 
left are merges of fluorescence and bright field and images on the right are gray scale 
fluorescence micrographs.  All images were taken at 10X magnification.  Additional 
brain tissue was used for immunofluorescence staining for the detection of virus, tumor, 
and the astrocytic marker, GFAP.  Representative fluorescence micrographs of (E-H) PC- 
and (I-K) FV-treated animals show expression of GFAP (blue) localized to GFP-
expressing tumor cells (green) and surrounding normal tissue.  (E-G) Virus (red) in PC-
treated tumors, at day three appears to be highly localized in an area surrounding the 
needle track within tumor tissue co-expressing GFP and GFAP.  At day 15, (I-K) FV-
treated tumors show virus within areas of GFP-expressing tumor.  (E) Brain tissue of the 
untreated, non-tumor bearing hemisphere is included in order to appreciate non-specific 
background of green fluorescence.  (H) Image of whole brain slice showing non-specific 
background of green fluorescence in the left hemisphere relative to GFP expressing 
tumor located in the right hemisphere.   
E, F- 10X magnification; G, I- 20X magnification; H= 0.4X magnification; J, K- 40X 
magnification 
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animals at any time point.  Cryo-sections of brain tissue were also used for 
immunohistochemical analysis in the detection of GFAP and VSV-nucleocapsid.  GFP 
expression was again used as a marker for tumor.  The astrocytic marker, GFAP, was 
observed in multiple areas of the brain, localized both within tumor and in areas devoid 
of tumor.  At day three post-treatment, brain tissue from PC-treated animals was positive 
for viral antigen.  Increased VSV expression was observed in areas that correlated with 
high GFP expressing tumor.  This area was surrounded by a GFAP positive/GFP negative 
(astrocytic/ non- tumor) tissue, which could correspond with normal astrocytic tissue  
or non-GFP expressing tumor (Figure 3-24F and G).  Figure 3-24F shows that infected 
tumor is specifically located along the needle track, an artifact of tumor implantation.  
This suggests that rNCP12.1-infected cells were capable of migrating to areas of tumor to 
allow spread of virus within pre-established tumor.  As we have seen from previous 
experiments, pre-infected cells lose the capacity to form tumors in vivo therefore infected 
cells at 3 days post-treatment are likely from previous implantation and not from 
treatment.  Normal uninfected tissue of the left hemisphere is shown in Figure  
3-24E and H for comparison. 
 
At day 15, on the other hand, virus was only recovered from serum of the FV-
treated animal and no virus was detected in the CSF or homogenized brain tissue (Figure 
3-24D).  Immunohistochemical analysis of cryosections from this same animal also 
demonstrated GFAP positive cells within tumor and surrounding normal tissue (Figure 
3-24I-K).  In addition, virus was also localized within tumor and not surrounding normal 
tissue. 
 
 
Innate and adaptive antiviral immune responses were not increased 
following carrier cell delivery 
 
Sera and CSF were also used to determine activity of both innate and acquired 
immunity.  Using the IFN bioassay, we found that systemic IFN activity was not elevated 
relative to controls following treatment with pre-infected cells at any time-point.  For 
comparison, IFN activity in serum of the FV treated animal at day 15 was elevated 
though not to levels observed in previous experiments (Figure 3-25A).  CSF samples 
were also tested for presence of active IFN in the CNS, which resulted in no detectable 
IFN regardless of treatment (data not shown).  In addition, neutralizing activity was 
tested using the previously described neutralization assay (Figure 3-25B and C).  A 
control animal sacrificed on day 15 and one PC-treated animal sacrificed on day 20 were 
compared to levels of neutralizing antibody in the sera of FV-treated animals.  Only 
animals receiving free virus demonstrated neutralizing activity with titers of 1000, the 
same as titers confirmed in the single injection study.  
 
In sum, the use of rNCP12.1 pretreated F98 glioma cells as a therapeutic vehicle 
in our rat glioma model demonstrated significant tumor load reduction.  At early time-
points, it appears tumor growth was delayed relative to controls yet when tumors became 
more active, evident by an increase in tumor load, viral replication increased causing a 
second peak in tumor load reduction and viral presence at later time-points.  Furthermore,  
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Figure 3-25. Evaluation of innate and adaptive immune responses following 
treatment with pre-infected tumor cells 
(A) Sera from 1-2 animals at various time points were collected and IFN activity 
determined by the IFN bioassay.  Pre-infected F98 cells did not induce peripheral IFN 
activity in contrast to animals that received free virus.  (B) Presence of neutralizing 
antibodies was first tested using Western blot analysis and sera of FV-treated animals 
only were found to have detectable antibodies directed against VSV G and M.  (C) 
Neutralizing activity was evaluated using a neutralizing assay in which sera was serially 
diluted 2 fold and tested for the inhibition of VSV infection in BHK cells.  Neutralizing 
titer was calculated as the inverse of the dilution found to cause inhibition of infection.  
+ control, TN-1 (rabbit polyclonal antibody formed against intact UV-inactivated virus, 
nAb titer- of 800).   
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infection appeared to be localized therefore infectious virus was not present in the CSF or 
serum of treated animals.  Not surprising, this translated to a lack of antiviral immune 
responses as seen by low IFN levels and absence of circulating nAbs.  On the other hand, 
we demonstrated that direct injection of free virus elicits a robust antiviral response as 
seen by increased IFN levels relative to untreated animals and presence of nAb in the 
periphery.  This immune response was directed against infectious virus recovered from 
the systemic circulation but not from brain tissue at 15 days following treatment.  Despite 
elicited systemic immune responses, virus was still localized to areas of tumor and not 
normal tissue even at 15 days post infection, which corresponded with lower (though 
non-significant) tumor load at both 15 and 20 days post-treatment. 
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CHAPTER 4.    DISCUSSION 
 
 
 Glioblastoma multiforme is one of the most destructive of adult tumors.  
Prognosis is poor even when patients receive all possible therapies.  Patients that are not 
suitable for surgical management, tend to do poorly and chemo-radiation alone may only 
extend life weeks to months at best resulting in a 2-year survival of only 10-18% [9, 381].  
Median survival of patients with GBM continues to be approximately one year, even 
considering advancements of modern medicine.  Long-term survivors (greater than 3 year 
survival) eventually succumb to disease as tumors typically recur and with a resistant 
phenotype, non-amenable to surgical or pharmacological therapy [1, 7, 382].  This shifts 
the focus of therapy from cure to comfort care as end of life issues become more critical.  
Not surprisingly, a push for therapies that have the potential to extend survival while 
maintaining a satisfactory quality of life have become an important focus for cancer 
researchers and medical practitioners of neuro-oncology, neurological surgery, and 
palliative care.  Specifically, oncolytic viruses have moved more into the spotlight as 
potential therapies for cancer in general but also as a unique therapeutic agent in the 
treatment of high-grade gliomas.  Multiple viruses along the vast spectrum of viral 
classes have been evaluated and have shown promise in both pre-clinical and clinical 
studies (reviewed in [63, 383, 384]).  Ideal characteristics of oncolytic viruses being 
considered as therapy for GBM should include a specificity to infect tumor while 
maintaining the ability to and preference for replication and cytolysis in these cells over 
those of normal tissues.  This is often challenging in the CNS especially considering the 
sensitive nature of neuronal tissue to damage and infection.  Additionally, viruses that are 
naturally oncolytic often maintain the ability to infect surrounding normal tissues.  Unlike 
non-biological therapies, viruses endure unique challenges that hinder their transition 
from cell culture and pre-clinical models to human patients.  These challenges often 
involve balancing safety with optimal therapeutic efficacy, therefore, it is not surprising 
that understanding the immune responses elicited during and by viral therapy may help 
address these obstacles.   
 
We have developed a novel viral therapy derived from a naturally selected non-
cytopathic variant of vesicular stomatitis virus [237, 366].  VSV, an RNA virus of the 
order Mononegavirales is no newcomer to pre-clinical studies, and its selectivity has 
been tested in a number of different tumor models including breast, prostate, melanoma, 
liver, and brain [294, 358, 359, 361, 371, 385, 386].  VSV specificity for tumor stems 
from the role of the matrix protein, particularly through its ability to inhibit host gene 
expression especially of genes related to antiviral responses.  Matrix binds at the nuclear 
pore complex (NPC) preventing the movement of message into the cytoplasm where it 
would be used to synthesize protein [275, 278].  Many tumor cells are vulnerable to these 
mutants due to inherent defects in their antiviral IFN responses rendering them unable to 
fight off viral infection while normal cells with intact IFN pathways are protected [289, 
291, 292].  A number of matrix variants have been tested including those that have been 
genetically engineered to express defective matrix proteins to those that have developed a 
natural selection for growth in specific tumor cells [285, 289, 354, 355, 371].  
Nevertheless, it is the inability to inhibit the innate IFN antiviral responses that is the 
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main focus of tumor oncolysis.  In addition to tumor specificity, other characteristics 
make VSV a suitable candidate for treatment of GBM.  These include its quick 
replication cycle, ability to grow to high titers in most cell lines, broad tropism, and ease 
of genetic manipulation for the insertion of foreign genes or of mutations of VSV genes 
that help attenuate viral infection in normal cells [207, 291, 343, 344].  We have shown 
that our novel matrix mutant, rNCP12.1, possesses these characteristics.  Specifically, 
viral growth and cytopathic effects represented by cell rounding vary between normal and 
tumor cells as well as between histologically identical tumor cells of different cell lines.  
Primary astrocytes have a more attenuated growth pattern with rNCP12.1 as well as 
wtVSV in comparison to growth in rat glioma cells however this mutant produced 10 fold 
less virus relative to wildtype.  Cytotoxicity was also attenuated and primary astrocytes 
infected with rNCP12.1 had minimal cell rounding.  On the other hand, in the majority of 
glioma cell lines, differences, though minimal, in growth of rNCP12.1 relative to 
wildtype virus were most noticeable in C6 earlier during infection with titers lagging 
behind but eventually catching up to wildtype titers at later timepoints.  Human glioma 
cell lines also varied in their sensitivity to rNCP12.1 infection.  For instance U87, known 
to have chromosomal aberrations in the IFN-I gene, is extremely sensitive to rNCP12.1 
infection, with cells forming large syncytia indicative of membrane fusion that is 
characteristic of VSV infection in vitro.  T98G human glioma cells, on the other hand, 
have an intact IFN signaling which correlated with an overall resistance to rNCP12.1 
infection evident by minimal expression of viral antigen and almost negligible cell 
rounding. 
 
With these results in mind, we were, naturally curious about the IFN activity in 
cells of our rat glioma model in order to determine if in fact IFN activity or lack thereof 
corresponded with cytopathic attenuation. Using semi-quantitative RT-PCR to check for 
the presence of IFN? mRNA, we observed an induction of IFN? following wtVSV 
infection in rat fibroblasts, though at extremely low levels whereas rNCP12.1 elicited a 
robust signal for IFN? message at both 6 and 12hpi.  IFN? signal following wtVSV 
infection in C6 rat glioma was negligible while rNCP12.1 increased IFN expression to 
levels comparable to that found in rNCP12.1 infected rat fibroblasts; however, expression 
was not sustained and substantially dissipated by 12hpi.  Quantitative analysis provided 
even stronger evidence of differences between normal and tumor cells to elicit IFN 
responses.  Though wtVSV induced some level of expression in all cell types, rNCP12.1 
caused a much greater level of induction.  This induction extended into tumor cell lines, 
as well, though at exponentially lower levels than normal cells.  These results in most 
studies would be interpreted as corresponding to equivalent levels of protein synthesis.  
In order to determine whether expression levels indeed translated into active protein, we 
tested for the presence of biologically active IFN levels as seen by antiviral activity in the 
supernatant of infected cells and we found that wtVSV caused production of very low 
amounts of active IFN only in primary astrocytes.  Robust antiviral IFN activity however 
was observed in normal rat fibroblasts infected with rNCP12.1.  These levels gradually 
increased over time showing that normal astrocytes like rat fibroblasts are able to amplify 
signal with time.  Not surprisingly, IFN activity was also observed in tumor cells 
however they lacked the ability to consistently amplify signal (C6, F98) or to elicit a 
robust production of IFN early during infection (F98).   
    140 
Generally, mRNA accounts for less than half of protein abundance and it is 
suggested that the ratio of mRNA abundance to that of protein leans more toward a 
higher prevalence of protein.  This ratio is sensitive to cellular conditions and often 
depends on the specific role a protein plays in cellular activity [370].  Nonetheless, it is 
assumed that if a specific gene transcript is detected, likely the corresponding protein will 
be detected also.  An interesting observation from these data was the imbalance between 
gene expression and protein activity in each cell line with mRNA abundance being more 
prominent than protein activity.  More specifically, there appeared to be much tighter 
regulation on the production of active IFN by the primary astrocytes. There are a number 
of potential levels of regulation that could account for this divergence.  As we know, 
VSV matrix protein inhibits nucleocytoplasmic transport (NCT) of message [278].  This 
is evident in our results with wtVSV, however mutants should be defective in their 
binding at the NPC therefore allowing transcripts to be exported from the nucleus.  This 
in fact appears to be true, however, there may be a difference in sensitivity to this 
inhibition that is cell specific.  For instance, a lower level, relative to other cells tested, of 
matrix binding to NPCs may be all that is required in astrocytes to block NCT.  
Regulation of post-transcriptional events including increased stability of IFN transcripts 
might also be at play.  Several studies have indeed addressed mechanisms that affect the 
stability of IFN transcripts following infection.  Johnsen et al demonstrated that IFN? 
transcripts possess a 3’ untranslated region that contains sequences involved in 
controlling mRNA stability.  During infection or in the presence of synthetic inducers of 
the antiviral pathway such as pI:C, IFN? transcripts become more stable, enhancing 
production of protein during infection, which increases the likelihood of a protective 
antiviral state [387].  It is possible that at this time point we are observing the effects of 
more stable mRNA in combination with continued cellular control over translation.  
Interference at the translational and posttranslational level is also a possibility.  These 
could include alterations in the half-life of protein due to increased degradation or protein 
stability as well as post-translational modifications rendering the protein inactive.   
 
From these results, the question becomes, whether or not more is better; is 
overabundance of active IFN necessarily biologically relevant?  Considering astrocytes 
are a vital component of the cellular network in the central nervous system, it is not 
surprising that there would be a tighter control over the availability of biologically active 
IFN.  In fact, outside of its role in antiviral responses, IFNs are also important in cell 
survival serving as a major inducer of apoptotic responses [23, 330].  In comparison to 
neuronal cells, astrocytes do maintain some level of competency to proliferate and are the 
most important CNS cell that responds to brain trauma by proliferating in a process 
known as gliosis [388, 389].  Despite this proliferative capacity, uncontrolled promotion 
of cell death would be detrimental therefore controlling IFN could serve as a survival 
mechanism in the face of infection.  A better understanding of the mechanisms involved 
in controlling IFN activity in primary astrocytes could aid in addressing these points.  
Future studies might first test whether control of active protein produced is the same as 
control of total protein in astrocytes.  This can be done by ELISA analysis to quantify 
total protein concentration of IFN.  If total protein adheres to the same pattern, it might be 
worthwhile to determine whether there is a noticeable gradient of mRNA from the 
nucleus to the cytoplasm as this would point more toward NCT as a cause for the  
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disproportion between gene expression and protein activity. 
 
IFN defects can happen at multiple points in the antiviral response pathway from 
the production of IFN to IFN sensitivity [331-333].  Therefore, it is possible that even 
though certain cells may not produce active IFN, they may in fact retain the ability to 
respond to IFN.  This response is evident by the promotion of downstream interferon 
stimulated genes (ISGs) that amplify the IFN pathway, promoting the protection of cells 
during viral infection.  We next tested the sensitivity of cells to exogenous IFN as 
determined by their ability to inhibit virus propagation in cell culture and found that 
primary astrocytes are highly sensitive to antiviral effects of IFN with protection 
observed at IFN levels  <5 U/mL.  On the other hand, glioma cells showed variable levels 
of sensitivity with F98 being completely resistant and C6 glioma having a more 
intermediate level of sensitivity requiring higher levels of exogenous IFN to create 
protection (summarized in Table 4-1). Generally speaking, cells that respond to IFN but 
do not produce IFN may likely have defects that are concentrated upstream of IFNAR 
activity.  On the other hand, cells that produce IFN but are not able to respond to IFN 
may harbor more defects downstream of IFN binding to its respective receptor, such as in 
JAK/STAT signaling.  
 
The focus has mostly been on whether individual cell types alone could elicit 
protective IFN responses by an endogenous pool of induced IFN.  Endogenous levels 
become more important in cell culture however, in a living system, we must take both 
pools of IFN into account, IFN produced by that specific cell population and IFN 
produced by surrounding cells of different types.  Hence, the combination of these data, 
which includes IFN production by cells correlated with viral titers and cell specific viral 
induced CPE versus protection by exogenous IFN suggest that they are both important.  
 
In adding to the above studies, we also performed more in depth analysis of IFN  
 
 
Table 4-1. Summary of in vitro results of VSV in normal and tumor glial cells 
 
Measurable 
Response to 
Infection?
PRA? ? C6? ? F98?
wt vs.  ?NCP12.1? ? wt vs. ?NCP12.1? ? wt vs. ?NCP12.1?
Cell Rounding? ??? ?? ? ????? ???? ? ????? ?????
Cell Viability? ?? ????? ? ??? ??? ? ?? ??
Viral Yield? ??? ?? ? ????? ??????????
? ????? ?????
IFN 
transcription*? ??? ?????
? ??? ???? ? ?? ???
IFN bioactivity*? ???? ???? ? ?? ???? ? ?? ???
 
Note: Scale of + to ++++ signifies lowest to highest for each measure of response to 
infection; -, negligible 
* IFN transcription and bioactivity are relative to control cells (FR, rat fibroblasts) 
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responses as determined by induction of specific ISGs, several of which have been 
studied more than others as responders of VSV infection.  Van den pol and associates 
tested the stimulation of genes in several human glioma cell lines (U87, U118, U373, 
A172, M059) as well as in primary glioma tissue compared to normal brain tissue and 
found that their glioma-adapted VSV mutant, VSV-rp30a (MOI of 2) and treatment with 
exogenous IFN (100U/mL) both demonstrated significant increases in expression levels 
of IFN? and MxA 6h post treatment [371].  Another key study by Barber and associates 
involving some of the first engineered attenuated matrix variants of VSV (AV1 and AV2) 
showed that wtVSV blocks transcription at the level of secondary ISG responders such as 
GBP1 and MxA while mutants allow, and actually, induce expression levels of the same 
transcripts [289].  Expression of these ISGs goes on to activate tertiary responders (e.g 
IFN?4), which augment antiviral activity.  This study tested ISG responses in an ovarian 
carcinoma cell until 12hpi.  Though our studies veered from the above studies in tumor 
cell type (human glial versus ovarian carcinoma versus rat glial), time post infection 
(6hpi versus 12hpi versus 24hpi) and specific mutant virus (vsv-rp30 versus AV1 and 
AV2 versus rNCP12.1), overall, we observed increases in expression levels by our 
mutant in comparison to wildtype.  Several differences in our results included that we did 
not see a total inhibition of secondary interferon responders however our study was 
carried out 12 hours after those showing inhibition and therefore it is possible that these 
responders eventually did become expressed as cells began to overcome the block of 
wtVSV.  Several individual ISGs were also noted to not follow the expected increases 
after mutant infection in our study.  Altogether, our non-tumor cell line, primary rat 
astrocytes, followed a pattern of ISG induction almost identical to that of control rat 
fibroblasts whereas glioma cell lines varied from this pattern and even from each other. 
Whether these differences affect rNCP12.1 related oncolysis of glioma cells will require 
additional studies.  At any rate, though specific interpretation of the intricacies of these 
patterns is beyond the scope of the project, several ISGs are worth mentioning in detail.   
 
RIG-I, for instance, is an important component of antiviral signaling through its 
role as a pattern recognition receptor.  Particularly, RIG-I has been shown to be 
indispensible in the activation of antiviral IFN activity in fibroblasts after VSV infection, 
with RIG-I knockout cells having up to 100 fold higher viral titers than normal cells 
[306].  RIG-I is constitutively active and has been shown to be most elevated in 
astrocytes at 4hpi returning to basal levels by 8hpi [372].  Our analysis of expression 
levels in astrocytes supported this as both PRAs and FR cells had very low levels at 24h 
following wtVSV infection.  In contrast, both glioma cell lines demonstrated a notable 
elevation following wild-type infection at the same time point.  Even more, expression in 
all cell types following rNCP12.1 was significantly elevated at 24hpi.  Though it is 
unknown whether this expression at 24hpi is due to a delayed induction of RIG-I or 
rather a constant, prolonged induction, it is of note that this contradicts what is known 
about RIG-I activity this late in infection.  Many cells display autonomous control of 
RIG-I activity, specifically by a splice variant, which is upregulated during viral infection 
or following exposure to Type I IFN [390].  This splice variant is determined at the 
transcriptional level and amplification of RNA in cells treated with IFN or after viral 
infection shows both wildtype and variant bands.  RIG-I responses have been shown to 
be inhibited by the heterodimer formation of the RIG-I splice variant with the wildtype 
    143 
form as a negative feedback mechanism to protect cells from unbalanced production of 
IFN [390, 391].  Our results specifically showed that wtVSV and rNCP12.1 induction of 
RIG-I was highest in C6 glioma but not normal cells.  Therefore, future studies might 
address whether this variant is present in our glioma cell lines specifically in C6 cells 
thus possibly causing the observed levels of IFN gene expression and ultimately IFN 
activity.  In addition, evaluation of RIG-I expression levels at earlier time points might 
reveal whether rNCP12.1 prolongs RIG-I expression or whether expression is actually 
delayed.  
  
Expression of plscr1 was also notable following infection.  This ISG is known to 
affect survival and terminal differentiation of myeloid cell lines [326].  The ability of 
plscr-1 to attach and insert into the cell plasma membrane is interesting as plscr1 contains 
the PPXY N-terminus motif just as is found in the N-terminus of VSV matrix, which has 
been shown to interact with SH3 and WW domains found in a host of cellular proteins.  
Moreover, depending on post-translation palmitoylation, plscr-1 migrates to the nucleus 
where it binds to DNA as a regulator of transcription, therefore IFN-induced gene 
expression.  It may be possible that, during VSV infection, especially events during the 
replication cycle such as assembly and budding where matrix is associated with the cell 
membrane, competition for similar cellular proteins might occur between matrix and 
plscr1 during viral infection.  Except for F98 levels, our studies revealed very low 
expression in all other cell types regardless of infecting virus.  F98 glioma demonstrated 
10 fold higher expression levels of plscr1 following rNCP12.1 infection.  Therefore, 
aside from results in F98 cells, expression levels in all other cell lines are in contrast to 
those observed by Barber et al in which plscr1 expression was inhibited by wtVSV but 
induced starting at 6hpi with attenuated VSV strains [289].  It is possible that like RIG-I, 
some cells especially non-tumor cells regulate the overexpression of plscr1 whereas F98 
cells are unable to, especially considering their role in effecting sensitivity to viral 
infection.  Additionally, it is possible that plscr1 levels were indeed elevated at earlier 
time points and, like RIG-I, should decrease back to lower basal levels at later time 
points.  Therefore, evaluation of plscr 1 expression at earlier time points leading up to 
24hpi would allow us to determine which is more likely.  It would also be of interest to 
see if in fact there are differences in localization of plscr1 as a result of VSV infection 
particularly of displacement of plscr1 from the cell membrane by competition with matrix 
for binding of cellular proteins and whether this relationship correlates with IFN activated 
responses.   
 
Lastly, IRF-1, an inducer and effector of the IFN pathway, is known to be directly 
upregulated in response to VSV infection, even in the absence of IFN [392].  IRF-1 levels 
are observed during states of cell cycle arrest as well as during apoptosis.  IRF-1 
increases expression not only of Type I IFN but also of a subset of ISGs including Mx1 
and 2, GBP1, OAS, PKR, and RIG-I [310].  Sgorbissa et al demonstrated that U87 and 
T98G, two human glioma cell lines that lie on the opposite ends of the IFN spectrum, 
expressed biphasic elevations of IRF1 following treatment with IFN? at 6h and later at 
24h [331].  IRF1 expression went on to induce expression of TRAIL, a known activator 
of apoptosis, in T98G cells but not in U87.  In our studies, glioma cells expressed similar 
levels of IFN?4 regardless of infecting virus.  IRF-1 expression also demonstrated this 
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same non-specific pattern in F98 as well with wtVSV inducing almost identical levels of 
expression as rNCP12.1.  This demonstrated that the expected elevations in IRF1 
expression following mutant infection was not observed in F98 glioma and that the 
relationship between IFN?4 and IRF1 induction was still intact.  On the other hand, IRF1 
levels showed a switch in expression with wtVSV inducing a higher expression over 
rNCP12.1 in C6 glioma even more so than increases in expression following rNCP12.1 in 
normal cells.  This may be that IFN independent induction of IRF1 following wtVSV 
infection in C6 cells is more important following wtVSV than in other cell types.   
 
Obviously, a thorough explanation for these results would require additional 
studies in order to determine the meaning of these patterns of induction and how they 
relate to the overall IFN phenotype of each cell line.  In combination with IFN activity 
and protection assays, unique cell specific IFN phenotypes are revealed and could 
possibly serve as predictors of cells that may likely respond to VSV oncolytic therapy.  
 
As we moved from in vitro studies into an immunocompetent animal model of 
glioma, we saw positive tumor response to rNCP12.1 therapy even after only a single 
injection of virus.  This tumor reduction, though highly significant was not sustainable 
and tumors eventually recurred at an expedited rate over untreated animals so much that 
at the time of euthanasia, tumors were virtually the same size as animals that never 
received virus.  Similar results have been observed in other studies particularly testing 
naturally oncolytic viruses like VSV.  In their evaluation of Semliki Forest Virus as 
treatment for glioma, Maatta et al demonstrated that when using an immunocompetent 
model for systemically administered OV, tumor growth is inhibited early during 
treatment resulting in significantly smaller tumors than controls; however, treated tumors 
do eventually catch up to the size of untreated tumors at an accelerated pace.  On the 
other hand, immunocompromised animals lacking an intact antibody response did not 
demonstrate this type of recurrence [393].  Non-published data from the same group, 
observed that in a different immunocompetent syngeneic model of glioma, SFV was 
more effective at the same dose of virus suggesting that specific tumor model 
characteristics play an important role in therapeutic efficacy [394].  Nonetheless, our 
evaluation of host innate and adaptive immune responses following intratumoral 
rNCP12.1 confirmed an obvious increase in both IFN and in VSV neutralizing activity.  
Specifically, neutralizing activity was observed at time points that coincide with natural 
progression of immune responses against VSV [395].  
 
The cause for accelerated tumor recurrence in the presence of heightened immune 
responses is likely multi-factorial.  As we stated, injury to normal brain tissue can 
activate proliferation of normal astrocytes.  It is possible that whatever factors trigger this 
response can be a cause of increased growth of astrocytic tumors as well.  Changes in the 
tumor microenvironment caused by virus may additionally serve as a factor and several 
studies have revealed key changes that occur with viral therapies.  For instance, 
Kurozumi et al showed that oncolytic viral infection promoted enhanced leakage of 
vessels when administered intratumorally even over the pro-angiogenic responses already 
encouraged by the tumor itself.  Enhanced tumor perfusion opens the flood gates for the 
movement of antiviral immune responders capable of inactivating virus therefore 
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decreasing viral effect [396].  Another possible cause of enhanced growth could be due to 
tumor-acquired resistance to virus.  With chemotherapeutic agents, resistance to therapy 
is a common occurrence during treatment of highly malignant brain tumors.  It is possible 
that these cells are also capable of acquiring resistance to viral therapy in the same 
manner.  In addition, cells have been known to acquire a tolerance to virus.  As a matter 
of fact, many of the attenuated strains of VSV were discovered during persistent 
infections [356, 357].  Previous studies in our lab have demonstrated the ability of VSV 
to establish persistent infections in cell culture.  This was even demonstrated in several 
studies involving the F98 glioma cell line (data not shown).  Persistence of infectious 
virus in our tumor model would likely terminate oncolysis, therefore, increasing the 
possibility of tumor proliferation.   
 
To test whether controlling immune mediated neutralization of virus could 
enhance tumor reduction and decrease or possibly inhibit later accelerated tumor growth, 
we performed another evaluation of intratumoral rNCP12.1 but by administering two 
separate injections.  Two treatment arms were designed, one group receiving 2 injections 
of the same serotype (Ind/Ind) and the other receiving 2 injections, one from Indiana 
serotype and the other from New Jersey serotype (Ind/ NJ) of VSV.  It is generally 
accepted that neutralizing activity against one serotype does not cross react with the 
other.  More accurately, cross reactivity of one serotype over another was found rather to 
be dependent upon several factors: route of administration; amount of viral antigen 
present; co-administration with immune adjuvants.  Live virus given into the peritoneal 
cavity only activates non-cross reactive antibodies whereas intravenous virus or virus 
given at high levels especially over a prolonged period of time (e.g. persistent infection) 
activates antibody with an assymetrical cross reactivity.  This means that antibodies 
produced by the New Jersey serotype are more cross reactive to Indiana than are Indiana 
antibodies against the New Jersey serotype [397].  To our knowledge, no studies have 
shown whether an assymetric cross reactivity exists when virus is administered in the 
CNS.  Based on our results, 2 doses of rNCP12.1 were just as effective at reducing tumor 
as one injection at earlier time points (up to 15 days).  Differences at later time points 
showed that animals treated with the same serotype experienced a robust recurrence of 
tumor while tumors of animals receiving a switch in serotype for the second dose 
maintained smaller tumors until the time of euthanasia.  Survival of both animals was 
identical.  It was not determined in this experiment whether neutralizing antibodies were 
produced in response to virus or whether these responses possessed cross reactivity 
between serotypes.  In addition, each injection was given 5 days apart, day 5 post-tumor 
implantation for the first injection and day 10 for the second injection.  Therefore, 
presence of a substantial neutralizing antibody population likely had not occurred.  Future 
studies should aim to determine the time course of nAb production from virus 
administration to neutralizing activity in order to optimize anti-tumor effect from the 
second dose of therapy.   
 
As mentioned before, the immune system is a double-edged sword in which 
immune responses activated by virus can also serve as key anti-tumor effectors that 
contribute to what is known as the bystander effect seen during therapy.  This means that 
non-infected tumor cells are killed by enhanced anti-tumor immunity triggered by an 
    146 
upregulation of immune mediators that, before viral infection, were not strong enough in 
their response to eliminate tumor.  The other side of the sword involves the early 
elimination of viral treatment in an effort to protect the infected host.  By amplifying the 
signal of danger to surrounding immune cells, viruses are able to disrupt the state of 
immune tolerance created by tumors and even increase visibility of tumor associated 
antigens (TAAs) that otherwise would go unnoticed [398]. 
 
Several studies have suggested the use of carrier cells as a mobile manufacturer of 
virus, shielding its product from immune regulators during transit.  As tumor cells should 
retain susceptibility to infection, viral dose would theoretically be amplified during 
transit, as they home to sites of tumor attracted by their preferred tumor niche [197, 399].  
One such study tested a combination of immunosuppressants with cell carriers of an 
oncolytic poxvirus in the treatment of a peritoneal carcinomatosis mouse model.  MC38, 
autologous murine colon carcinoma cells were used as carriers.  This therapy not only 
enhanced survival but also promoted recovery of virus from tumor tissue confirming the 
continued replication of virus within tumor even at eight days post treatment [400].  We 
tested the use of autologous F98 glioma cells as vehicles for rNCP12.1 in the treatment of 
glioma in our immunocompetent Fischer rat model.  Tumors responded to treatment 
significantly as demonstrated by a reduction in tumor load until day 15 at which point 
treated tumors were equal in size to those of control animals.  Though comparisons of 
tumor size following this time point were unable to be determined due to quality of tissue 
samples, of note, at day 20, one animal showed complete regression of tumor while tissue 
of other animals demonstrated areas of high cellular infiltrate on H&E that did not 
correlate with GFP expression on fluorescence microscopy.  In addition, analyses of 
immune responses proved that carrier cells were effective in their ability to shield virus 
from potential antiviral responses.  There was an absence of neutralizing antibody in the 
serum of PC-treated animals even at 20 days post-treatment, despite recovery of virus 
from brain tissue at the same time point.  This was opposite of what was observed in FV-
treated animals which were positive for IFN and neutralizing antibodies in the periphery.  
Virus in these animals was not recovered from brain tissue but rather from systemic 
circulation.  It appears from these results as well as of previous experiments that 
neutralizing antibody directly correlates with the size of tumor and that the concept of  
“the more, the better” pertaining to IFN activity during viral treatment may not 
necessarily be a marker for predicting effective response to therapy (See Table 4-2 for 
summary of in vivo experiments). 
 
Another theory that has been proposed concerning autologous tumor carrier cells 
is that they could possibly initiate or encourage anti-tumor activity.  A number of very 
successful therapies are based on this possibility including monoclonal antibodies that are 
directed against specific tumor proteins or those of the tumor microenvironment (i.e. 
VEGF, Her2).  As a preliminary study, we evaluated immune recognition of tumor cells 
by testing for the presence of anti-tumor antibodies.  Using Western blot analysis, we 
analyzed serum for the presence of systemic antibodies that may have been produced 
against F98 specific tumor antigens during treatment (See Appendix A).  Results revealed 
a pattern of tumor antigen recognition that was specific to FV- versus PC-treated animals.  
The majority of antigens more immunogenic in FV-treated animals were antigens that  
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Table 4-2. Summary of in vivo experiments of rNCP12.1 in the syngeneic F98 
glioma/ Fischer rat model 
 
Study 
Treatment 
Acute, A 
or 
Survival, 
S 
Tumor Load ?? 
(%) 
Significant 
Survival ? 
Median 
Survival 
Single injection: 
10
9
pfu rNCP12.1 -
GFP??
A Yes (65%) N/A N/A 
S No Yes 23 (C) vs. 
29 (Tx) 
 
Single injection w/ 
Alzet Pump: 
High Dose, HD; 
Medium Dose, MD; 
Low Dose, LD 
 
S No Yes 
(CV vs LD) 
21 (CV) vs. 
27 (LD) 
Double Injection/  
Serotype Switch: 
10
9
pfu rNCP12.1 (I/I) 
and 10
9
pfu rNCP12.1 
(I/NJ) 
 
A Yes 
(63%, I/I; 
65%, I/NJ) 
 
N/A N/A 
S No 
(54%, I/NJ) 
Yes 21 (C) vs. 24 
(I/I and I/NJ) 
Pre-infected Tumor 
Cell Carriers: 
103 cells infected at 
MOI of 3 
N/A* Yes** (69%) N/A N/A 
 
*This experiment was a time course in which animals were sacrificed at 3-5 day 
intervals. 
**Tumor load was significantly decreased up to 10 days following treatment; Later time 
points will need to be repeated 
N/A, not applicable; Tx, treated; C, control; CV, control with vehicle; LD, low dose; I/I, 
Indiana/ Indiana; I/NJ; Indiana/ New Jersey 
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were not recognized in the other treatment groups whereas most antigens that were more 
immunogenic in PC-treated animals were also immunogenic in the other groups though at 
much higher levels of reactivity.  Of note, the greatest level of tumor antigen recognition 
was observed at day 15 following treatment for both FV- and PC-treated animals.  These 
preliminary data are encouraging and more in depth analysis into the importance of these 
immunogenic antigens could provide a platform for more sophisticated 
immunotherapeutic adjuvants for the treatment of high-grade brain tumors.  
 
In summary, we have revealed unique cell specific patterns of gene expression in 
various cell types that must be taken into account in order to determine if rNCP12.1 
would be an optimal therapy in that system.  Just as every high-grade glioma does not 
respond as anticipated to temozolamide (TMZ), the standard chemotherapeutic agent for 
GBM, there is a subset of tumors especially sensitive to TMZ based on mutations in the 
DNA repair enzyme, MGMT.  Therefore a pre-determined molecular signature can be 
extremely helpful in making sure that a particular treatment will have optimal effect as an 
anti-tumor agent.  Similarly, determination of proposed IFN phenotypes that are defined 
by the ability of cells to produce IFN and respond to IFN, evident by the ability to 
upregulate the expression of particular ISGs as well as to create an antiviral state 
following exposure to exogenous IFN, could prove to be just as important in determining 
whether a specific tumor is right for rNCP12.1 therapy (Figure 4-1).  The push for a less 
histologically oriented and more molecular signature based classification system of 
gliomas stems from the importance of these molecular signatures on therapeutic 
outcomes.  Supporting evidence for this concept as it relates to VSV oncolytic therapy is 
evident in several studies that confirmed differences in response to viral therapy based on 
IFN expression profiles.  One such study involved the evaluation of another RNA virus, 
Semliki Forest virus (SFV) as a cancer therapeutic in several cancer models including 
melanoma and glioma.  GL261 and CT-2A glioma cells were shown to be producers of 
and responders to IFN and therefore were protected against in vitro infection with SFV.  
When pre-infected GL261 were implanted intracranially, these cells retained the ability to 
form aggressive intracranial tumors in immunocompetent mice [401].  On the other hand, 
a study by Ruotsalainen et al demonstrated the IFN resistant cell line CT26 were highly 
susceptible to SFV infection in a syngeneic model of colon carcinoma.  This is not to say 
that VSV based OVs would not work in the face of IFN sensitive cells [401].  As Alain et 
al have shown, tumor models responsive to IFN benefit from the addition of adjuvant 
immunomodulatory therapies such as rapamycin which inhibits IFN activity.  They 
demonstrate in this study that though rapamycin decreases the production of IFN, levels 
of IFN produced are still able to protect normal tissue resulting in a significant increase in  
survival over virus alone [193]. 
 
As oncolytic viruses continue down the road to clinical studies, it is important to 
remember that in vitro results as compelling as they may be are not always relevant in 
living models.  As is the case of rNCP12.1 viral therapy, neutralizing activity proved to 
be as important if not more to IFN phenotype in the potential to reach optimal efficacy in 
vivo.  In addition the ability to enhance anti-tumor activity may prove to be the most 
important factor related to long-term outcome measures resulting from viral therapy.  
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Figure 4-1. Interferon phenotypes of glial cells in response to rNCP12.1 infection 
In summary, these normal and tumor rat glial cells have unique IFN phenotypes.  These 
phenotypes can be described as either (A) IFN sensitive in which cells sufficiently 
produce and respond to exogenous IFN, (B) IFN intermediate in which cells 
insufficiently produce IFN at levels unable to create an antiviral state and they respond to 
exogenous IFN at much higher levels than are needed to protect normal cells.  It is 
unknown whether this protective state is sustainable past 24 hours, (C) IFN resistant cells 
that insufficiently produce and respond to exogenous IFN.   
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APPENDIX A.  SUPPLEMENTARY FIGURES AND TABLES 
 
 
 
 
 
Figure A-1. Expression of housekeeping genes in FR cells 
The expression of several housekeeping genes was tested in order to determine the best 
gene for normalization of interferon stimulated genes studies.  FR cells were transfected 
with pI:C.  At 24 hours post-treatment, cells were harvested and total RNA was extracted 
using Trizol reagent.  cDNA was synthesized using M-MLV reverse transcriptase 
(Invitrogen) and random hexamers as primer.  Quantitative PCR was performed on the 
LightCycler 480 (Molecular Resource Center, UTHSC) using Universal Probe Library 
(UPL) protocol for rat gene expression (Roche) (Table A-1).  Universal probes are 
specific for the detection of the rat transcriptome and are labeled with fluorescein at the 
5’ end and a dark quencher dye at the 3’end that allow detection by standard SYBR 
Green I filters.  The LightCycler 480 Taqman90 protocol was used which is pre-
programmed to perform the following cycles: activation of DNA polymerase for 5 
minutes at 95oC; amplification of cDNA for 40 cycles which includes 10 seconds at 95oC 
denature, 20 seconds at 60oC annealing, and 10 seconds at 72oC extension; cool down for 
30 seconds at 40oC.  From these results, ?-actin was chosen as the housekeeping gene to 
use in further experiments.  Each experiment was done in duplicate and results are 
expressed as the mean ± SD. 
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Table A-1. qRT-PCR UPL primers for housekeeping genes 
 
Gene Left Primer Right Primer UPL 
Probe # 
Cyclophilin B Acgtggttttcggcaaagt Cttggtgttctccaccttcc 97 
?-actin Cccgcgagtacaaccttct cgtcatccatggcgaact 17 
HPRT1 (Hypoxanthine 
phosphoribosyl-
transferase 1) 
Gaccggttctgtcatgtcg acctggttcatcatcactaatcac 95 
?-tubulin Cagagccattctggtggac Gccagcaccactctgacc 116 
TBP (TATA Box binding 
protein) 
Cccaccagcagttcagtag
c 
Cattctgggtttgatcattctg 129 
S5 (ribosomal protein S5) Gactgagaagcccggtttg cttgatgtccggggtctct 5 
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Figure A-2. Expression of Cyclophilin B in infected FR cells  
Due to results observed following infection in C6 cells discussed in Chapter 3, Cyclophin 
B was chosen for further testing to determine the appropriate housekeeping gene for 
subsequent qRT-PCR studies.  FR cells were infected with either wtVSV or rNCP12.1-
GFP at an MOI of 10 for one hour at 31oC.  At 24 hpi, cells were harvested and qRT-
PCR was performed as describe on the LightCycler 480 (Molecular Resource Center, 
UTHSC) using Universal Primary Library (UPL) protocol for rat gene expression 
(Roche) (Table A-1).  Expression levels of Cyclophilin B were consistent despite 
infection.  (–)RT controls demonstrated high Cp values as expected for samples not 
contaminated with chromosomal DNA.  Therefore, Cyclophilin B was determined to be 
the most appropriate housekeeping gene for use in further qRT-PCR studies.  Each 
experiment was done in duplicate and results are expressed as the mean ± SD 
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Figure A-3. Test of UPL primer sets for the expression of ISGs in multiple cell 
lines 
Non-tumor (PRA) and tumor (C6, F98) glial cell lines were treated with 10?g transfected 
pI:C for 4 hours.  At 24 hours post-transfection, cells were harvested and total RNA was 
extracted and used to quantify expression levels of several interferon stimulated genes 
including IRF-1, GBP-1, and Mx1/2.  qRT-PCR was performed as described on the 
LightCycler 480 (Molecular Resource Center, UTHSC) using Universal Primary Library 
(UPL) protocol for rat gene expression (Roche) (See Chapter 2 for description of primer 
sets).  Levels of expression were compared to those induced in FR rat fibroblasts.  
Results were normalized to the housekeeping gene, Cyclophilin B.  From these results, 
we were able to confirm that the designed primer sets worked in these cell models and 
that non-tumor cells demonstrate higher levels of expression for each of the ISGs tested 
over glioma cell lines.  
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Figure A-4. BCA protein assay of proteins derived from glial cell lysate 
In order to determine the concentration of proteins derived from cell lysate of several 
glial cell lines, a BCA colorimetric assay was performed according to manufacturer 
instructions (BCA Protein Assay Reagent, Pierce).  Cells were lysed in RIPA buffer 
(25mM Tris–HCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 0.15M NaCl, 
1mM EDTA) and measurements were taken by spectrophotometer at A562.  
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Figure A-5. Detection of circulating anti-tumor antibodies in animals treated with 
pre-infected cells versus free virus 
Sera from intracranial F98 glioma bearing animals that were not treated or treated with 
either pre-infected (PC) F98 tumor cells or Free Virus (FV) were collected at the time of 
euthanasia as described.  Cultured F98 cells from a 10cm dish were harvested and lysed 
in 1mL RIPA buffer.  Protein concentrations were determined using the BCA 
colorimetric method against known concentrations of BSA (Pierce, Rockford, IL) as 
described.  For SDS-PAGE, lysates were suspended in Laemmli reducing sample buffer 
and heated in 100 ?C sand bath for 5 minutes.  Samples were then centrifuged at 
15,000xg for one minute and left on the bench to come to room temperature. Ten 
microliters of SeeBlue Plus2 protein standard (Invitrogen) were loaded next to 10?g of 
lysate and resolved on 0.75mm 9% SDSPAGE gel.  Gels were transferred to PVDF 
membrane which were then blocked in 5% NFDM/TTBS at room temperature for one 
hour. Membranes were then cut and incubated at room temperature for two hours in sera 
at 1:500 in 5% NFDM/TTBS.  Membranes were washed in TTBS and then incubated at 
room temperature for two hours in goat ?-rat secondary antibody conjugated to HRP 
(Jackson Immunoresearch Laboratories) at a dilution of 1:5000.   Signal was visualized 
using chemiluminescence (SuperSignal West Dura, Pierce) followed by exposure to and 
development of X-ray film 
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APPENDIX B.  STANDARDIZING THE IFN BIOASSAY AFTER VSV 
INFECTION 
 
 
Introduction and Purpose 
 
 A number of studies have evaluated IFN activity following infection with wtVSV 
as well as with a number of VSV matrix (M) mutants that are thought to be interferon 
inducers [276, 289, 291, 292].  Very often these studies determine IFN activity based on 
levels of gene expression using semi-quantitative or quantitative RT-PCR [289, 371] or 
by quantifying total IFN protein using methods such as ELISA [193, 289].  As we have 
seen, the induction of IFN gene expression does not necessarily correlate with the amount 
of biologically active IFN produced.  In fact, from our results, the production of active 
IFN appears to be highly regulated in non-tumor cells such as primary astrocytes 
regardless of the high levels of induced IFN gene expression.  In order to test for IFN 
activity, we have used an IFN bioassay in which IFN in a sample is determined by its 
ability to inhibit VSV-induced CPE [367].  In samples already containing infectious 
virus, the IFN bioassay is impossible to interpret.  Various neutralizing techniques have 
been used in other studies such as acid treatment [290] or heat inactivation [344], 
however, results do not take into account the effects these methods potentially have on 
the stability of IFN.  In the following studies, we evaluated several neutralizing methods 
including acid treatment, heat neutralization, and ultracentrifugation.  The following 
results show the effectiveness of these methods by determining the amount of residual 
infectious particles post-treatment and by testing the effect of these treatments on IFN 
activity.   
 
 
Materials and Methods 
 
 
Cells 
 
L929 murine fibroblasts were provided by Dr. Lawrence Pfeffer.  BHK21 cells 
were supplied by Dr. Michael Whitt.  
 
 
Neutralization Methods 
 
Based on the high viral progeny produced by F98 glioma cells during rNCP12.1 
infection in vitro (107-109pfu/mL), we tested several methods of neutralization against 
samples containing high titers of virus, specifically 108 pfu wtVSV.  For each technique, 
residual virus was detected by standard plaque assay on BHKs.  Effects on IFN activity 
were determined by comparing 200U of treated IFN with non-treated rIFN using the IFN 
bioassay in L929 murine fibroblasts.  rIFN units were previously determined with respect 
to the international reference standard for mouse interferon alpha/beta (mouse IFN-?/? 
(NIH). 
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Neutralization by anti-VSV neutralizing antibody (TN-1) 
 
TN-1 is a polyclonal antibody developed in rabbits immunized with intact UV-
inactivated wtVSV.  In previous studies, 10?L of TN-1 neutralized 105 pfu wtVSV (data 
not shown).  For these studies, 20?L of TN-1 was incubated at 37oC for one hour with 
108 pfu wtVSV.  Residual virus was detected using a standard plaque assay on BHKs.  
 
 
Heat inactivation 
 
Virus and rIFN were both heated separately in a 56oC water bath for 30 minutes 
[344].  
 
 
Acid neutralization 
 
Virus and rIFN were treated with 50?L of 0.5M HCl (pH= 2) and incubated for 
2h at 4oC then neutralized by adding 45-50?L of 0.5M NaOH [290].  
 
 
Combination of heat inactivation and acid neutralization 
 
We evaluated combination treatment of heat (56oC) and acid neutralization (pH of 
2) on wtVSV and IFN activity.  Samples were first heated for 30 minutes then treated 
with acid for 2 hours at 4oC.  
 
 
20% sucrose cushion 
 
108 pfu wtVSV was suspended in 2mL of serum free DMEM, over-layed onto a 
20% sucrose cushion, and centrifuged for 35 minutes at 45,000 rpm using an AH650 
rotor at 4oC.  200U IFN diluted into 2mL SF-DMEM was also spun through a 20% 
sucrose cushion in the same manner.   
 
 
Combination of 20% sucrose cushion and acid neutralization 
 
108 pfu virus was treated with 0.5M HCl at a pH of 2 for 2 hours at 4oC then 
brought back to neutral pH using NaOH.  Acid treated samples were then spun through a 
20% sucrose cushion as described.   
 
 
Ultra centrifugal filtration 
 
Virus was suspended in 1mL of SF DMEM.  Samples were centrifuged in 
Amicon Millipore Ultracel Filters with a pore cutoff 100,000 NMWL.  This cutoff would 
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ensure that viral particles would be separated from IFN in the media based on the 
inability of intact virus particles to move through the membrane pores.  IFN, on the other 
hand, having a size of approximately 20kDa, would be able to pass freely.  Samples were 
spun at 5000rpm for 10 minutes at 4oC using JS 4.2 rotor.  Following one spin, filtered 
supernatant was titered using a standard plaque assay on BHKs.  Five hundred microliters 
of IFN at a concentration of 1U/?L was also filtered as described. 
  
 
Results 
  
Following treatment with TN-1, no residual virus was detected by plaque assay at 
24hpi however between 36-48 hours, multiple plaques began to form.  Heat inactivation 
resulted in no remaining infectious virions for one sample and 2 pfu/mL in another, 
however, IFN activity was decreased 4 fold relative to the untreated IFN standard. 
Plaque analysis of acid treated virus resulted in a titer of 3.1x103 pfu/mL.  A subsequent 
study using acid neutralization however resulted in no detectable infectious virus.  
Results showed that acid decreased IFN activity 2 fold.  A combination of heat and acid 
treatment neutralized all virus however IFN activity was decreased 4 fold relative to the 
IFN standard in one sample and was undetectable following heat and acid treatment in 
another sample.  A titer of 1.6x102 pfu/mL was detected following centrifugation through 
a 20% sucrose cushion and IFN activity was shown to be 2 fold lower relative to 
untreated rIFN?.  A combination of acid with 20% sucrose cushion was able to remove 
and inactivate all virus from one sample with 40 pfu/mL virus remaining in another. 
However IFN activity was decreased 4 fold.  Lastly, following one spin using the 
ultracentrifugal filters, supernatants were found to have 26 pfu/mL of virus remaining 
however a second spin resulted in no residual virus.  IFN activity was found to be 
unaffected by this technique after one or two cycles of filtration.  
 
 
Discussion 
 
Because the IFN bioassay requires that L929 cells be treated for 24 hours in 
neutralized supernatant followed by another 24 hours to score inhibition of viral induced 
CPE, the likelihood that results would be contaminated by non- neutralized virus in 
samples treated with neutralizing antibody would be high.  Therefore, this strategy would 
not be appropriate for our purposes.  Heat, acid, and sucrose treatments all diminished 
IFN activity between two and four-fold with one sample having undetectable IFN 
activity.  In addition, inactivation of infectious virus was inconsistent as some samples 
had no detectable virus while others demonstrated infectious viral particles as seen by 
plaque assay following treatments.  Therefore, these treatments would not be appropriate 
as well for our studies.  Ultra-centrifugal filtration was found to be the most appropriate, 
effective, and reliable method.  Though one spin allowed some virus to filter likely 
through defects in the membrane, a second spin was able to separate all viral particles 
without any reduction in IFN activity.  Therefore, we concluded that two spins using the 
Amicon Millipore filters at 5000rpm for 10 minutes each would be used for subsequent 
studies.  
    182 
VITA 
 
 
 Erika Alicia Dillard-Cannon was born in 1979 in Memphis, Tennessee.  She 
graduated from S.R. Butler High School in Huntsville, Alabama in 1997 and, later, from 
Vanderbilt University in Nashville, Tennessee in 2001 with a Bachelor of Science in 
Neuroscience.  After graduation, she worked in several labs at Vanderbilt University, the 
University of Memphis, and the University of Tennessee Health Science Center 
(UTHSC) on projects ranging from neurobiology to pharmacology.  Erika then enrolled 
in the College of Medicine with the entering class of 2004 at UTHSC and, in 2006, 
matriculated into the MD/PhD dual degree program in the College of Graduate Health 
Sciences at UTHSC where she joined the Integrated Program of Biomedical Sciences 
(IPBS) in the Cancer and Developmental Biology track.  Under the guidance of Dr. 
Michael A. Whitt (Microbiology, Immunology, and Biochemistry) Erika has worked on 
developing an oncolytic virus for the treatment of glioblastoma multiforme. 
 
Erika will graduate from the MD/PhD dual degree program in December 2013 
and will be pursuing a career in neurosurgery with a research focus in experimental 
therapies for malignant brain tumors.   
 
